

APPROVED DRUG PRODUCTS


With Therapeutic Equivalence Evaluations



The "Orange Book"

FDA data supplied by [DrugPatentWatch.com](https://www.drugpatentwatch.com)

**CUMULATIVE
SUPPLEMENT 6**
June 2012



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

32nd EDITION

Department of Health and Human Services

Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs

2012

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

32nd EDITION

Cumulative Supplement 6

June 2012

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION	iii
1.1 How to use the Cumulative Supplement	iii
1.2 Cumulative Supplement Content.....	iv
1.3 Applicant Name Changes.....	v
1.4 Levothyroxine Sodium.....	v
1.5 Availability of the Edition	vi
1.6 Report of Counts for the Prescription Drug Product List	vii
1.7 Cumulative Supplement Legend	viii
 DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

32nd EDITION

**CUMULATIVE SUPPLEMENT 6
June 2012**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 30th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 32nd Edition List will then be added to the "Discontinued Drug Product List" appearing in the 33rd Edition. The current Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - o Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - o Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).
- New Drug Application (NDA) approvals (20,000 and 50,000 series) appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at drugproducts@fda.hhs.gov. Send Changes by FAX: 240-276-8974; mail to:

FDA/CDER Orange Book Staff
Office of Generic Drugs, HFD-610
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
ALCON UNIVERSAL LTD (ALCON UNIVERSAL)	ALCON PHARMACEUTICALS LTD (ALCON PHARMS LTD)
OVATION PHARMACEUTICALS INC (OVATION PHARMS)	OAK PHARMACEUTICALS INC (OAK PHARMS)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) and Levo-T (Alara NDA 21342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets. Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levotheroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB1	21402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	21342	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB2	76752	001
LEVOXYL	KUNG PHARMS	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB3	76752	001
LEVOTHROID	LLOYD	0.025MG	AB4	21116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	76187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2011) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use

in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2011</u>	<u>MAR 2012</u>	<u>JUN 2012</u>	<u>SEPT 2012</u>	<u>DEC 2012</u>
DRUG PRODUCTS LISTED	14480	14711	14834		
SINGLE SOURCE	2451 (16.9%)	2446 (16.6%)	2428 (16.4%)		
MULTISOURCE	11953 (82.5%)	12187 (82.8%)	12328 (83.1%)		
THERAPEUTICALLY EQUIVALENT	11792 (81.4%)	12037 (81.8%)	12187 (82.2%)		
NOT THERAPEUTICALLY EQUIVALENT	161 (1.1%)	150 (1.0%)	141 (1.0%)		
EXCEPTIONS ¹	76 (0.5%)	78 (0.5%)	78 (0.5%)		
NEW MOLECULAR ENTITIES APPROVED	6	8	7		
NUMBER OF APPLICANTS	810	826	826		

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.

CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

PRESCRIPTION DRUG PRODUCT LIST - 32ND EDITION

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2012

1-1

ABACAVIR SULFATE

TABLET; ORAL

>A>		ABACAVIR SULFATE						
>A>	AB	MYLAN PHARMS INC	EQ 300MG BASE	A091294	001	Jun 18, 2012	Jun	NEWA
		ZIAGEN						
>D>	+	VIIIV HLTHCARE	EQ 300MG BASE	N020977	001	Dec 17, 1998	Jun	CFTG
>A>	AB	+	EQ 300MG BASE	N020977	001	Dec 17, 1998	Jun	CFTG

ACARBOSE

TABLET; ORAL

ACARBOSE

AB	EMCURE PHARMS LTD	25MG	A202271	001	Feb 07, 2012	Jan	NEWA
AB		50MG	A202271	002	Feb 07, 2012	Jan	NEWA
AB		100MG	A202271	003	Feb 07, 2012	Jan	NEWA

ACETAMINOPHEN; BUTALBITAL

TABLET; ORAL

BUTAPAP

>D>	AA	MIKART	325MG;50MG	A089987	001	Oct 26, 1992	Jun	CRLD	
>A>	+		325MG;50MG	A089987	001	Oct 26, 1992	Jun	CRLD	
>D>		PHRENILIN							
>D>	AA	+	VALEANT	325MG;50MG	A087811	001	Jun 19, 1985	Jun	DISC
>A>	@		325MG;50MG	A087811	001	Jun 19, 1985	Jun	DISC	

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA	+	PHARM ASSOC	120MG/5ML;12MG/5ML	A087508	001		Jan	CRLD
		SUSPENSION; ORAL						
		CAPITAL AND CODEINE						
>D>	+	VALEANT	120MG/5ML;12MG/5ML	A086024	001		Jun	CAHN
	+		120MG/5ML;12MG/5ML	A086024	001		Jan	CTEC
>A>	+	VALEANT PHARMS LLC	120MG/5ML;12MG/5ML	A086024	001		Jun	CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

>D>	AA	NESHER PHARMS	500MG/15ML;7.5MG/15ML	A040366	001	Jan 23, 2002	Jun	DISC
>A>	@		500MG/15ML;7.5MG/15ML	A040366	001	Jan 23, 2002	Jun	DISC
AA		VISTAPHARM	325MG/15ML;7.5MG/15ML	A200343	001	Jan 25, 2012	Jan	NEWA

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	AUROLIFE PHARMA LLC	325MG;5MG	A201013	001	Apr 11, 2012	Mar	NEWA
AA		325MG;7.5MG	A201013	002	Apr 11, 2012	Mar	NEWA
AA		325MG;10MG	A201013	003	Apr 11, 2012	Mar	NEWA

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE AND ACETAMINOPHEN

AA	ACTAVIS TOTOWA	325MG;7.5MG	A040800	001	Apr 03, 2012	Mar	NEWA
AA		325MG;10MG	A040800	002	Apr 03, 2012	Mar	NEWA

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

AB	ALVOGEN INC	325MG;37.5MG	A202076 001	Mar 30, 2012	Mar	NEWA
----	-------------	--------------	-------------	--------------	-----	------

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

ACETAZOLAMIDE SODIUM

AP	SAGENT STRIDES	EQ 500MG BASE/VIAL	A200880 001	May 09, 2012	Apr	NEWA
----	----------------	--------------------	-------------	--------------	-----	------

AP	+ X GEN PHARMS	EQ 500MG BASE/VIAL	A040784 001	Dec 10, 2008	Apr	CRLD
----	----------------	--------------------	-------------	--------------	-----	------

DIAMOX

@ TEVA WOMENS	EQ 500MG BASE/VIAL	N009388 001	Dec 05, 1990	Apr	DISC
---------------	--------------------	-------------	--------------	-----	------

ACETYLCYSTEINE

SOLUTION; INHALATION, ORAL

ACETYLCYSTEINE

>A>	AN	INNOPHARMA INC	20%	A203853 001	Jun 21, 2012	Jun	NEWA
-----	----	----------------	-----	-------------	--------------	-----	------

ACYCLOVIR

CAPSULE; ORAL

ACYCLOVIR

@ HERITAGE PHARMS INC	200MG	A074889 001	Oct 31, 1997	May	CAHN
-----------------------	-------	-------------	--------------	-----	------

TABLET; ORAL

ACYCLOVIR

@ HERITAGE PHARMS INC	400MG	A074891 001	Oct 31, 1997	May	CAHN
-----------------------	-------	-------------	--------------	-----	------

@	800MG	A074891 002	Oct 31, 1997	May	CAHN
---	-------	-------------	--------------	-----	------

ADAPALENE

CREAM; TOPICAL

ADAPALENE

AB	FOUGERA PHARMS	0.1%	A090824 001	Jun 30, 2010	Jan	CAHN
----	----------------	------	-------------	--------------	-----	------

GEL; TOPICAL

ADAPALENE

>A>	AB	TOLMAR	0.3%	A200298 001	Jun 14, 2012	Jun	NEWA
-----	----	--------	------	-------------	--------------	-----	------

DIFFERIN

>D>	+	GALDERMA LABS LP	0.3%	N021753 001	Jun 19, 2007	Jun	CFTG
-----	---	------------------	------	-------------	--------------	-----	------

>A>	AB	+	0.3%	N021753 001	Jun 19, 2007	Jun	CFTG
-----	----	---	------	-------------	--------------	-----	------

LOTION; TOPICAL

DIFFERIN

+	GALDERMA LABS LP	0.1%	N022502 001	Mar 17, 2010	Apr	CAHN
---	------------------	------	-------------	--------------	-----	------

ADENOSINE

INJECTABLE; INJECTION

ADENOSINE

@ TEVA PARENTERAL	3MG/ML	A078676 001	Jul 31, 2008	Mar	DISC
-------------------	--------	-------------	--------------	-----	------

@	3MG/ML	A076564 001	Jun 16, 2004	Jan	DISC
---	--------	-------------	--------------	-----	------

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

SOLUTION; INHALATION

ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

@ SANDOZ INC	EQ 0.083% BASE;0.017%	A076867 001	Dec 21, 2006	Apr	DISC
--------------	-----------------------	-------------	--------------	-----	------

ALCLOMETASONE DIPROPIONATE

CREAM; TOPICAL

ALCLOMETASONE DIPROPIONATE

AB	FOUGERA PHARMS	0.05%	A076973	001	Jul 12, 2005	Jan	CAHN
----	----------------	-------	---------	-----	--------------	-----	------

OINTMENT; TOPICAL

ALCLOMETASONE DIPROPIONATE

AB	FOUGERA PHARMS	0.05%	A076884	001	Jul 18, 2005	Jan	CAHN
----	----------------	-------	---------	-----	--------------	-----	------

ALENDRONATE SODIUM

TABLET, EFFERVESCENT; ORAL

BINOSTO

+ MISSION PHARMA EQ 70MG BASE

N202344	001	Mar 12, 2012	Mar	NEWA
---------	-----	--------------	-----	------

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ALFUZOSIN HYDROCHLORIDE

AB	INVAGEN PHARMS	10MG	A090284	001	Jan 17, 2012	Jan	NEWA
----	----------------	------	---------	-----	--------------	-----	------

ALGLUCERASE

INJECTABLE; INJECTION

CEREDASE

@ GENZYME 80 UNITS/ML

N020057	003	Apr 05, 1991	Mar	DISC
---------	-----	--------------	-----	------

ALPRAZOLAM

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

@ SANDOZ INC 0.5MG

A077777	001	Jun 30, 2006	Mar	DISC
---------	-----	--------------	-----	------

@ 1MG

A077777	002	Jun 30, 2006	Mar	DISC
---------	-----	--------------	-----	------

@ 2MG

A077777	003	Jun 30, 2006	Mar	DISC
---------	-----	--------------	-----	------

@ 3MG

A077777	004	Jun 30, 2006	Mar	DISC
---------	-----	--------------	-----	------

TABLET, ORALLY DISINTEGRATING; ORAL

NIRAVAM

AB	UCB INC	0.25MG	N021726	001	Jan 19, 2005	Jan	CAHN
----	---------	--------	---------	-----	--------------	-----	------

AB		0.5MG	N021726	002	Jan 19, 2005	Jan	CAHN
----	--	-------	---------	-----	--------------	-----	------

AB	+	1MG	N021726	003	Jan 19, 2005	Jan	CAHN
----	---	-----	---------	-----	--------------	-----	------

AB		2MG	N021726	004	Jan 19, 2005	Jan	CAHN
----	--	-----	---------	-----	--------------	-----	------

ALVIMOPAN

CAPSULE; ORAL

ENTEREG

+ CUBIST PHARMS 12MG

N021775	001	May 20, 2008	Feb	CAHN
---------	-----	--------------	-----	------

AMCINONIDE

CREAM; TOPICAL

AMCINONIDE

AB	+	FOUGERA PHARMS	0.1%	A076065	001	May 15, 2003	Jan	CAHN
----	---	----------------	------	---------	-----	--------------	-----	------

LOTION; TOPICAL

AMCINONIDE

+ FOUGERA PHARMS 0.1%

A076329	001	Nov 06, 2002	Jan	CAHN
---------	-----	--------------	-----	------

OINTMENT; TOPICAL

AMCINONIDE

AB	+	FOUGERA PHARMS	0.1%	A076096	001	Nov 19, 2002	Jan	CAHN
----	---	----------------	------	---------	-----	--------------	-----	------

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN SULFATE

>D>	AP	HOSPIRA	EQ 50MG BASE/ML	A063263 001	Nov 30, 1994	Jun	DISC
>A>		@	EQ 50MG BASE/ML	A063263 001	Nov 30, 1994	Jun	DISC

AMINO ACIDS

INJECTABLE; INJECTION

AMINO ACIDS

		B BRAUN	15%(150GM/1000ML)	A091112 001	Apr 13, 2012	Mar	NEWA
			15%(300GM/2000ML)	A091112 002	Apr 13, 2012	Mar	NEWA
		CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER					
>A>		BAXTER HLTHCARE	15% (15GM/100ML)	A020512 001	Aug 30, 1996	Jun	CAHN
>D>		CLINTEC NUTR	15% (15GM/100ML)	A020512 001	Aug 30, 1996	Jun	CAHN
		NOVAMINE 15%					
		@ HOSPIRA INC	15% (75GM/500ML)	N017957 004	Nov 28, 1986	Mar	CPOT

AMINOCAPROIC ACID

INJECTABLE; INJECTION

AMICAR

@ CLOVER PHARMS

250MG/ML

N015229 002 Mar CAHN

SYRUP; ORAL

AMICAR

AA + CLOVER PHARMS

1.25GM/5ML

N015230 002 Mar CAHN

TABLET; ORAL

AMICAR

AB CLOVER PHARMS

500MG

N015197 001 Mar CAHN

+

1GM

N015197 002 Jun 24, 2004 Mar CAHN

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

AMIODARONE HYDROCHLORIDE

>D>	AP	+	BEDFORD	50MG/ML	A076018 001	Oct 15, 2002	Jun	DISC
>A>			@	50MG/ML	A076018 001	Oct 15, 2002	Jun	DISC
>D>	AP	+	BEDFORD LABS	50MG/ML	A076299 001	Oct 24, 2002	Jun	DISC
>A>			@	50MG/ML	A076299 001	Oct 24, 2002	Jun	DISC
			@ TEVA PARENTERAL	50MG/ML	A076163 001	Sep 05, 2003	Jan	DISC

TABLET; ORAL

AMIODARONE HYDROCHLORIDE

AB MURTY PHARMS

200MG

A077069 001 Apr 08, 2005 May CAHN

AB

400MG

A077069 002 Apr 08, 2005 May CAHN

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HYDROCHLORIDE

AB CARACO

10MG

A040816 002 Jun 27, 2008 Apr NEWA

AB

50MG

A040816 003 Jun 27, 2008 Apr NEWA

AB

75MG

A040816 004 Jun 27, 2008 Apr NEWA

AB

100MG

A040816 005 Jun 27, 2008 Apr NEWA

AB

150MG

A040816 006 Jun 27, 2008 Apr NEWA

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

MYLAN PHARMS INC

EQ 12.5MG BASE;5MG

A071297 002 Dec 10, 1986 Feb CTEC

TABLET; ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

+	MYLAN PHARMS INC	EQ 25MG BASE;10MG	A071297 001	Dec 10, 1986	Feb	CRLD
	LIMBITROL					
	@ VALEANT PHARM INTL	EQ 12.5MG BASE;5MG	N016949 001		Feb	DISC
	LIMBITROL DS					
	@ VALEANT PHARM INTL	EQ 25MG BASE;10MG	N016949 002		Feb	DISC

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

AB	MACLEODS PHARMS LTD	EQ 5MG BASE	A201380 001	Apr 13, 2012	Mar	NEWA
AB		EQ 10MG BASE	A201380 002	Apr 13, 2012	Mar	NEWA

AMOXICILLIN

TABLET, FOR SUSPENSION; ORAL

DISPERMOX

	@ RANBAXY LABS LTD	600MG	A065159 001	Dec 04, 2003	Apr	DISC
--	--------------------	-------	-------------	--------------	-----	------

AMOXICILLIN; CLAVULANATE POTASSIUM

TABLET; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	AUROBINDO PHARMA LTD	250MG;EQ 125MG BASE	A091569 001	Jan 20, 2012	Jan	NEWA
AB		500MG;EQ 125MG BASE	A091569 002	Jan 20, 2012	Jan	NEWA
AB		875MG;EQ 125MG BASE	A091568 001	Jan 20, 2012	Jan	NEWA

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

ADDERALL XR 10

>D>	SHIRE	2.5MG;2.5MG;2.5MG;2.5MG	N021303 001	Oct 11, 2001	Jun	CFTG
-----	-------	-------------------------	-------------	--------------	-----	------

>A>	AB	2.5MG;2.5MG;2.5MG;2.5MG	N021303 001	Oct 11, 2001	Jun	CFTG
-----	----	-------------------------	-------------	--------------	-----	------

ADDERALL XR 15

>D>	SHIRE	3.75MG;3.75MG;3.75MG;3.75MG	N021303 006	May 22, 2002	Jun	CFTG
-----	-------	-----------------------------	-------------	--------------	-----	------

>A>	AB	3.75MG;3.75MG;3.75MG;3.75MG	N021303 006	May 22, 2002	Jun	CFTG
-----	----	-----------------------------	-------------	--------------	-----	------

ADDERALL XR 20

>D>	SHIRE	5MG;5MG;5MG;5MG	N021303 002	Oct 11, 2001	Jun	CFTG
-----	-------	-----------------	-------------	--------------	-----	------

>A>	AB	5MG;5MG;5MG;5MG	N021303 002	Oct 11, 2001	Jun	CFTG
-----	----	-----------------	-------------	--------------	-----	------

ADDERALL XR 25

>D>	SHIRE	6.25MG;6.25MG;6.25MG;6.25MG	N021303 004	May 22, 2002	Jun	CFTG
-----	-------	-----------------------------	-------------	--------------	-----	------

>A>	AB	6.25MG;6.25MG;6.25MG;6.25MG	N021303 004	May 22, 2002	Jun	CFTG
-----	----	-----------------------------	-------------	--------------	-----	------

ADDERALL XR 30

>D>	+	SHIRE	7.5MG;7.5MG;7.5MG;7.5MG	N021303 003	Oct 11, 2001	Jun	CFTG
-----	---	-------	-------------------------	-------------	--------------	-----	------

>A>	AB	+	7.5MG;7.5MG;7.5MG;7.5MG	N021303 003	Oct 11, 2001	Jun	CFTG
-----	----	---	-------------------------	-------------	--------------	-----	------

ADDERALL XR 5

>D>	SHIRE	1.25MG;1.25MG;1.25MG;1.25MG	N021303 005	May 22, 2002	Jun	CFTG
-----	-------	-----------------------------	-------------	--------------	-----	------

>A>	AB	1.25MG;1.25MG;1.25MG;1.25MG	N021303 005	May 22, 2002	Jun	CFTG
-----	----	-----------------------------	-------------	--------------	-----	------

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

>A>	AB	ACTAVIS ELIZABETH	1.25MG;1.25MG;1.25MG;1.25MG	A077302 001	Jun 22, 2012	Jun	NEWA
-----	----	-------------------	-----------------------------	-------------	--------------	-----	------

>A>	AB		2.5MG;2.5MG;2.5MG;2.5MG	A077302 002	Jun 22, 2012	Jun	NEWA
-----	----	--	-------------------------	-------------	--------------	-----	------

>A>	AB		3.75MG;3.75MG;3.75MG;3.75MG	A077302 003	Jun 22, 2012	Jun	NEWA
-----	----	--	-----------------------------	-------------	--------------	-----	------

>A>	AB		5MG;5MG;5MG;5MG	A077302 004	Jun 22, 2012	Jun	NEWA
-----	----	--	-----------------	-------------	--------------	-----	------

>A>	AB		6.25MG;6.25MG;6.25MG;6.25MG	A077302 005	Jun 22, 2012	Jun	NEWA
-----	----	--	-----------------------------	-------------	--------------	-----	------

>A>	AB		7.5MG;7.5MG;7.5MG;7.5MG	A077302 006	Jun 22, 2012	Jun	NEWA
-----	----	--	-------------------------	-------------	--------------	-----	------

AMPHOTERICIN B

INJECTABLE; LIPID COMPLEX; INJECTION

AMPHOTEC

+	ALKOPHARMA USA	50MG/VIAL	N050729 001	Nov 22, 1996	May	CAHN
+		100MG/VIAL	N050729 002	Nov 22, 1996	May	CAHN

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL

AGRYLIN

AB	SHIRE LLC	EQ 0.5MG BASE	N020333 001	Mar 14, 1997	Jan	CAHN
----	-----------	---------------	-------------	--------------	-----	------

ANAGRELIDE HYDROCHLORIDE

@	SANDOZ INC	EQ 0.5MG BASE	A076683 001	Apr 18, 2005	Mar	DISC
---	------------	---------------	-------------	--------------	-----	------

@		EQ 1MG BASE	A076683 002	Apr 18, 2005	Mar	DISC
---	--	-------------	-------------	--------------	-----	------

ANASTROZOLE

TABLET; ORAL

ANASTROZOLE

AB	APOTEX INC	1MG	A200654 001	May 11, 2012	Apr	NEWA
----	------------	-----	-------------	--------------	-----	------

AB	IMPAX LABS INC	1MG	A091242 001	May 31, 2012	May	NEWA
----	----------------	-----	-------------	--------------	-----	------

APROTININ

INJECTABLE; INJECTION

TRASYLOL

@	BAYER HLTHCARE	10,000KIU/ML	N020304 001	Dec 29, 1993	May	DISC
---	----------------	--------------	-------------	--------------	-----	------

ARGATROBAN

INJECTABLE; INJECTION

ACOVA

AP	+	PFIZER	250MG/2.5ML (100MG/ML)	N020883 001	Jun 30, 2000	Jan	CTNA
----	---	--------	------------------------	-------------	--------------	-----	------

ARGATROBAN

AP		HIKMA PHARM CO LTD	250MG/2.5ML (100MG/ML)	N203049 001	Jan 05, 2012	Jan	NEWA
----	--	--------------------	------------------------	-------------	--------------	-----	------

ARMODAFINIL

TABLET; ORAL

ARMODAFINIL

AB	MYLAN PHARMS INC	50MG	A200043 001	Jun 01, 2012	May	NEWA
----	------------------	------	-------------	--------------	-----	------

AB		150MG	A200043 002	Jun 01, 2012	May	NEWA
----	--	-------	-------------	--------------	-----	------

AB		250MG	A200043 003	Jun 01, 2012	May	NEWA
----	--	-------	-------------	--------------	-----	------

NUVIGIL

AB	CEPHALON	50MG	N021875 001	Jun 15, 2007	May	CFTG
----	----------	------	-------------	--------------	-----	------

AB		150MG	N021875 003	Jun 15, 2007	May	CFTG
----	--	-------	-------------	--------------	-----	------

AB	+	250MG	N021875 004	Jun 15, 2007	May	CFTG
----	---	-------	-------------	--------------	-----	------

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION; ORAL

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

AA	NOVEL LABS INC	4.7GM;100GM;1.015GM;5.9MG;2.691GM ;7.5GM	A090145 001	Jan 25, 2012	Jan	NEWA
----	----------------	---	-------------	--------------	-----	------

MOVIPREP

AA	+	SALIX PHARMS	4.7GM;100GM;1.015GM;5.9MG;2.691GM ;7.5GM	N021881 001	Aug 02, 2006	Jan	CFTG
----	---	--------------	---	-------------	--------------	-----	------

ASPIRIN; CARISOPRODOL

TABLET; ORAL

CARISOPRODOL AND ASPIRIN

AB	PROSAM LABS	325MG;200MG	A040252	001	Dec 10,	1997	Feb	CAHN
----	-------------	-------------	---------	-----	---------	------	-----	------

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET; ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

AB	PROSAM LABS	325MG;200MG;16MG	A040283	001	Dec 29,	1998	Feb	CAHN
----	-------------	------------------	---------	-----	---------	------	-----	------

ATOMOXETINE HYDROCHLORIDE

CAPSULE; ORAL

ATOMOXETINE HYDROCHLORIDE

>D>	AB	ZYDUS PHARMS USA INC	18MG	A079017	001	Sep 17,	2010	Jun	DISC
>A>		@	18MG	A079017	001	Sep 17,	2010	Jun	DISC
>D>	AB		25MG	A079017	002	Sep 17,	2010	Jun	DISC
>A>		@	25MG	A079017	002	Sep 17,	2010	Jun	DISC
>D>	AB		40MG	A079017	003	Sep 17,	2010	Jun	DISC
>A>		@	40MG	A079017	003	Sep 17,	2010	Jun	DISC
>D>	AB		60MG	A079017	004	Sep 17,	2010	Jun	DISC
>A>		@	60MG	A079017	004	Sep 17,	2010	Jun	DISC
>D>	AB		80MG	A079017	005	Sep 17,	2010	Jun	DISC
>A>		@	80MG	A079017	005	Sep 17,	2010	Jun	DISC
>D>	AB		100MG	A079017	006	Sep 17,	2010	Jun	DISC
>A>		@	100MG	A079017	006	Sep 17,	2010	Jun	DISC
		STRATTERA							
>D>	AB	LILLY	10MG	N021411	002	Nov 26,	2002	Jun	CTEC
>A>			10MG	N021411	002	Nov 26,	2002	Jun	CTEC
>D>	AB		18MG	N021411	003	Nov 26,	2002	Jun	CTEC
>A>			18MG	N021411	003	Nov 26,	2002	Jun	CTEC
>D>	AB		25MG	N021411	004	Nov 26,	2002	Jun	CTEC
>A>			25MG	N021411	004	Nov 26,	2002	Jun	CTEC
>D>	AB		40MG	N021411	005	Nov 26,	2002	Jun	CTEC
>A>			40MG	N021411	005	Nov 26,	2002	Jun	CTEC
>D>	AB	+	60MG	N021411	006	Nov 26,	2002	Jun	CTEC
>A>		+	60MG	N021411	006	Nov 26,	2002	Jun	CTEC
>D>	AB		80MG	N021411	007	Feb 14,	2005	Jun	CTEC
>A>			80MG	N021411	007	Feb 14,	2005	Jun	CTEC
>D>	AB		100MG	N021411	008	Feb 14,	2005	Jun	CTEC
>A>			100MG	N021411	008	Feb 14,	2005	Jun	CTEC

ATORVASTATIN CALCIUM

TABLET; ORAL

ATORVASTATIN CALCIUM

AB	APOTEX INC	EQ 10MG BASE	A090548	001	May 29,	2012	May	NEWA
AB		EQ 20MG BASE	A090548	002	May 29,	2012	May	NEWA
AB		EQ 40MG BASE	A090548	003	May 29,	2012	May	NEWA
AB		EQ 80MG BASE	A090548	004	May 29,	2012	May	NEWA
AB	MYLAN PHARMS INC	EQ 10MG BASE	A091226	001	May 29,	2012	May	NEWA
AB		EQ 20MG BASE	A091226	002	May 29,	2012	May	NEWA
AB		EQ 40MG BASE	A091226	003	May 29,	2012	May	NEWA
AB		EQ 80MG BASE	A091226	004	May 29,	2012	May	NEWA
AB	SANDOZ INC	EQ 10MG BASE	A077575	001	May 29,	2012	May	NEWA
AB		EQ 20MG BASE	A077575	002	May 29,	2012	May	NEWA
AB		EQ 40MG BASE	A077575	003	May 29,	2012	May	NEWA

TABLET; ORAL

ATORVASTATIN CALCIUM

AB	SANDOZ INC	EQ 80MG BASE	A077575 004	May 29, 2012	May	NEWA
AB	TEVA PHARMS	EQ 10MG BASE	A078773 001	May 29, 2012	May	NEWA
AB		EQ 20MG BASE	A078773 002	May 29, 2012	May	NEWA
AB		EQ 40MG BASE	A078773 003	May 29, 2012	May	NEWA
AB		EQ 80MG BASE	A078773 004	May 29, 2012	May	NEWA

ATRACURIUM BESYLATE

INJECTABLE; INJECTION

ATRACURIUM BESYLATE

AP	+	BEDFORD	10MG/ML	A074901 001	Jul 18, 1997	Feb	CTEC
AP		SAGENT PHARMS	10MG/ML	A091489 001	Feb 17, 2012	Feb	NEWA
ATRACURIUM BESYLATE PRESERVATIVE FREE							
AP	+	BEDFORD	10MG/ML	A074900 001	Jul 18, 1997	Feb	CTEC
AP		SAGENT PHARMS	10MG/ML	A091488 001	Feb 17, 2012	Feb	NEWA

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

SOLUTION; ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

AA	+	ROXANE	0.025MG/5ML;2.5MG/5ML	A087708 001	May 03, 1982	Apr	CRLD
		LOMOTIL					
		@ GD SEARLE LLC	0.025MG/5ML;2.5MG/5ML	N012699 001		Apr	DISC

AVANAFIL

TABLET; ORAL

STENDRA

VIVUS

		50MG	N202276 001	Apr 27, 2012	Apr	NEWA
		100MG	N202276 002	Apr 27, 2012	Apr	NEWA
+		200MG	N202276 003	Apr 27, 2012	Apr	NEWA

AXITINIB

TABLET; ORAL

INLYTA

PFIZER

		1MG	N202324 001	Jan 27, 2012	Jan	NEWA
+		5MG	N202324 002	Jan 27, 2012	Jan	NEWA

AZELAIC ACID

GEL; TOPICAL

FINACEA

>A>	+	BAYER HLTHCARE	15%	N021470 001	Dec 24, 2002	Jun	CAHN
>D>	+	INTENDIS	15%	N021470 001	Dec 24, 2002	Jun	CAHN

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AZELASTINE HYDROCHLORIDE

AT		ALCON PHARMA	0.05%	A202305 001	May 31, 2012	May	NEWA
----	--	--------------	-------	-------------	--------------	-----	------

SPRAY, METERED; NASAL

AZELASTINE HYDROCHLORIDE

AB		SUN PHARMA GLOBAL	EQ 0.125MG BASE/SPRAY	A090423 001	May 23, 2012	May	NEWA
----	--	-------------------	-----------------------	-------------	--------------	-----	------

AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE

SPRAY, METERED; NASAL

DYMISTA

+		MEDA PHARMS	EQ 0.125MG BASE/SPRAY;0.05MG/SPRAY	N202236 001	May 01, 2012	May	NEWA
---	--	-------------	---------------------------------------	-------------	--------------	-----	------

AZILSARTAN KAMEDOXOMIL

TABLET; ORAL

EDARBI

TAKEDA PHARMS USA	EQ 40MG MEDOXOMIL	N200796 001	Feb 25, 2011	Apr	CAHN
+	EQ 80MG MEDOXOMIL	N200796 002	Feb 25, 2011	Apr	CAHN

AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE

TABLET; ORAL

EDARBYCLOR

TAKEDA PHARMS USA	EQ 40MG MEDOXOMIL;12.5MG	N202331 001	Dec 20, 2011	Apr	CAHN
+	EQ 40MG MEDOXOMIL;25MG	N202331 002	Dec 20, 2011	Apr	CAHN

AZITHROMYCIN

INJECTABLE; INJECTION

AZITHROMYCIN

>D>	AP	+	TEVA PARENTERAL	EQ 500MG BASE/VIAL	N050809 001	Dec 19, 2006	Jun	DISC
>A>		@		EQ 500MG BASE/VIAL	N050809 001	Dec 19, 2006	Jun	DISC
>D>		+		EQ 2.5GM BASE/VIAL	N050809 002	Dec 19, 2006	Jun	DISC
>A>		@		EQ 2.5GM BASE/VIAL	N050809 002	Dec 19, 2006	Jun	DISC

BACLOFEN

INJECTABLE; INTRATHECAL

GABLOFEN

>A>			CNS THERAPS INC	1MG/ML	N022462 004	Jun 22, 2012	Jun	NEWA
-----	--	--	-----------------	--------	-------------	--------------	-----	------

TABLET; ORAL

BACLOFEN

AB			PROSAM LABS	10MG	A077089 001	Oct 31, 2007	Feb	CAHN
AB				20MG	A077088 001	Oct 31, 2007	Feb	CAHN

TABLET, ORALLY DISINTEGRATING; ORAL

KEMSTRO

@	UCB INC	10MG	N021589 001	Oct 30, 2003	Jan	CAHN
@		20MG	N021589 002	Oct 30, 2003	Jan	CAHN

BALSALAZIDE DISODIUM

TABLET; ORAL

GIAZO

+	SALIX PHARMS	1.1GM	N022205 001	Feb 03, 2012	Feb	NEWA
---	--------------	-------	-------------	--------------	-----	------

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED; NASAL

QNASL

+	TEVA BRANDED PHARM	0.08MG/ACTIVATION	N202813 001	Mar 23, 2012	Mar	NEWA
---	--------------------	-------------------	-------------	--------------	-----	------

BENZONATATE

CAPSULE; ORAL

BENZONATATE

>D>	AA		NESHER PHARMS	100MG	A040795 001	Oct 31, 2007	Jun	DISC
>A>		@		100MG	A040795 001	Oct 31, 2007	Jun	DISC
>D>	AA			200MG	A040795 002	Oct 31, 2007	Jun	DISC
>A>		@		200MG	A040795 002	Oct 31, 2007	Jun	DISC

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

BENZACLIN

BT	+	VALEANT INTL	5%;EQ 1% BASE	N050756 002	Apr 20, 2007	Apr	CAHN
----	---	--------------	---------------	-------------	--------------	-----	------

GEL; TOPICALBENZACLIN

AB		VALEANT INTL	5%;EQ 1% BASE	N050756	001	Dec 21, 2000	Apr	CAHN
>A>		CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE						
>A>	AB	PERRIGO ISRAEL	5%;1.2%	A090979	001	Jun 26, 2012	Jun	NEWA
		DUAC						
>D>	BT	+	STIEFEL	5%;EQ 1% BASE	N050741	001	Aug 26, 2002	Jun CFTG
>A>	AB	+		5%;1.2%	N050741	001	Aug 26, 2002	Jun CFTG

BENZOYL PEROXIDE; ERYTHROMYCINGEL; TOPICALBENZAMYCIN

AB	+	VALEANT INTL	5%;3%	N050557	001	Oct 26, 1984	Jan	CAHN
		BENZAMYCIN PAK						
>D>	+	SANOFI AVENTIS US	5%;3%	N050769	001	Nov 27, 2000	Jun	CAHN
>A>	+	VALEANT INTL	5%;3%	N050769	001	Nov 27, 2000	Jun	CAHN

BENZPHETAMINE HYDROCHLORIDETABLET; ORALBENZPHETAMINE HYDROCHLORIDE

AA		EMCURE PHARMS LTD	50MG	A202061	001	Jan 27, 2012	Jan	NEWA
----	--	-------------------	------	---------	-----	--------------	-----	------

BENZTROPINE MESYLATEINJECTABLE; INJECTIONBENZTROPINE MESYLATE

AP		APP PHARMS LLC	1MG/ML	A090233	001	Jul 28, 2009	May	CAHN
		COGENTIN						
AP	+	OAK PHARMS AKORN	1MG/ML	N012015	001		Feb	CAHN

TABLET; ORALBENZTROPINE MESYLATE

		@ LANNETT HOLDINGS INC	0.5MG	A088877	001	Apr 11, 1985	Jan	DISC
		@	1MG	A088894	001	Apr 11, 1985	Jan	DISC
		@	2MG	A088895	001	Apr 11, 1985	Jan	DISC
AA		PROSAM LABS	0.5MG	A040699	001	Feb 14, 2008	Feb	CMFD
AA			1MG	A040705	001	Feb 14, 2008	Feb	CMFD
AA			2MG	A040706	001	Feb 14, 2008	Feb	CMFD
AA	+	USL PHARMA	0.5MG	A040103	001	Dec 12, 1996	Jan	CRLD
AA	+		1MG	A040103	002	Dec 12, 1996	Jan	CRLD
AA	+		2MG	A040103	003	Dec 12, 1996	Jan	CRLD

BETAMETHASONESYRUP; ORALCELESTONE

		@ SCHERING	0.6MG/5ML	N014215	002		May	DISC
--	--	------------	-----------	---------	-----	--	-----	------

BETAMETHASONE DIPROPIONATECREAM; TOPICALBETAMETHASONE DIPROPIONATE

AB	+	FOUGERA PHARMS	EQ 0.05% BASE	N019137	001	Jun 26, 1984	Jan	CAHN
		CREAM, AUGMENTED; TOPICAL						
		BETAMETHASONE DIPROPIONATE						
AB		FOUGERA PHARMS	EQ 0.05% BASE	A076215	001	Dec 09, 2003	Jan	CAHN
		GEL, AUGMENTED; TOPICAL						
		BETAMETHASONE DIPROPIONATE						
AB	+	FOUGERA PHARMS	EQ 0.05% BASE	A075276	001	May 13, 2003	Jan	CAHN

LOTION, AUGMENTED; TOPICAL

	BETAMETHASONE DIPROPIONATE							
AB	FOUGERA PHARMS	EQ 0.05% BASE	A077111	001	May 21, 2007	Jan	CAHN	

OINTMENT, AUGMENTED; TOPICAL

	BETAMETHASONE DIPROPIONATE							
AB	FOUGERA PHARMS	EQ 0.05% BASE	A075373	001	Jun 22, 1999	Jan	CAHN	

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM; TOPICAL

	CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE							
AB	FOUGERA PHARMS	EQ 0.05% BASE;1%	A075502	001	Jun 05, 2001	Jan	CAHN	

LOTION; TOPICAL

	CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE							
AB	FOUGERA PHARMS	EQ 0.05% BASE;1%	A076516	001	Jun 16, 2005	Jan	CAHN	

LOTRISONE

AB	+	SCHERING CORP	EQ 0.05% BASE;1%	N020010	001	Dec 08, 2000	Feb	CAHN
----	---	---------------	------------------	---------	-----	--------------	-----	------

BETAMETHASONE VALERATE

AEROSOL, FOAM; TOPICAL

	LUXIQ							
	+	STIEFEL	EQ 0.12% BASE	N020934	001	Feb 28, 1999	Jan	CAHN

BISOPROLOL FUMARATE

TABLET; ORAL

	ZEBETA							
AB	TEVA WOMENS	5MG	N019982	002	Jul 31, 1992	Jan	CAHN	
AB	+	10MG	N019982	001	Jul 31, 1992	Jan	CAHN	

BOCEPREVIR

CAPSULE; ORAL

	VICTRELIS							
	+	MERCK SHARP DOHME	200MG	N202258	001	May 13, 2011	Mar	CAHN

BORTEZOMIB

INJECTABLE; INTRAVENOUS, SUBCUTANEOUS

	VELCADE							
	+	MILLENNIUM PHARMS	3.5MG/VIAL	N021602	001	May 13, 2003	Jan	CDFR

BOSENTAN

TABLET; ORAL

	TRACLEER							
	ACTELION PHARMS LTD	62.5MG	N021290	001	Nov 20, 2001	May	CAHN	
	+	125MG	N021290	002	Nov 20, 2001	May	CAHN	

BUDESONIDE

POWDER, METERED; INHALATION

>D>	PULMICORT							
>D>	+	ASTRAZENECA	0.16MG/INH	N020441	002	Jun 24, 1997	Jun	DISC
>A>	@		0.16MG/INH	N020441	002	Jun 24, 1997	Jun	DISC

BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE

AEROSOL, METERED; INHALATION

	SYMBICORT							
	+	ASTRAZENECA	0.08MG/INH;0.0045MG/INH	N021929	001	Jul 21, 2006	Jan	CDFR
	+		0.16MG/INH;0.0045MG/INH	N021929	002	Jul 21, 2006	Jan	CDFR

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM; SUBLINGUAL

SUBOXONE

RECKITT BENCKISER	EQ 2MG BASE;EQ 0.5MG BASE	N022410 001	Aug 30, 2010	Apr	CAIN
+	EQ 8MG BASE;EQ 2MG BASE	N022410 002	Aug 30, 2010	Apr	CAIN

TABLET; SUBLINGUAL

SUBOXONE

RECKITT BENCKISER	EQ 2MG BASE;EQ 0.5MG BASE	N020733 001	Oct 08, 2002	Apr	CPOT
+	EQ 8MG BASE;EQ 2MG BASE	N020733 002	Oct 08, 2002	Apr	CPOT

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

FORFIVO XL

+	EDGEMONT PHARMS LLC	450MG	N022497 001	Nov 10, 2011	Mar	CAHN
---	---------------------	-------	-------------	--------------	-----	------

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPIRONE HYDROCHLORIDE

>D>	AB	@ APOTEX	5MG	A075521 001	Apr 05, 2002	Mar	DISC
		@	10MG	A075521 002	Apr 05, 2002	Mar	DISC
		@	15MG	A075521 003	Apr 05, 2002	Mar	DISC
		@ EGIS	5MG	A075119 001	Mar 14, 2002	Mar	DISC
		@	10MG	A075119 002	Mar 14, 2002	Mar	DISC
		@	15MG	A075119 003	Jan 23, 2003	Mar	DISC
>D>	AB	NESHER PHARMS	5MG	A075572 001	Feb 27, 2002	Jun	DISC
>A>		@	5MG	A075572 001	Feb 27, 2002	Jun	DISC
>D>	AB		10MG	A075572 002	Feb 27, 2002	Jun	DISC
>A>		@	10MG	A075572 002	Feb 27, 2002	Jun	DISC
>D>	AB		15MG	A075572 003	Feb 27, 2002	Jun	DISC
>A>		@	15MG	A075572 003	Feb 27, 2002	Jun	DISC
		@ PROSAM LABS	5MG	A075388 001	May 09, 2002	Mar	DISC
	AB		5MG	A075388 001	May 09, 2002	Feb	CMFD
		@	10MG	A075388 002	May 09, 2002	Mar	DISC
	AB		10MG	A075388 002	May 09, 2002	Feb	CMFD
		@	15MG	A075388 003	May 09, 2002	Mar	DISC
	AB		15MG	A075388 003	May 09, 2002	Feb	CMFD
	AB		30MG	A078302 001	Dec 17, 2007	Feb	CMFD

BUTOCONAZOLE NITRATE

CREAM; VAGINAL

BUTOCONAZOLE NITRATE

@ PERRIGO ISRAEL	2%	A200923 001	May 18, 2012	Apr	NEWA
------------------	----	-------------	--------------	-----	------

CAFFEINE CITRATE

SOLUTION; INTRAVENOUS

CAFCIT

AP	+	BEDFORD LABS	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N020793 001	Sep 21, 1999	Jan	CAHN
----	---	--------------	------------------------------------	-------------	--------------	-----	------

SOLUTION; ORAL

CAFCIT

AA	+	BEDFORD LABS	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N020793 002	Apr 12, 2000	Jan	CAHN
----	---	--------------	------------------------------------	-------------	--------------	-----	------

CALCIPOTRIENE

CREAM; TOPICAL

CALCIPOTRIENE

AB	TOLMAR	0.005%	A200935	001	May 30, 2012	May	NEWA
	DOVONEX						
AB	+ LEO PHARMA AS	0.005%	N020554	001	Jul 22, 1996	May	CFTG
	SOLUTION; TOPICAL						
	CALCIPOTRIENE						
AT	FOUGERA PHARMS	0.005%	A078305	001	May 06, 2008	Jan	CAHN

CALCIUM ACETATE

CAPSULE; ORAL

CALCIUM ACETATE

AB	PADDOK LLC	EQ 169MG CALCIUM	A091312	001	Jun 01, 2012	May	NEWA
----	------------	------------------	---------	-----	--------------	-----	------

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET; ORAL

CARBIDOPA, LEVODOPA AND ENTACAPONE

AB	SUN PHARMA GLOBAL	25MG;200MG;100MG	A079085	001	May 10, 2012	Apr	NEWA
AB		37.5MG;200MG;150MG	A079085	002	May 10, 2012	Apr	NEWA
	STALEVO 100						
AB	ORION PHARMA	25MG;200MG;100MG	N021485	002	Jun 11, 2003	Apr	CFTG
	STALEVO 150						
AB	ORION PHARMA	37.5MG;200MG;150MG	N021485	003	Jun 11, 2003	Apr	CFTG

CARBIDOPA; LEVODOPA

TABLET, ORALLY DISINTEGRATING; ORAL

PARCOPA

AB	UCB INC	10MG;100MG	A076699	001	Aug 27, 2004	Jan	CAHN
AB		25MG;100MG	A076699	002	Aug 27, 2004	Jan	CAHN
AB	+	25MG;250MG	A076699	003	Aug 27, 2004	Jan	CAHN

CARBOPLATIN

INJECTABLE; INJECTION

CARBOPLATIN

AP	CIPLA LTD	50MG/VIAL	A077383	001	Jan 27, 2006	Mar	CAHN
AP		150MG/VIAL	A077383	002	Jan 27, 2006	Mar	CAHN
AP		450MG/VIAL	A077383	003	Jan 27, 2006	Mar	CAHN
AP	ONCO THERAPIES LTD	50MG/VIAL	A091510	001	May 29, 2012	May	NEWA
AP		150MG/VIAL	A091510	002	May 29, 2012	May	NEWA
AP		450MG/VIAL	A091510	003	May 29, 2012	May	NEWA
	PARAPLATIN						
	@ CORDEN PHARMA	50MG/VIAL	N019880	001	Mar 03, 1989	Feb	CAHN
	@	150MG/VIAL	N019880	002	Mar 03, 1989	Feb	CAHN
	@	450MG/VIAL	N019880	003	Mar 03, 1989	Feb	CAHN

INJECTABLE; IV (INFUSION)

CARBOPLATIN

AP	ACTAVIS TOTOWA	50MG/5ML (10MG/ML)	A078732	001	Feb 06, 2012	Jan	NEWA
AP		150MG/15ML (10MG/ML)	A078732	002	Feb 06, 2012	Jan	NEWA
AP		450MG/45ML (10MG/ML)	A078732	003	Feb 06, 2012	Jan	NEWA
AP		600MG/60ML (10MG/ML)	A078732	004	Feb 06, 2012	Jan	NEWA
AP	CIPLA LTD	50MG/5ML (10MG/ML)	A077861	001	Jan 18, 2007	Mar	CAHN
AP		150MG/15ML (10MG/ML)	A077861	002	Jan 18, 2007	Mar	CAHN
AP		450MG/45ML (10MG/ML)	A077861	003	Jan 18, 2007	Mar	CAHN
AP		600MG/60ML (10MG/ML)	A077861	004	Jan 18, 2007	Mar	CAHN

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

AA	PROSAM LABS	350MG	A040188 001	Mar 07, 1997	Feb	CAHN
----	-------------	-------	-------------	--------------	-----	------

CEFACLOR

CAPSULE; ORAL

CEFACLOR

@ RANBAXY

EQ 250MG BASE

A064156 001 Aug 28, 1997 Apr DISC

@

EQ 500MG BASE

A064156 002 Aug 28, 1997 Apr DISC

FOR SUSPENSION; ORAL

CEFACLOR

@ RANBAXY

EQ 125MG BASE/5ML

A064166 001 Oct 02, 1997 Apr DISC

AB	+	EQ 125MG BASE/5ML	A064166 001	Oct 02, 1997	Feb	CTEC
----	---	-------------------	-------------	--------------	-----	------

@

EQ 187MG BASE/5ML

A064165 001 Oct 02, 1997 Apr DISC

AB	+	EQ 187MG BASE/5ML	A064165 001	Oct 02, 1997	Feb	CTEC
----	---	-------------------	-------------	--------------	-----	------

@

EQ 250MG BASE/5ML

A064164 001 Oct 02, 1997 Apr DISC

AB	+	EQ 250MG BASE/5ML	A064164 001	Oct 02, 1997	Feb	CTEC
----	---	-------------------	-------------	--------------	-----	------

@

EQ 375MG BASE/5ML

A064155 001 Oct 02, 1997 Apr DISC

AB	+	EQ 375MG BASE/5ML	A064155 001	Oct 02, 1997	Feb	CTEC
----	---	-------------------	-------------	--------------	-----	------

AB		YUNG SHIN PHARM	EQ 125MG BASE/5ML	A065412 001	Feb 17, 2012	Feb	NEWA
----	--	-----------------	-------------------	-------------	--------------	-----	------

AB			EQ 187MG BASE/5ML	A065412 002	Feb 17, 2012	Feb	NEWA
----	--	--	-------------------	-------------	--------------	-----	------

AB			EQ 250MG BASE/5ML	A065412 003	Feb 17, 2012	Feb	NEWA
----	--	--	-------------------	-------------	--------------	-----	------

AB			EQ 375MG BASE/5ML	A065412 004	Feb 17, 2012	Feb	NEWA
----	--	--	-------------------	-------------	--------------	-----	------

TABLET, CHEWABLE; ORAL

RANICLOR

@ RANBAXY LABS LTD

EQ 125MG BASE

A065092 001 Dec 22, 2003 Apr DISC

@

EQ 187MG BASE

A065092 002 Dec 22, 2003 Apr DISC

@

EQ 250MG BASE

A065092 003 Dec 22, 2003 Apr DISC

@

EQ 375MG BASE

A065092 004 Dec 22, 2003 Apr DISC

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL

CEFADROXIL

@ RANBAXY LABS LTD

EQ 500MG BASE

A065015 001 Jun 22, 1999 Apr DISC

TABLET; ORAL

CEFADROXIL

@ RANBAXY

EQ 1GM BASE

A065018 001 Apr 23, 1999 Apr DISC

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN AND DEXTROSE

B BRAUN

EQ 2GM BASE/VIAL

N050779 003 Jan 13, 2012 May NEWA

CEFDITOREN PIVOXIL

TABLET; ORAL

SPECTRACEF

VANSSEN PHARMA

200MG

N021222 001 Aug 29, 2001 Mar CAHN

+

400MG

N021222 002 Jul 21, 2008 Mar CAHN

CEFIXIME

>A> CAPSULE; ORAL

>A> SUPRAX

>A> + LUPIN LTD 400MG

N203195 001 Jun 01, 2012 Jun NEWA

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CLAFORAN

AP	+	SANOFI AVENTIS US	EQ 1GM BASE/VIAL	A062659 001	Jan 13, 1987	Mar	CRLD
AP	+		EQ 2GM BASE/VIAL	A062659 002	Jan 13, 1987	Mar	CRLD

CEFPROZIL

FOR SUSPENSION; ORAL

CEFPROZIL

AB		APOTEX INC	125MG/5ML	A065351 001	Feb 29, 2012	Feb	NEWA
AB			250MG/5ML	A065351 002	Feb 29, 2012	Feb	NEWA
		@ RANBAXY LABS LTD	125MG/5ML	A065202 001	Jun 30, 2006	Apr	DISC
		@	250MG/5ML	A065202 002	Jun 30, 2006	Apr	DISC

TABLET; ORAL

CEFPROZIL

@ RANBAXY LABS LTD

@

CEFZIL

@ CORDEN PHARMA

@

250MG	A065198 001	Dec 13, 2006	Apr	DISC
500MG	A065198 002	Dec 13, 2006	Apr	DISC
250MG	N050664 001	Dec 23, 1991	Feb	CAHN
500MG	N050664 002	Dec 23, 1991	Feb	CAHN

CEFTAZIDIME

INJECTABLE; INJECTION

FORTAZ

AP	+	COVIS PHARMA	500MG/VIAL	N050578 001	Jul 19, 1985	Apr	CAHN
AP	+		1GM/VIAL	N050578 002	Jul 19, 1985	Apr	CAHN
AP	+		2GM/VIAL	N050578 003	Jul 19, 1985	Apr	CAHN
AP	+		6GM/VIAL	N050578 004	Jul 19, 1985	Apr	CAHN

CEFTAZIDIME SODIUM

INJECTABLE; INJECTION

FORTAZ IN PLASTIC CONTAINER

@ COVIS PHARMA

+

+

EQ 10MG BASE/ML	N050634 001	Apr 28, 1989	Apr	CAHN
EQ 20MG BASE/ML	N050634 002	Apr 28, 1989	Apr	CAHN
EQ 40MG BASE/ML	N050634 003	Apr 28, 1989	Apr	CAHN

CEFTRIAXONE SODIUM

INJECTABLE; INJECTION

CEFTRIAXONE

AP	+	SANDOZ INC	EQ 1GM BASE/VIAL	A065204 001	May 03, 2005	Mar	CRLD
AP	+		EQ 2GM BASE/VIAL	A065204 002	May 03, 2005	Mar	CRLD

CEFUROXIME AXETIL

TABLET; ORAL

CEFUROXIME AXETIL

@ RANBAXY LABS LTD

@

@

EQ 125MG BASE	A065043 003	Feb 15, 2002	Apr	DISC
EQ 250MG BASE	A065043 002	Feb 15, 2002	Apr	DISC
EQ 500MG BASE	A065043 001	Feb 15, 2002	Apr	DISC

CEFUROXIME SODIUM

INJECTABLE; IM-IV

ZINACEF

AB	+	COVIS PHARMA	EQ 750MG BASE/VIAL	N050558 002	Oct 19, 1983	Apr	CAHN
----	---	--------------	--------------------	-------------	--------------	-----	------

INJECTABLE; INJECTION

ZINACEF

AP	+	COVIS PHARMA	EQ 1.5GM BASE/VIAL	N050558	003	Oct 19, 1983	Apr	CAHN
AP	+		EQ 7.5GM BASE/VIAL	N050558	004	Oct 23, 1986	Apr	CAHN
ZINACEF IN PLASTIC CONTAINER								
	+	COVIS PHARMA	EQ 15MG BASE/ML	N050643	001	Apr 28, 1989	Apr	CAHN
	+		EQ 30MG BASE/ML	N050643	002	Apr 28, 1989	Apr	CAHN

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CETIRIZINE HYDROCHLORIDE

AA		SILARX	5MG/5ML	A078876	001	May 11, 2012	Apr	NEWA
----	--	--------	---------	---------	-----	--------------	-----	------

CHLORAMBUCIL

TABLET; ORAL

LEUKERAN

	+	ASPEN GLOBAL INC	2MG	N010669	002		May	CAHN
--	---	------------------	-----	---------	-----	--	-----	------

CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

HYDROCODONE POLISTIREX AND CHLORPHENIRAMNE POLISTIREX

>A>	AB	CORNERSTONE THERAP	EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML	A091671	001	Jun 29, 2012	Jun	NEWA
-----	----	--------------------	---	---------	-----	--------------	-----	------

CICLESONIDE

AEROSOL, METERED; INHALATION

ALVESCO

		NYCOMED GMBH	0.08MG/INH	N021658	002	Jan 10, 2008	May	CAHN
	+		0.16MG/INH	N021658	003	Jan 10, 2008	May	CAHN

AEROSOL, METERED; NASAL

ZETONNA

	+	NYCOMED GMBH	0.037MG/INH	N202129	001	Jan 20, 2012	Jan	NEWA
--	---	--------------	-------------	---------	-----	--------------	-----	------

SPRAY, METERED; NASAL

OMNARIS

	+	NYCOMED GMBH	0.05MG/INH	N022004	001	Oct 20, 2006	May	CAHN
--	---	--------------	------------	---------	-----	--------------	-----	------

CICLOPIROX

CREAM; TOPICAL

CICLOPIROX

AB		FOUGERA PHARMS	0.77%	A076435	001	Dec 29, 2004	Jan	CAHN
----	--	----------------	-------	---------	-----	--------------	-----	------

GEL; TOPICAL

CICLOPIROX

AB		FOUGERA PHARMS	0.77%	A077896	001	Jun 10, 2008	Jan	CAHN
----	--	----------------	-------	---------	-----	--------------	-----	------

AB		GLENMARK GENERICS	0.77%	A091595	001	Feb 29, 2012	Feb	NEWA
----	--	-------------------	-------	---------	-----	--------------	-----	------

SHAMPOO; TOPICAL

CICLOPIROX

AT		FOUGERA PHARMS	1%	A090146	001	May 25, 2010	Jan	CAHN
----	--	----------------	----	---------	-----	--------------	-----	------

SOLUTION; TOPICAL

CICLOPIROX

AT		MYLAN PHARMS INC	8%	A078567	001	Sep 18, 2007	Feb	CAHN
----	--	------------------	----	---------	-----	--------------	-----	------

SUSPENSION; TOPICAL

CICLOPIROX

AB		FOUGERA PHARMS	0.77%	A076422	001	Aug 06, 2004	Jan	CAHN
----	--	----------------	-------	---------	-----	--------------	-----	------

CIDOFOVIR

INJECTABLE; INJECTION

>A>		CIDOFOVIR							
>A>	AP	MYLAN LLC	EQ 75MG BASE/ML	A201276	001	Jun 27, 2012	Jun	NEWA	
		VISTIDE							
>D>	+	GILEAD	EQ 75MG BASE/ML	N020638	001	Jun 26, 1996	Jun	CFTG	
>A>	AP	+	GILEAD SCIENCES INC	EQ 75MG BASE/ML	N020638	001	Jun 26, 1996	Jun	CFTG

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CIMETIDINE HYDROCHLORIDE

>D>	AP	HOSPIRA	EQ 300MG BASE/2ML	A074344	001	Jan 31, 1995	Jun	DISC	
>D>	AP		EQ 300MG BASE/2ML	A074345	001	Jan 31, 1995	Jun	DISC	
>A>		@	EQ 300MG BASE/2ML	A074345	001	Jan 31, 1995	Jun	DISC	
>A>		@	EQ 300MG BASE/2ML	A074344	001	Jan 31, 1995	Jun	DISC	

CIPROFLOXACIN

INJECTABLE; INJECTION

CIPROFLOXACIN

		@ TEVA PARENTERAL	200MG/20ML (10MG/ML)	A077782	001	Aug 28, 2006	Mar	DISC	
		@	400MG/40ML (10MG/ML)	A077782	002	Aug 28, 2006	Jan	DISC	
		CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER							
>D>	AP	BAXTER HLTHCARE	200MG/100ML	A077888	001	Mar 18, 2008	Jun	DISC	
>A>		@	200MG/100ML	A077888	001	Mar 18, 2008	Jun	DISC	
>D>	AP		400MG/200ML	A077888	002	Mar 18, 2008	Jun	DISC	
>A>		@	400MG/200ML	A077888	002	Mar 18, 2008	Jun	DISC	

CIPROFLOXACIN HYDROCHLORIDE

TABLET; ORAL

CIPROFLOXACIN HYDROCHLORIDE

		@ PLIVA	EQ 100MG BASE	A076426	001	Jun 15, 2005	Jan	DISC	
		@	EQ 250MG BASE	A076426	002	Jun 15, 2005	Jan	DISC	
		@	EQ 500MG BASE	A076426	003	Jun 15, 2005	Jan	DISC	
		@	EQ 750MG BASE	A076426	004	Jun 15, 2005	Jan	DISC	

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CIPROFLOXACIN EXTENDED RELEASE

AB		DR REDDYS LABS LTD	212.6MG;EQ 287.5MG BASE	A077701	002	Oct 31, 2007	Apr	NEWA	
----	--	--------------------	-------------------------	---------	-----	--------------	-----	------	--

CISATRACURIUM BESYLATE

INJECTABLE; INJECTION

CISATRACURIUM BESYLATE

AP		SANDOZ INC	EQ 2MG BASE/ML	A200159	001	Feb 03, 2012	Jan	NEWA	
		CISATRACURIUM BESYLATE PRESERVATIVE FREE							
AP		SANDOZ INC	EQ 2MG BASE/ML	A200154	001	Feb 03, 2012	Jan	NEWA	
AP			EQ 10MG BASE/ML	A200154	002	Feb 03, 2012	Jan	NEWA	
		NIMBEX							
AP	+	ABBOTT	EQ 2MG BASE/ML	N020551	001	Dec 15, 1995	Jan	CFTG	
		NIMBEX PRESERVATIVE FREE							
AP	+	ABBOTT	EQ 2MG BASE/ML	N020551	003	Dec 15, 1995	Jan	CFTG	
AP	+		EQ 10MG BASE/ML	N020551	002	Dec 15, 1995	Jan	CFTG	

CISPLATIN

INJECTABLE; INJECTION

CISPLATIN

AP	ONCO THERAPIES LTD	1MG/ML	A091062 001	Apr 18, 2012	Apr	NEWA
	@ TEVA PARENTERAL	1MG/ML	A074814 001	May 16, 2000	Mar	DISC

CLINDAMYCIN PHOSPHATE

CREAM; VAGINAL

CLINDAMYCIN PHOSPHATE

AB	FOUGERA PHARMS	EQ 2% BASE	A065139 001	Dec 27, 2004	Jan	CAHN
----	----------------	------------	-------------	--------------	-----	------

GEL; TOPICAL

CLINDAMYCIN PHOSPHATE

AB	FOUGERA PHARMS	EQ 1% BASE	A064160 001	Jan 28, 2000	Jan	CAHN
----	----------------	------------	-------------	--------------	-----	------

INJECTABLE; INJECTION

CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	+	PHARMACIA AND UPJOHN	EQ 6MG BASE/ML	N050639 001	Aug 30, 1989	May	CFTG
AP	+		EQ 12MG BASE/ML	N050639 002	Aug 30, 1989	May	CFTG
AP	+		EQ 18MG BASE/ML	N050639 003	Apr 10, 1991	May	CFTG

CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER

AP		SANDOZ INC	EQ 6MG BASE/ML	A201692 001	May 31, 2012	May	NEWA
AP			EQ 12MG BASE/ML	A201692 002	May 31, 2012	May	NEWA
AP			EQ 18MG BASE/ML	A201692 003	May 31, 2012	May	NEWA

LOTION; TOPICAL

CLINDAMYCIN PHOSPHATE

AB	FOUGERA PHARMS	EQ 1% BASE	A065067 001	Jan 31, 2002	Jan	CAHN
----	----------------	------------	-------------	--------------	-----	------

SOLUTION; TOPICAL

CLINDAMYCIN PHOSPHATE

AT	FOUGERA PHARMS	EQ 1% BASE	A065254 001	Feb 14, 2006	Jan	CAHN
----	----------------	------------	-------------	--------------	-----	------

CLINDAMYCIN PHOSPHATE; TRETINOIN

GEL; TOPICAL

VELTIN

BX	+	STIEFEL GSK	1.2%;0.025%	N050803 001	Jul 16, 2010	May	CRLD
----	---	-------------	-------------	-------------	--------------	-----	------

CLOBAZAM

TABLET; ORAL

ONFI

		LUNDBECK LLC	5MG	N202067 001	Oct 21, 2011	Mar	CAHN
			10MG	N202067 002	Oct 21, 2011	Mar	CAHN
	+		20MG	N202067 003	Oct 21, 2011	Mar	CAHN

CLOBETASOL PROPIONATE

CREAM; TOPICAL

CLOBETASOL PROPIONATE

>D>	@	ACTAVIS MID ATLANTIC	0.05%	A074139 001	Aug 03, 1994	Jun	CAHN
>A>	@	G AND W LABS INC	0.05%	A074139 001	Aug 03, 1994	Jun	CAHN

CLOBETASOL PROPIONATE (EMOLLIENT)

AB2	FOUGERA PHARMS	0.05%	A075430 001	May 26, 1999	Jan	CAHN
-----	----------------	-------	-------------	--------------	-----	------

TEMOVATE

AB1	+	FOUGERA PHARMS	0.05%	N019322 001	Dec 27, 1985	Jan	CAHN
-----	---	----------------	-------	-------------	--------------	-----	------

GEL; TOPICAL

CLOBETASOL PROPIONATE

AB	FOUGERA PHARMS	0.05%	A075368 001	Feb 15, 2000	Jan	CAHN
----	----------------	-------	-------------	--------------	-----	------

TEMOVATE

AB	+	FOUGERA PHARMS	0.05%	N020337 001	Apr 29, 1994	Jan	CAHN
----	---	----------------	-------	-------------	--------------	-----	------

		LOTION; TOPICAL					
		CLOBETASOL PROPIONATE					
>A>	AB	TARO	0.05%	A200302	001	Jul 02, 2012	Jun NEWA
		OINTMENT; TOPICAL					
		CLOBETASOL PROPIONATE					
	AB	FOUGERA PHARMS	0.05%	A074407	001	Feb 23, 1996	Jan CAHN
		TEMOVATE					
	AB	+ FOUGERA PHARMS	0.05%	N019323	001	Dec 27, 1985	Jan CAHN
		SOLUTION; TOPICAL					
		CLOBETASOL PROPIONATE					
>D>		@ ACTAVIS MID ATLANTIC	0.05%	A074331	001	Dec 15, 1995	Jun CAHN
	AT	FOUGERA PHARMS	0.05%	A075391	001	Feb 08, 1999	Jan CAHN
>A>		@ G AND W LABS INC	0.05%	A074331	001	Dec 15, 1995	Jun CAHN
		TEMOVATE					
	AT	+ FOUGERA PHARMS	0.05%	N019966	001	Feb 22, 1990	Jan CAHN

CLONIDINE HYDROCHLORIDE

		INJECTABLE; INJECTION					
		DURACLON					
	AP	MYLAN INSTITUTIONAL	1 MG/10 ML (0.1 MG/ML)	N020615	001	Oct 02, 1996	Feb CAHN
	AP	+	5 MG/10 ML (0.5 MG/ML)	N020615	002	Apr 27, 1999	Feb CAHN
		TABLET, EXTENDED RELEASE; ORAL					
		KAPVAY					
		SHIONOGI INC	0.2MG	N022331	004	Sep 28, 2010	May CMFD

CLOPIDOGREL BISULFATE

		TABLET; ORAL					
		CLOPIDOGREL BISULFATE					
	AB	APOTEX INC	EQ 75MG BASE	A076274	001	May 17, 2012	Apr NEWA
	AB	AUROBINDO PHARMA LTD	EQ 75MG BASE	A090540	001	May 17, 2012	Apr NEWA
	AB	DR REDDYS LABS INC	EQ 75MG BASE	A076273	001	Jan 14, 2008	Mar CMFD
	AB	DR REDDYS LABS LTD	EQ 300MG BASE	A091023	001	May 17, 2012	Apr NEWA
	AB	GATE PHARMS	EQ 300MG BASE	A091216	001	May 17, 2012	Apr NEWA
	AB	MYLAN PHARMS INC	EQ 75MG BASE	A077665	001	May 17, 2012	Apr NEWA
	AB		EQ 300MG BASE	A077665	002	May 17, 2012	Apr NEWA
	AB	ROXANE	EQ 75MG BASE	A078004	001	May 17, 2012	Apr NEWA
	AB	SUN PHARMA GLOBAL	EQ 75MG BASE	A090494	001	May 17, 2012	Apr NEWA
	AB	TEVA	EQ 75MG BASE	A076999	001	May 17, 2012	Apr NEWA
	AB	TEVA PHARMS	EQ 300MG BASE	A090625	001	May 17, 2012	Apr NEWA
	AB	TORRENT PHARMS LTD	EQ 75MG BASE	A090844	001	May 17, 2012	Apr NEWA
		PLAVIX					
	AB	SANOFI AVENTIS US	EQ 75MG BASE	N020839	001	Nov 17, 1997	Mar CTEC
	AB	+	EQ 300MG BASE	N020839	002	Sep 20, 2007	Apr CTEC

CLORAZEPATE DIPOTASSIUM

		CAPSULE; ORAL					
		TRANXENE					
		@ LUNDBECK LLC	3.75MG	N017105	001		Mar CAHN
		@	7.5MG	N017105	002		Mar CAHN
		@	15MG	N017105	003		Mar CAHN
		TABLET; ORAL					
		TRANXENE					
	AB	LUNDBECK LLC	3.75MG	N017105	006		Mar CAHN
	AB		7.5MG	N017105	007		Mar CAHN
	AB	+	15MG	N017105	008		Mar CAHN

TABLET; ORAL

TRANXENE SD

@ LUNDBECK LLC

11.25MG

N017105 005

Mar CAHN

@

22.5MG

N017105 004

Mar CAHN

CLOTTRIMAZOLE

CREAM; TOPICAL

CLOTTRIMAZOLE

AB FOUGERA PHARMS

1%

A078338 001 Sep 02, 2008 Jan CAHN

CLOZAPINE

TABLET, ORALLY DISINTEGRATING; ORAL

FAZACLO ODT

>D>	JAZZ	12.5MG	N021590 004	May 30, 2007	Jun	CAHN
		12.5MG	N021590 004	May 30, 2007	Apr	CAHN
>D>		25MG	N021590 001	Feb 10, 2004	Jun	CAHN
		25MG	N021590 001	Feb 10, 2004	Apr	CAHN
>D>	@	50MG	N021590 003	Jun 03, 2005	Jun	CAHN
	@	50MG	N021590 003	Jun 03, 2005	Apr	CAHN
>D>	+	100MG	N021590 002	Feb 10, 2004	Jun	CAHN
	+	100MG	N021590 002	Feb 10, 2004	Apr	CAHN
>D>		150MG	N021590 005	Jul 09, 2010	Jun	CAHN
		150MG	N021590 005	Jul 09, 2010	Apr	CAHN
>D>		200MG	N021590 006	Jul 09, 2010	Jun	CAHN
		200MG	N021590 006	Jul 09, 2010	Apr	CAHN
>A>	JAZZ PHARMS III	12.5MG	N021590 004	May 30, 2007	Jun	CAHN
>A>		25MG	N021590 001	Feb 10, 2004	Jun	CAHN
>A>	@	50MG	N021590 003	Jun 03, 2005	Jun	CAHN
>A>	+	100MG	N021590 002	Feb 10, 2004	Jun	CAHN
>A>		150MG	N021590 005	Jul 09, 2010	Jun	CAHN
>A>		200MG	N021590 006	Jul 09, 2010	Jun	CAHN

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

>A>	AA	TRIS PHARMA INC	10MG/5ML;6.25MG/5ML	A200386 001	Jun 29, 2012	Jun	NEWA
-----	----	-----------------	---------------------	-------------	--------------	-----	------

COPPER

INTRAUTERINE DEVICE; INTRAUTERINE

PARAGARD T 380A

+	TEVA WOMENS	309MG/COPPER	N018680 001	Nov 15, 1984	May	CAHN
---	-------------	--------------	-------------	--------------	-----	------

COSYNTROPIN

INJECTABLE; INJECTION

COSYNTROPIN

>A>	AP	INNOPHARMA INC	0.25MG/VIAL	A202147 001	Jun 29, 2012	Jun	NEWA
-----	----	----------------	-------------	-------------	--------------	-----	------

>D> CROMOLYN SODIUM

>D>	AEROSOL, METERED; INHALATION					
>D>	INTAL					
>A>	@ KING PFIZER	0.8MG/INH	N018887 001	Dec 05, 1985	Jun	DISC
>D>	+ KING PHARMS	0.8MG/INH	N018887 001	Dec 05, 1985	Jun	DISC

CONCENTRATE; ORAL

GASTROCROM

>D>	AA	+	JAZZ PHARMS COMMERCIAL	100MG/5ML	N020479 001	Feb 29, 1996	Jun	CAHN
	AA	+		100MG/5ML	N020479 001	Feb 29, 1996	Mar	CAHN

		CONCENTRATE; ORAL							
		GASTROCROM							
>A>	AA	+	JAZZ PHARMS INTL	100MG/5ML	N020479	001	Feb 29, 1996	Jun	CAHN
<u>CYCLOBENZAPRINE HYDROCHLORIDE</u>									
		TABLET; ORAL							
		CYCLOBENZAPRINE HYDROCHLORIDE							
	AB		PROSAM LABS	5MG	A077291	001	Feb 03, 2006	Feb	CAHN
	AB			10MG	A077209	001	Oct 04, 2005	Feb	CAHN
<u>CYCLOPHOSPHAMIDE</u>									
		INJECTABLE; INJECTION							
		CYTOXAN							
	AP	+	BAXTER HLTHCARE	500MG/VIAL	N012142	003		Apr	CRLD
	AP	+		1GM/VIAL	N012142	004	Aug 30, 1982	Apr	CRLD
	AP	+		2GM/VIAL	N012142	005	Aug 30, 1982	Apr	CRLD
<u>CYCLOSPORINE</u>									
		CAPSULE; ORAL							
		CYCLOSPORINE							
	AB1		WATSON LABS INC	25MG	A065044	002	Dec 20, 2000	May	CAHN
	AB1			100MG	A065044	001	Dec 20, 2000	May	CAHN
<u>CYTARABINE</u>									
		INJECTABLE; INJECTION							
		CYTARABINE							
	AP		ONCO THERAPIES LTD	100MG/ML	A201784	001	Jan 30, 2012	Jan	NEWA
<u>DACTINOMYCIN</u>									
		INJECTABLE; INJECTION							
		COSMEGEN							
	AP	+	LUNDBECK LLC	0.5MG/VIAL	N050682	001		Mar	CAHN
<u>DARUNAVIR ETHANOLATE</u>									
		SUSPENSION; ORAL							
		PREZISTA							
		+	JANSSEN PRODS	EQ 100MG BASE/ML	N202895	001	Dec 16, 2011	Feb	CAHN
		TABLET; ORAL							
		PREZISTA							
			JANSSEN PRODS	EQ 75MG BASE	N021976	004	Dec 18, 2008	Feb	CAHN
				EQ 150MG BASE	N021976	005	Dec 18, 2008	Feb	CAHN
		@		EQ 300MG BASE	N021976	001	Jun 23, 2006	Feb	CAHN
				EQ 400MG BASE	N021976	003	Oct 21, 2008	Feb	CAHN
		+		EQ 600MG BASE	N021976	002	Feb 25, 2008	Feb	CAHN
<u>DESLOMATADINE</u>									
		TABLET; ORAL							
		DESLOMATADINE							
	AB		BELCHER PHARMS	5MG	A078355	001	Apr 19, 2012	Apr	NEWA
	AB		MYLAN PHARMS INC	5MG	A078351	001	Feb 10, 2012	Jan	NEWA
<u>DESMOPRESSIN ACETATE</u>									
		SOLUTION; NASAL							
		DDAVP							
	AB	+	SANOFI AVENTIS US	0.01%	N017922	001		Mar	CFTG

SOLUTION; NASAL

DESMOPRESSIN ACETATE

AB		SUN PHARM INDS	0.01%	A077212	001	Apr 12, 2012	Mar	NEWA
----	--	----------------	-------	---------	-----	--------------	-----	------

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28

MIRCETTE

>A>	AB	+	TEVA BRANDED PHARM	0.15MG,N/A;0.02MG,0.01MG	N020713	001	Apr 22, 1998	Jun	CAHN
-----	----	---	--------------------	--------------------------	---------	-----	--------------	-----	------

>D>	AB	+	TEVA WOMENS	0.15MG,N/A;0.02MG,0.01MG	N020713	001	Apr 22, 1998	Jun	CAHN
-----	----	---	-------------	--------------------------	---------	-----	--------------	-----	------

VIORELE

AB		GLENMARK GENERICS	.15MG,N/A; 0.02MG,0.01MG	A091346	001	Apr 02, 2012	Mar	NEWA
----	--	-------------------	--------------------------	---------	-----	--------------	-----	------

DESONIDE

LOTION; TOPICAL

DESONIDE

AB		FOUGERA PHARMS	0.05%	A075860	001	Mar 19, 2002	Jan	CAHN
----	--	----------------	-------	---------	-----	--------------	-----	------

OINTMENT; TOPICAL

DESONIDE

AB		FOUGERA PHARMS	0.05%	A075751	001	Mar 12, 2001	Jan	CAHN
----	--	----------------	-------	---------	-----	--------------	-----	------

DESOXIMETASONE

CREAM; TOPICAL

DESOXIMETASONE

AB		FOUGERA PHARMS	0.25%	A078369	001	Jun 29, 2010	Jan	CAHN
----	--	----------------	-------	---------	-----	--------------	-----	------

TOPICORT

+	TARO	0.05%	A073210	001	Nov 30, 1990	Apr	CTNA
---	------	-------	---------	-----	--------------	-----	------

+		0.25%	A073193	001	Nov 30, 1990	Apr	CTNA
---	--	-------	---------	-----	--------------	-----	------

@	TARO PHARMS NORTH	0.25%	N017856	001		Apr	DISC
---	-------------------	-------	---------	-----	--	-----	------

TOPICORT LP

@	TARO PHARMS NORTH	0.05%	N018309	001		Apr	DISC
---	-------------------	-------	---------	-----	--	-----	------

GEL; TOPICAL

TOPICORT

AB	+	TARO	0.05%	A074904	001	Jul 14, 1998	Apr	CTNA
----	---	------	-------	---------	-----	--------------	-----	------

@	TARO PHARMS NORTH	0.05%	N018586	001	Mar 29, 1982	Apr	DISC
---	-------------------	-------	---------	-----	--------------	-----	------

OINTMENT; TOPICAL

DESOXIMETASONE

AB	+	TARO	0.25%	A074286	001	Jun 07, 1996	Mar	CRLD
----	---	------	-------	---------	-----	--------------	-----	------

TOPICORT

+	TARO	0.25%	A074286	001	Jun 07, 1996	Apr	CTNA
---	------	-------	---------	-----	--------------	-----	------

@	TARO PHARMS NORTH	0.25%	N018763	001	Sep 30, 1983	Mar	DISC
---	-------------------	-------	---------	-----	--------------	-----	------

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

DEXAMETHASONE SODIUM PHOSPHATE

AP	+	APP PHARMS LLC	EQ 10MG PHOSPHATE/ML	A040572	001	Apr 22, 2005	Feb	CRLD
----	---	----------------	----------------------	---------	-----	--------------	-----	------

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE; INJECTION

TOTECT

>A>	+	APRICUS PHARMS	EQ 500MG BASE/VIAL	N022025	001	Sep 06, 2007	Jun	CAHN
-----	---	----------------	--------------------	---------	-----	--------------	-----	------

>D>	+	TOPOTARGET	EQ 500MG BASE/VIAL	N022025	001	Sep 06, 2007	Jun	CAHN
-----	---	------------	--------------------	---------	-----	--------------	-----	------

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

>A>	AA		TRIS PHARMA INC	15MG/5ML;6.25MG/5ML	A091687	001	Jun 28, 2012	Jun	NEWA
-----	----	--	-----------------	---------------------	---------	-----	--------------	-----	------

DIAZEPAM

INJECTABLE; INJECTION

DIAZEPAM

@ HOSPIRA

5MG/ML

A071584 001 Oct 13, 1987 Apr DISC

DICLOFENAC POTASSIUM

CAPSULE; ORAL

ZIPSOR

>A> + DEPOMED INC 25MG

N022202 001 Jun 16, 2009 Jun CAHN

>D> + XANODYNE PHARM 25MG

N022202 001 Jun 16, 2009 Jun CAHN

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE; ORAL

ARTHROTEC

>D> GD SEARLE LLC 50MG;0.2MG

N020607 001 Dec 24, 1997 Jun CFTG

>A> AB 50MG;0.2MG

N020607 001 Dec 24, 1997 Jun CFTG

>D> + 75MG;0.2MG

N020607 002 Dec 24, 1997 Jun CFTG

>A> AB + 75MG;0.2MG

N020607 002 Dec 24, 1997 Jun CFTG

DICLOFENAC SODIUM AND MISOPROSTOL

>A> AB WATSON LABS INC 50MG;0.2MG

A201089 001 Jul 09, 2012 Jun NEWA

>A> AB 75MG;0.2MG

A201089 002 Jul 09, 2012 Jun NEWA

DIFLORASONE DIACETATE

CREAM; TOPICAL

DIFLORASONE DIACETATE

AB1 + FOUGERA PHARMS 0.05%

A075187 001 Mar 30, 1998 Jan CAHN

BX + 0.05%

A076263 001 Dec 20, 2002 Jan CAHN

OINTMENT; TOPICAL

DIFLORASONE DIACETATE

AB FOUGERA PHARMS 0.05%

A075374 001 Apr 27, 1999 Jan CAHN

DIFLUNISAL

TABLET; ORAL

DIFLUNISAL

AB EMCURE PHARMS USA 500MG

A202845 001 Mar 08, 2012 Feb NEWA

AB + TEVA 500MG

A073673 001 Jul 31, 1992 Feb CTEC

DIGOXIN

INJECTABLE; INJECTION

DIGOXIN

>D> AP HOSPIRA 0.25MG/ML

A040093 001 May 16, 1996 Jun DISC

>A> @ 0.25MG/ML

A040093 001 May 16, 1996 Jun DISC

DILTIAZEM HYDROCHLORIDE

INJECTABLE; INJECTION

DILTIAZEM HYDROCHLORIDE

@ TEVA PARENTERAL

5MG/ML

A074894 001 Aug 26, 1997 Jan DISC

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

BENADRYL

@ MCNEIL CONS

50MG/ML

N006146 002

Mar DISC

BENADRYL PRESERVATIVE FREE

@ MCNEIL CONS

50MG/ML

N009486 001

Mar DISC

INJECTABLE; INJECTION

DIPHENHYDRAMINE HYDROCHLORIDE

AP	+	BAXTER HLTHCARE	50MG/ML	A080817 002		Apr	CRLD
----	---	-----------------	---------	-------------	--	-----	------

DIPYRIDAMOLE

INJECTABLE; INJECTION

DIPYRIDAMOLE

	@	TEVA PARENTERAL	5MG/ML	A074952 001	Nov 26, 1997	Jan	DISC
--	---	-----------------	--------	-------------	--------------	-----	------

TABLET; ORAL

DIPYRIDAMOLE

AB		PROSAM LABS	25MG	A040542 001	Apr 21, 2006	Feb	CAHN
AB			50MG	A040542 002	Apr 21, 2006	Feb	CAHN
AB			75MG	A040542 003	Apr 21, 2006	Feb	CAHN

DISOPYRAMIDE PHOSPHATE

CAPSULE, EXTENDED RELEASE; ORAL

>D> DISOPYRAMIDE PHOSPHATE

>D>	AB	NESHER PHARMS	EQ 150MG BASE	A071200 001	Dec 15, 1987	Jun	DISC
-----	----	---------------	---------------	-------------	--------------	-----	------

>A>		@	EQ 150MG BASE	A071200 001	Dec 15, 1987	Jun	DISC
-----	--	---	---------------	-------------	--------------	-----	------

DIVALPROEX SODIUM

TABLET, EXTENDED RELEASE; ORAL

DIVALPROEX SODIUM

AB		DR REDDYS LABS LTD	EQ 250MG VALPROIC ACID	A090161 001	Mar 15, 2012	Feb	NEWA
AB		REDDYS	EQ 500MG VALPROIC ACID	A090070 001	Mar 12, 2012	Feb	NEWA

DOCETAXEL

INJECTABLE; INJECTION

DOCETAXEL

AP		ACCORD HLTHCARE	20MG/ML (20MG/ML)	N201195 003	Apr 20, 2012	Apr	NEWA
AP			20MG/0.5ML (40MG/ML)	N201195 001	Jun 08, 2011	Jan	CTEC
AP			80MG/4ML (20MG/ML)	N201195 004	Apr 20, 2012	Apr	NEWA
AP			80MG/2ML (40MG/ML)	N201195 002	Jun 08, 2011	Jan	CTEC
			160MG/8ML (20MG/ML)	N201195 005	Apr 20, 2012	Apr	NEWA
AP		APOTEX INC	20MG/0.5ML (40MG/ML)	N022312 001	Jan 11, 2012	Jan	NEWA
AP			80MG/2ML (40MG/ML)	N022312 002	Jan 11, 2012	Jan	NEWA

TAXOTERE

AP	+	SANOFI AVENTIS US	20MG/ML (20MG/ML)	N020449 003	Aug 03, 2010	Apr	CTEC
AP	+		80MG/4ML (20MG/ML)	N020449 004	Aug 02, 2010	Apr	CTEC

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL

DONEPEZIL HYDROCHLORIDE

>D>	AB	HUAHAI US INC	5MG	A200292 001	May 31, 2011	Jun	CAHN
>D>	AB		10MG	A200292 002	May 31, 2011	Jun	CAHN
>A>	AB	PRINSTON INC	5MG	A200292 001	May 31, 2011	Jun	CAHN
>A>	AB		10MG	A200292 002	May 31, 2011	Jun	CAHN

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

COSOPT PF

	+	MERCK SHARP DOHME	EQ 2% BASE;EQ 0.5% BASE	N202667 001	Feb 01, 2012	Feb	NEWA
--	---	-------------------	-------------------------	-------------	--------------	-----	------

DOXAZOSIN MESYLATE

TABLET; ORAL

DOXAZOSIN MESYLATE

@ NESHER PHARMS	EQ 1MG BASE	A075609 001	Oct 18, 2000	Feb	DISC
@	EQ 2MG BASE	A075609 002	Oct 18, 2000	Feb	DISC
@	EQ 4MG BASE	A075609 003	Oct 18, 2000	Feb	DISC
@	EQ 8MG BASE	A075609 004	Oct 18, 2000	Feb	DISC

DOXEPIN HYDROCHLORIDE

CREAM; TOPICAL

ZONALON

+ FOUGERA PHARMS	5%	N020126 001	Apr 01, 1994	Jan	CAHN
------------------	----	-------------	--------------	-----	------

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

DOXORUBICIN HYDROCHLORIDE

AP ONCO THERAPIES LTD	2MG/ML	A200901 001	Feb 14, 2012	Jan	NEWA
AP SUN PHARM INDS	2MG/ML	A091418 001	Feb 15, 2012	Jan	NEWA

INJECTABLE, LIPOSOMAL; INJECTION

DOXIL

+ JANSSEN R AND D	20MG/10ML (2MG/ML)	N050718 001	Nov 17, 1995	Jan	CAHN
+	50MG/25ML (2MG/ML)	N050718 002	Jun 13, 2000	Jan	CAHN

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

AB MYLAN PHARMS INC	EQ 150MG BASE	A202778 001	Jun 08, 2012	May	NEWA
@ SANDOZ INC	EQ 50MG BASE	A065032 001	Jun 30, 2000	Mar	DISC
@	EQ 100MG BASE	A065032 002	Jun 30, 2000	Mar	DISC

TABLET; ORAL

DOXYCYCLINE

@ SANDOZ INC	EQ 50MG BASE	A065353 001	Nov 27, 2006	Mar	DISC
@	EQ 75MG BASE	A065353 002	Nov 27, 2006	Mar	DISC
@	EQ 100MG BASE	A065353 003	Nov 27, 2006	Mar	DISC

DOXYCYCLINE HYCLATE

TABLET; ORAL

DOXYCYCLINE HYCLATE

AB LARKEN LABS	EQ 20MG BASE	A065287 001	Feb 28, 2006	Apr	CMFD
----------------	--------------	-------------	--------------	-----	------

TABLET, DELAYED RELEASE; ORAL

DORYX

AB + MAYNE PHARMA	EQ 150MG BASE	N050795 003	Jun 20, 2008	Jan	CTEC
-------------------	---------------	-------------	--------------	-----	------

DOXYCYCLINE HYCLATE

AB MYLAN PHARMS INC	EQ 150MG BASE	A091052 001	Feb 08, 2012	Jan	NEWA
---------------------	---------------	-------------	--------------	-----	------

DROSPIRENONE; ESTRADIOL

TABLET; ORAL

ANGELIQ

BAYER HLTHCARE	0.25MG;0.5MG	N021355 001	Feb 29, 2012	Feb	NEWA
----------------	--------------	-------------	--------------	-----	------

ECONAZOLE NITRATE

CREAM; TOPICAL

ECONAZOLE NITRATE

AB + FOUGERA PHARMS	1%	A076075 001	Nov 26, 2002	Jan	CAHN
---------------------	----	-------------	--------------	-----	------

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

COMPLERA

+	GILEAD SCIENCES INC	200MG;EQ 25MG BASE;300MG	N202123	001	Aug 10, 2011	Apr	CAIN
---	---------------------	--------------------------	---------	-----	--------------	-----	------

ENALAPRIL MALEATE

TABLET; ORAL

ENALAPRIL MALEATE

@	SANDOZ INC	2.5MG	A075621	001	Aug 22, 2000	Feb	DISC
@		2.5MG	A075496	001	Aug 22, 2000	Jan	DISC
@		5MG	A075621	002	Aug 22, 2000	Feb	DISC
@		5MG	A075496	002	Aug 22, 2000	Jan	DISC
@		10MG	A075621	003	Aug 22, 2000	Feb	DISC
@		10MG	A075459	001	Aug 22, 2000	Jan	DISC
@		20MG	A075621	004	Aug 22, 2000	Feb	DISC
@		20MG	A075459	002	Aug 22, 2000	Jan	DISC

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

@	SANDOZ INC	5MG;12.5MG	A076116	001	Sep 19, 2001	Mar	DISC
@		10MG;25MG	A076116	002	Sep 19, 2001	Mar	DISC

ENTACAPONE

TABLET; ORAL

COMTAN

+	ORION PHARMA	200MG	N020796	001	Oct 19, 1999	May	CAHN
---	--------------	-------	---------	-----	--------------	-----	------

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

EPINASTINE HYDROCHLORIDE

AT	LUITPOLD	0.05%	A090951	001	Oct 31, 2011	Mar	CAHN
----	----------	-------	---------	-----	--------------	-----	------

EPINEPHRINE

INJECTABLE; IM-SC

ADRENALINE

BX	+	COREPHARMA	EQ 0.15MG /DELIVERY	N020800	003	Nov 25, 2009	Mar	CAHN
BX	+		EQ 0.3MG /DELIVERY	N020800	004	Nov 25, 2009	Mar	CAHN
		TWINJECT 0.15						
BX	+	COREPHARMA	EQ 0.15MG /DELIVERY	N020800	002	May 28, 2004	Mar	CAHN
		TWINJECT 0.3						
BX	+	COREPHARMA	EQ 0.3MG /DELIVERY	N020800	001	May 30, 2003	Mar	CAHN

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

OCTOCAINE

AP	+	SEPTODONT	0.01MG/ML;2%	A084048	001		May	CRLD
		XYLOCAINE DENTAL WITH EPINEPHRINE						
	@	DENTSPLY PHARM	0.01MG/ML;2%	N021381	001		May	DISC
	@		0.02MG/ML;2%	N021381	002		May	DISC

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

EPIRUBICIN HYDROCHLORIDE

AP		CIPLA LTD	50MG/25ML (2MG/ML)	A065361	001	Oct 22, 2007	Mar	CAHN
----	--	-----------	--------------------	---------	-----	--------------	-----	------

INJECTABLE; INJECTIONEPIRUBICIN HYDROCHLORIDE

AP	CIPLA LTD	200MG/100ML (2MG/ML)	A065361	002	Oct 22, 2007	Mar	CAHN
AP	HISUN PHARM HANGZHOU	50MG/25ML (2MG/ML)	A090075	001	Mar 25, 2010	Mar	CAHN
AP		200MG/100ML (2MG/ML)	A090075	002	Mar 25, 2010	Mar	CAHN
AP	ONCO THERAPIES LTD	50MG/25ML (2MG/ML)	A091599	001	Mar 12, 2012	Mar	NEWA
AP		200MG/100ML (2MG/ML)	A091599	002	Mar 12, 2012	Mar	NEWA

EPOPROSTENOL SODIUMINJECTABLE; INJECTIONVELETRI

>A>	ACTELION PHARMS LTD	EQ 0.5MG BASE/VIAL	N022260	002	Jun 28, 2012	Jun	NEWA
	+	EQ 1.5MG BASE/VIAL	N022260	001	Jun 27, 2008	May	CAHN

ERYTHROMYCINCAPSULE, DELAYED REL PELLETS; ORALERYC

>D>	AB	WARNER CHILCOTT	250MG	A062338	001		Jun	CAHN
>A>	AB	WARNER CHILCOTT LLC	250MG	A062338	001		Jun	CAHN

GEL; TOPICALERYTHROMYCIN

AT		FOUGERA PHARMS	2%	A064184	001	Sep 30, 1997	Jan	CAHN
----	--	----------------	----	---------	-----	--------------	-----	------

SOLUTION; TOPICALC-SOLVE-2

AT		FOUGERA PHARMS	2%	A062468	001	Jul 03, 1985	Jan	CMFD
----	--	----------------	----	---------	-----	--------------	-----	------

SWAB; TOPICALERYCETTE

@ JOHNSON AND JOHNSON

2%

N050594 001 Feb 15, 1985 Apr CAHN

ERYTHROMYCIN

AT	+	FOUGERA PHARMS	2%	A065320	001	Jul 25, 2006	Jan	CAHN
----	---	----------------	----	---------	-----	--------------	-----	------

ESCITALOPRAM OXALATESOLUTION; ORALESCITALOPRAM OXALATE

AA		AMNEAL PHARMS	EQ 5MG BASE/5ML	A202227	001	Mar 14, 2012	Feb	NEWA
AA		AUROBINDO PHARMA LTD	EQ 5MG BASE/5ML	A079062	001	Apr 02, 2012	Mar	NEWA
AA		HETERO LABS LTD III	EQ 5MG BASE/5ML	A202221	001	Jun 12, 2012	May	NEWA
AA		TARO	EQ 5MG BASE/5ML	A079121	001	May 03, 2012	Apr	NEWA

LEXAPRO

AA	+	FOREST LABS	EQ 5MG BASE/5ML	N021365	001	Nov 27, 2002	Feb	CFTG
----	---	-------------	-----------------	---------	-----	--------------	-----	------

TABLET; ORALESCITALOPRAM OXALATE

AB		IVAX SUB TEVA PHARMS	EQ 5MG BASE	A076765	001	Mar 14, 2012	Feb	NEWA
AB			EQ 10MG BASE	A076765	002	Mar 14, 2012	Feb	NEWA
AB			EQ 20MG BASE	A076765	003	Mar 14, 2012	Feb	NEWA

LEXAPRO

AB		FOREST LABS	EQ 5MG BASE	N021323	001	Aug 14, 2002	Feb	CFTG
AB			EQ 10MG BASE	N021323	002	Aug 14, 2002	Feb	CFTG
AB	+		EQ 20MG BASE	N021323	003	Aug 14, 2002	Feb	CFTG

ESMOLOL HYDROCHLORIDEINJECTABLE; INJECTIONBREVIBLOC

>A>		@ BAXTER HLTHCARE	10MG/ML	N019386	003	Aug 15, 1988	Jun	CAHN
>A>	AP	+	10MG/ML	N019386	006	Feb 25, 2003	Jun	CAHN
>A>		@	20MG/ML	N019386	007	May 28, 2003	Jun	CAHN

INJECTABLE; INJECTION

BREVIBLOC

>D>	AP	+	BAXTER HLTHCARE CORP	10MG/ML	N019386	006	Feb 25, 2003	Jun	CAHN
>D>		@		10MG/ML	N019386	003	Aug 15, 1988	Jun	CAHN
>D>		@		20MG/ML	N019386	007	May 28, 2003	Jun	CAHN
BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER									
>A>		+	BAXTER HLTHCARE	2GM/100ML	N019386	005	Jan 27, 2003	Jun	CAHN
>D>		+	BAXTER HLTHCARE CORP	2GM/100ML	N019386	005	Jan 27, 2003	Jun	CAHN
BREVIBLOC IN PLASTIC CONTAINER									
>A>		+	BAXTER HLTHCARE	1GM/100ML	N019386	004	Feb 16, 2001	Jun	CAHN
>D>		+	BAXTER HLTHCARE CORP	1GM/100ML	N019386	004	Feb 16, 2001	Jun	CAHN

ESOMEPRAZOLE MAGNESIUM

FOR SUSPENSION, DELAYED RELEASE; ORAL

NEXIUM

>A>			ASTRAZENECA	EQ 2.5MG BASE/PACKET	N021957	003	Dec 15, 2011	Jun	NEWA
>A>				EQ 5MG BASE/PACKET	N021957	004	Dec 15, 2011	Jun	NEWA

ESTRADIOL

CREAM; VAGINAL

ESTRACE

>D>		+	WARNER CHILCOTT	0.01%	A086069	001	Jan 31, 1984	Jun	CAHN
>A>		+	WARNER CHILCOTT US	0.01%	A086069	001	Jan 31, 1984	Jun	CAHN

GEL, METERED; TRANSDERMAL

ELESTRIN

>D>		+	AZUR PHARMA II	0.06% (0.87GM/ACTIVATION)	N021813	001	Dec 15, 2006	Jun	CAHN
>A>		+	JAZZ PHARMS COMMERCL	0.06% (0.87GM/ACTIVATION)	N021813	001	Dec 15, 2006	Jun	CAHN

ESTRADIOL ACETATE

INSERT, EXTENDED RELEASE; VAGINAL

FEMRING

			WARNER IRELAND	EQ 0.05MG BASE/24HR	N021367	001	Mar 20, 2003	May	CAHN
		+		EQ 0.1MG BASE/24HR	N021367	002	Mar 20, 2003	May	CAHN

TABLET; ORAL

FEMTRACE

>D>			WARNER CHILCOTT	0.45MG	N021633	001	Aug 20, 2004	Jun	CAHN
>D>				0.9MG	N021633	002	Aug 20, 2004	Jun	CAHN
>D>		+		1.8MG	N021633	003	Aug 20, 2004	Jun	CAHN
>A>			WARNER CHILCOTT LLC	0.45MG	N021633	001	Aug 20, 2004	Jun	CAHN
>A>				0.9MG	N021633	002	Aug 20, 2004	Jun	CAHN
>A>		+		1.8MG	N021633	003	Aug 20, 2004	Jun	CAHN

ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

ESTRADIOL AND NORETHINDRONE ACETATE

AB			TEVA PHARMS USA	0.5MG;0.1MG	A200747	001	Mar 08, 2012	Feb	NEWA
----	--	--	-----------------	-------------	---------	-----	--------------	-----	------

ESTROGENS, CONJUGATED SYNTHETIC A

TABLET; ORAL

CENESTIN

>A>			TEVA BRANDED PHARM	0.3MG	N020992	001	Jun 21, 2002	Jun	CAHN
>A>				0.45MG	N020992	005	Feb 05, 2004	Jun	CAHN
>A>				0.625MG	N020992	002	Mar 24, 1999	Jun	CAHN
>A>				0.9MG	N020992	003	Mar 24, 1999	Jun	CAHN
>A>		+		1.25MG	N020992	004	Mar 13, 2000	Jun	CAHN
>D>			TEVA WOMENS	0.3MG	N020992	001	Jun 21, 2002	Jun	CAHN

TABLET; ORAL

CENESTIN

>D>		TEVA WOMENS	0.45MG	N020992 005	Feb 05, 2004	Jun	CAHN
>D>			0.625MG	N020992 002	Mar 24, 1999	Jun	CAHN
>D>			0.9MG	N020992 003	Mar 24, 1999	Jun	CAHN
>D>	+		1.25MG	N020992 004	Mar 13, 2000	Jun	CAHN

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL

LEVONORGESTREL AND ETHINYL ESTRADIOL

	+	WATSON LABS	0.02MG;0.09MG	A079218 001	Jun 06, 2011	May	CRLD
		LOSEASONIQUE					
>A>	AB	TEVA BRANDED PHARM	0.02MG,0.01MG;0.1MG,N/A	N022262 001	Oct 24, 2008	Jun	CAHN
>D>	AB	TEVA WOMENS	0.02MG,0.01MG;0.1MG,N/A	N022262 001	Oct 24, 2008	Jun	CAHN
		LYBREL					
		@ WYETH PHARMS INC	0.02MG;0.09MG	N021864 001	May 22, 2007	May	DISC
		PREVEN EMERGENCY CONTRACEPTIVE KIT					
>D>		@ DURAMED	0.05MG;0.25MG	N020946 001	Sep 01, 1998	Jun	CAHN
>A>		@ TEVA BRANDED PHARM	0.05MG;0.25MG	N020946 001	Sep 01, 1998	Jun	CAHN
		SEASONIQUE					
>A>	AB	+ TEVA BRANDED PHARM	0.03MG,0.01MG;0.15MG,N/A	N021840 001	May 25, 2006	Jun	CAHN
>D>	AB	+ TEVA WOMENS	0.03MG,0.01MG;0.15MG,N/A	N021840 001	May 25, 2006	Jun	CAHN

TABLET; ORAL-21

NORDETTE-21

>D>		@ DURAMED RES	0.03MG;0.15MG	N018668 001	May 10, 1982	Jun	CAHN
>A>		@ TEVA BRANDED PHARM	0.03MG;0.15MG	N018668 001	May 10, 1982	Jun	CAHN

TABLET; ORAL-28

FALMINA

AB1		NOVAST LABS LTD	0.02MG;0.1MG	A090721 001	Mar 28, 2012	Mar	NEWA
		MARLISSA					
AB		GLENMARK GENERICS	0.03MG;0.15MG	A091452 001	Feb 29, 2012	Feb	NEWA
		MYZILRA					
AB		VINTAGE PHARMS	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	A077502 001	Nov 23, 2011	May	CDFR
		NORDETTE-28					
>D>	AB	+ DURAMED	0.03MG;0.15MG	N018782 001	Jul 21, 1982	Jun	CAHN
>A>	AB	+ TEVA BRANDED PHARM	0.03MG;0.15MG	N018782 001	Jul 21, 1982	Jun	CAHN

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE; TRANSDERMAL

ORTHO EVRA

>D>	+	JANSSEN PHARMS	0.02MG/24HR;0.15MG/24HR	N021180 001	Nov 20, 2001	Jun	CPOT
>A>	+		0.75MG;6MG	N021180 001	Nov 20, 2001	Jun	CPOT

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28

ALYACEN 1/35

AB		GLENMARK GENERICS	0.035MG;1MG	A091634 001	Jan 19, 2012	Jan	NEWA
		ALYACEN 7/7/7					
AB		GLENMARK GENERICS	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	A091636 001	Jan 19, 2012	Jan	NEWA
		OVCON-35					
>D>	AB	+ WARNER CHILCOTT	0.035MG;0.4MG	N017716 001		Jun	CAHN
>A>	AB	+ WARNER CHILCOTT LLC	0.035MG;0.4MG	N017716 001		Jun	CAHN
		OVCON-50					
>D>	+	WARNER CHILCOTT	0.05MG;1MG	N017576 001		Jun	CAHN
>A>	+	WARNER CHILCOTT LLC	0.05MG;1MG	N017576 001		Jun	CAHN

TABLET; ORAL-28

WERA

AB	NOVAST LABS LTD	0.035MG;0.5MG	A091204 001	Mar 27, 2012	Mar	NEWA
----	-----------------	---------------	-------------	--------------	-----	------

TABLET, CHEWABLE; ORAL

FEMCON FE

>D>	AB	+	WARNER CHILCOTT	0.035MG;0.4MG	N021490 001	Nov 14, 2003	Jun	CAHN
-----	----	---	-----------------	---------------	-------------	--------------	-----	------

>A>	AB	+	WARNER CHILCOTT LLC	0.035MG;0.4MG	N021490 001	Nov 14, 2003	Jun	CAHN
-----	----	---	---------------------	---------------	-------------	--------------	-----	------

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

FEMHRT

>D>			WARNER CHILCOTT	0.0025MG;0.5MG	N021065 001	Jan 14, 2005	Jun	CAHN
-----	--	--	-----------------	----------------	-------------	--------------	-----	------

>D>	AB	+		0.005MG;1MG	N021065 002	Oct 15, 1999	Jun	CAHN
-----	----	---	--	-------------	-------------	--------------	-----	------

>A>			WARNER CHILCOTT LLC	0.0025MG;0.5MG	N021065 001	Jan 14, 2005	Jun	CAHN
-----	--	--	---------------------	----------------	-------------	--------------	-----	------

>A>	AB	+		0.005MG;1MG	N021065 002	Oct 15, 1999	Jun	CAHN
-----	----	---	--	-------------	-------------	--------------	-----	------

LO LOESTRIN FE

>D>		+	WARNER CHILCOTT CO	0.01MG,0.01MG;1MG,N/A	N022501 001	Oct 21, 2010	Jun	CAHN
-----	--	---	--------------------	-----------------------	-------------	--------------	-----	------

>A>		+	WARNER CHILCOTT LLC	0.01MG,0.01MG;1MG,N/A	N022501 001	Oct 21, 2010	Jun	CAHN
-----	--	---	---------------------	-----------------------	-------------	--------------	-----	------

TABLET; ORAL-21

ESTROSTEP 21

>D>		@	WARNER CHILCOTT	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	N020130 001	Oct 09, 1996	Jun	CAHN
-----	--	---	-----------------	-----------------------------------	-------------	--------------	-----	------

>A>		@	WARNER CHILCOTT LLC	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	N020130 001	Oct 09, 1996	Jun	CAHN
-----	--	---	---------------------	-----------------------------------	-------------	--------------	-----	------

LOESTRIN 21 1.5/30

>D>	AB		WARNER CHILCOTT	0.03MG;1.5MG	N017875 001		Jun	CAHN
-----	----	--	-----------------	--------------	-------------	--	-----	------

>A>	AB		WARNER CHILCOTT LLC	0.03MG;1.5MG	N017875 001		Jun	CAHN
-----	----	--	---------------------	--------------	-------------	--	-----	------

LOESTRIN 21 1/20

>D>	AB		WARNER CHILCOTT	0.02MG;1MG	N017876 001		Jun	CAHN
-----	----	--	-----------------	------------	-------------	--	-----	------

>A>	AB		WARNER CHILCOTT LLC	0.02MG;1MG	N017876 001		Jun	CAHN
-----	----	--	---------------------	------------	-------------	--	-----	------

TABLET; ORAL-28

ESTROSTEP FE

>D>	AB	+	WARNER CHILCOTT	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	N020130 002	Oct 09, 1996	Jun	CAHN
-----	----	---	-----------------	-----------------------------------	-------------	--------------	-----	------

>A>	AB	+	WARNER CHILCOTT LLC	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	N020130 002	Oct 09, 1996	Jun	CAHN
-----	----	---	---------------------	-----------------------------------	-------------	--------------	-----	------

LOESTRIN FE 1.5/30

>D>	AB	+	WARNER CHILCOTT	0.03MG;1.5MG	N017355 001		Jun	CAHN
-----	----	---	-----------------	--------------	-------------	--	-----	------

>A>	AB	+	WARNER CHILCOTT LLC	0.03MG;1.5MG	N017355 001		Jun	CAHN
-----	----	---	---------------------	--------------	-------------	--	-----	------

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28

MONO-LINYAH

AB	NOVAST LABS LTD	0.035MG;0.25MG	A090523 001	May 23, 2012	May	NEWA
----	-----------------	----------------	-------------	--------------	-----	------

NORGESTIMATE AND ETHINYL ESTRADIOL

AB	GLENMARK GENERICS	0.035MG;0.25MG	A200538 001	Apr 05, 2012	Mar	NEWA
----	-------------------	----------------	-------------	--------------	-----	------

>A>	AB	LUPIN PHARMS	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	A200541 001	Jun 25, 2012	Jun	NEWA
-----	----	--------------	---	-------------	--------------	-----	------

TRI-LINYAH

AB	NOVAST LABS LTD	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	A090524 001	May 30, 2012	May	NEWA
----	-----------------	---	-------------	--------------	-----	------

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-28

ELINEST

AB	NOVAST LABS LTD	0.03MG;0.3MG	A091105 001	Mar 28, 2012	Mar	NEWA
----	-----------------	--------------	-------------	--------------	-----	------

ETODOLAC

TABLET; ORAL

ETODOLAC

AB	PROSAM LABS	400MG	A074819 001	Feb 28, 1997	Feb	CMFD
----	-------------	-------	-------------	--------------	-----	------

TABLET; ORAL									
ETODOLAC									
AB	PROSAM LABS	500MG		A074819	002	Apr 28,	1998	Feb	CMFD
<u>ETOMIDATE</u>									
INJECTABLE; INJECTION									
ETOMIDATE									
>A>	AP	MYLAN INSTITUTIONAL	2MG/ML		A091297	001	Jun 20,	2012	Jun NEWA
<u>ETOPOSID</u>									
CAPSULE; ORAL									
VEPESID									
	@ CORDEN PHARMA	50MG		N019557	001	Dec 30,	1986	Feb	CAHN
	@	100MG		N019557	002	Dec 30,	1986	Feb	CAHN
INJECTABLE; INJECTION									
ETOPOSID									
AP	+	APP PHARMS LLC	20MG/ML		A074983	001	Sep 30,	1998	Mar CRLD
AP		BEDFORD	20MG/ML		A074290	001	Jul 17,	1995	Mar CRLD
VEPESID									
	@ CORDEN PHARMA	20MG/ML		N018768	001	Nov 10,	1983	Feb	CAHN
<u>ETRAVIRINE</u>									
TABLET; ORAL									
INTELENCE									
	JANSSEN R AND D	25MG		N022187	003	Mar 26,	2012	Mar	NEWA
		100MG		N022187	001	Jan 18,	2008	Feb	CAHN
	+	200MG		N022187	002	Dec 22,	2010	Feb	CAHN
<u>EVEROLIMUS</u>									
TABLET; ORAL									
AFINITOR									
	NOVARTIS	7.5MG		N022334	004	Mar 30,	2012	Apr	NEWA
<u>EXENATIDE SYNTHETIC</u>									
FOR SUSPENSION, EXTENDED RELEASE; SUBCUTANEOUS									
BYDUREON									
	+	AMYLIN	2MG/VIAL		N022200	001	Jan 27,	2012	Jan NEWA
<u>EZETIMIBE</u>									
TABLET; ORAL									
ZETIA									
	+	MSD INTL GMBH	10MG		N021445	001	Oct 25,	2002	Feb CAHN
	+	MSP SINGAPORE	10MG		N021445	001	Oct 25,	2002	Jan CAHN
<u>EZETIMIBE; SIMVASTATIN</u>									
TABLET; ORAL									
VYTORIN									
	MSD INTL	10MG;10MG		N021687	001	Jul 23,	2004	Jan	CAHN
		10MG;20MG		N021687	002	Jul 23,	2004	Jan	CAHN
		10MG;40MG		N021687	003	Jul 23,	2004	Jan	CAHN
	+	10MG;80MG		N021687	004	Jul 23,	2004	Jan	CAHN
<u>EZOGABINE</u>									
TABLET; ORAL									
POTIGA									
	GLAXOSMITHKLINE	50MG		N022345	001	Jun 10,	2011	May	CAHN

TABLET; ORAL

POTIGA

GLAXOSMITHKLINE

200MG

N022345 002 Jun 10, 2011 May CAHN

300MG

N022345 003 Jun 10, 2011 May CAHN

+

400MG

N022345 004 Jun 10, 2011 May CAHN

FAMCICLOVIR

TABLET; ORAL

FAMCICLOVIR

AB MACLEODS PHARMS LTD

125MG

A201022 001 Jan 12, 2012 Jan NEWA

AB

250MG

A201022 002 Jan 12, 2012 Jan NEWA

AB

500MG

A201022 003 Jan 12, 2012 Jan NEWA

FAMOTIDINE

TABLET; ORAL

PEPCID

AB MARATHON PHARMS

20MG

N019462 001 Oct 15, 1986 Jan CAHN

AB

+

40MG

N019462 002 Oct 15, 1986 Jan CAHN

TABLET, ORALLY DISINTEGRATING; ORAL

FLUXID

@ UCB INC

20MG

N021712 001 Sep 24, 2004 Jan CAHN

@

40MG

N021712 002 Sep 24, 2004 Jan CAHN

FEBUXOSTAT

TABLET; ORAL

ULORIC

TAKEDA PHARMS USA

40MG

N021856 001 Feb 13, 2009 Apr CAHN

+

80MG

N021856 002 Feb 13, 2009 Apr CAHN

FENOFIBRATE

CAPSULE; ORAL

ANTARA (MICRONIZED)

AB LUPIN ATLANTIS

43MG

N021695 001 Nov 30, 2004 Feb CFTG

AB

+

130MG

N021695 003 Nov 30, 2004 Feb CFTG

FENOFIBRATE (MICRONIZED)

AB DR REDDYS LABS SA

43MG

A090859 001 Mar 01, 2012 Feb NEWA

AB

130MG

A090859 002 Mar 01, 2012 Feb NEWA

TABLET; ORAL

FENOFIBRATE

AB IMPAX LABS

160MG

A076509 002 Mar 26, 2008 May CRLD

AB

+

160MG

A076509 002 Mar 26, 2008 Mar CRLD

AB

TEVA

54MG

A076433 001 May 13, 2005 May CMFD

@

54MG

A076433 001 May 13, 2005 Mar DISC

AB

+

160MG

A076433 002 May 13, 2005 May CMFD

@

160MG

A076433 002 May 13, 2005 Mar DISC

AB VALEANT INTL

48MG

A090715 001 Apr 05, 2012 Mar NEWA

AB

145MG

A090715 002 Apr 05, 2012 Mar NEWA

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL

FENTANYL-100

>A> AB AVEVA

100MCG/HR

A077449 004 Oct 20, 2008 Jun CAHN

>D> AB TEVA PHARMS

100MCG/HR

A077449 004 Oct 20, 2008 Jun CAHN

FENTANYL-25

>A> AB AVEVA

25MCG/HR

A077449 001 Oct 20, 2008 Jun CAHN

>D> AB TEVA PHARMS

25MCG/HR

A077449 001 Oct 20, 2008 Jun CAHN

FILM, EXTENDED RELEASE; TRANSDERMAL

FENTANYL-50

>A>	AB	AVEVA	50MCG/HR	A077449	002	Oct 20,	2008	Jun	CAHN
>D>	AB	TEVA PHARMS	50MCG/HR	A077449	002	Oct 20,	2008	Jun	CAHN

FENTANYL-75

>A>	AB	AVEVA	75MCG/HR	A077449	003	Oct 20,	2008	Jun	CAHN
>D>	AB	TEVA PHARMS	75MCG/HR	A077449	003	Oct 20,	2008	Jun	CAHN

SPRAY; SUBLINGUAL

SUBSYS

		INSYS THERAP	0.1MG	N202788	001	Jan 04,	2012	Mar	CPOT
			0.1MCG	N202788	001	Jan 04,	2012	Jan	NEWA
			0.2MG	N202788	002	Jan 04,	2012	Mar	CPOT
			0.2MCG	N202788	002	Jan 04,	2012	Jan	NEWA
	+		0.4MG	N202788	003	Jan 04,	2012	Mar	CPOT
	+		0.4MCG	N202788	003	Jan 04,	2012	Jan	NEWA
			0.6MG	N202788	004	Jan 04,	2012	Mar	CPOT
			0.6MCG	N202788	004	Jan 04,	2012	Jan	NEWA
			0.8MG	N202788	005	Jan 04,	2012	Mar	CPOT
			0.8MCG	N202788	005	Jan 04,	2012	Jan	NEWA

FENTANYL CITRATE

SPRAY, METERED; NASAL

LAZANDA

		ARCHIMEDES	EQ 0.1MG BASE	N022569	001	Jun 30,	2011	Jan	CPOT
	+		EQ 0.4MG BASE	N022569	002	Jun 30,	2011	Jan	CPOT

TROCHE/LOZENGE; TRANSMUCOSAL

FENTANYL CITRATE

AB	PAR PHARM	EQ 0.2MG BASE	A077312	001	Oct 30,	2009	Feb	CAHN
AB		EQ 0.4MG BASE	A077312	002	Oct 30,	2009	Feb	CAHN
AB		EQ 0.6MG BASE	A077312	003	Oct 30,	2009	Feb	CAHN
AB		EQ 0.8MG BASE	A077312	004	Oct 30,	2009	Feb	CAHN
AB		EQ 1.2MG BASE	A077312	005	Oct 30,	2009	Feb	CAHN
AB		EQ 1.6MG BASE	A077312	006	Oct 30,	2009	Feb	CAHN

>D> FERUMOXIDES

>D> INJECTABLE; INJECTION

>D> FERIDEX I.V.

>D>	+	AMAG PHARMS INC	EQ 11.2MG IRON/ML	N020416	001	Aug 30,	1996	Jun	DISC
>A>	@		EQ 11.2MG IRON/ML	N020416	001	Aug 30,	1996	Jun	DISC

FLORBETAPIR F-18

SOLUTION; INTRAVENOUS

AMYVID

>D>	+	AVID RADIOPHARMS INC	10-50ML (13.5-51CMI/ML)	N202008	003	Apr 06,	2012	Jun	CPOT
>A>	+		10-50ML (13.5-51MCI/ML)	N202008	003	Apr 06,	2012	Jun	CPOT
	+		10-30ML (13.5-51MCI/ML)	N202008	002	Apr 06,	2012	Apr	NEWA
	+		10-50ML (13.5-51CMI/ML)	N202008	003	Apr 06,	2012	Apr	NEWA
	+		10ML (13.5-51MCI/ML)	N202008	001	Apr 06,	2012	Apr	NEWA

FLUCONAZOLE

INJECTABLE; INJECTION

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	HIKMA FARMACEUTICA	200MG/100ML (2MG/ML)	A078764	001	Jan 30,	2012	Jan	NEWA
AP		400MG/200ML (2MG/ML)	A078764	002	Jan 30,	2012	Jan	NEWA

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	HIKMA FARMACEUTICA	200MG/100ML (2MG/ML)	A078698	001	Jan 30,	2012	Jan	NEWA
----	--------------------	----------------------	---------	-----	---------	------	-----	------

INJECTABLE; INJECTION						
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
AP	HIKMA FARMACEUTICA	400MG/200ML (2MG/ML)	A078698 002	Jan 30, 2012	Jan	NEWA
TABLET; ORAL						
FLUCONAZOLE						
	@ PLIVA	50MG	A076424 001	Jul 29, 2004	Feb	DISC
	@	100MG	A076424 002	Jul 29, 2004	Feb	DISC
	@	150MG	A076424 003	Jul 29, 2004	Feb	DISC
	@	200MG	A076424 004	Jul 29, 2004	Feb	DISC
	@ RANBAXY LABS LTD	50MG	A076386 001	Jul 29, 2004	Apr	DISC
	@	100MG	A076386 002	Jul 29, 2004	Apr	DISC
	@	150MG	A076386 003	Jul 29, 2004	Apr	DISC
	@	200MG	A076386 004	Jul 29, 2004	Apr	DISC
FLUDARABINE PHOSPHATE						
INJECTABLE; INJECTION						
FLUDARA						
	@ GENZYME CORP	50MG/VIAL	N020038 001	Apr 18, 1991	Mar	DISC
FLUDARABINE PHOSPHATE						
AP	+ HOSPIRA	50MG/VIAL	A077790 001	Apr 06, 2007	Mar	CRLD
TABLET; ORAL						
OFORTA						
	@ SANOFI AVENTIS US	10MG	N022273 001	Dec 18, 2008	May	DISC
FLUMAZENIL						
INJECTABLE; INJECTION						
FLUMAZENIL						
	@ TEVA PARENTERAL	0.5MG/5ML (0.1MG/ML)	A076589 002	Oct 12, 2004	Jan	DISC
	@	1MG/10ML (0.1MG/ML)	A076589 001	Oct 12, 2004	Jan	DISC
FLUOCINOLONE ACETONIDE						
OIL/DROPS; OTIC						
FLUOCINOLONE ACETONIDE						
AT	IDENTI PHARMS INC	0.01%	A091306 001	Oct 17, 2011	Jan	CPOT
FLUOCINONIDE						
CREAM; TOPICAL						
FLUOCINONIDE EMULSIFIED BASE						
AB2	FOUGERA PHARMS	0.05%	A076586 001	Jun 23, 2004	Jan	CAHN
	@ G AND W LABS INC	0.05%	A074204 001	Jun 13, 1995	May	CAHN
OINTMENT; TOPICAL						
FLUOCINONIDE						
AB	FOUGERA PHARMS	0.05%	A074905 001	Aug 26, 1997	Jan	CAHN
FLUOROURACIL						
CREAM; TOPICAL						
FLUOROPLEX						
	+ AQUA PHARMS	1%	N016988 001		Jan	CAHN
FLUOXETINE HYDROCHLORIDE						
CAPSULE; ORAL						
PROZAC						
AB1	ELI LILLY AND CO	EQ 10MG BASE	N018936 006	Dec 23, 1992	Apr	CAHN
AB1		EQ 20MG BASE	N018936 001	Dec 29, 1987	Apr	CAHN
AB	+	EQ 40MG BASE	N018936 003	Jun 15, 1999	Apr	CAHN
	@	EQ 60MG BASE	N018936 004	Jun 15, 1999	Apr	CAHN

CAPSULE; ORAL

SARAFEM

AB2	ELI LILLY AND CO	EQ 10MG BASE	N018936 007	Jul 06, 2000	Apr	CAHN
AB2	+	EQ 20MG BASE	N018936 008	Jul 06, 2000	Apr	CAHN

TABLET; ORAL

SARAFEM

>D>	WARNER CHILCOTT	EQ 10MG BASE	N021860 001	May 19, 2006	Jun	CAHN
>D>		EQ 15MG BASE	N021860 002	May 19, 2006	Jun	CAHN
>D>	+	EQ 20MG BASE	N021860 003	May 19, 2006	Jun	CAHN
>A>	WARNER CHILCOTT LLC	EQ 10MG BASE	N021860 001	May 19, 2006	Jun	CAHN
>A>		EQ 15MG BASE	N021860 002	May 19, 2006	Jun	CAHN
>A>	+	EQ 20MG BASE	N021860 003	May 19, 2006	Jun	CAHN

FLUOXETINE HYDROCHLORIDE; OLANZAPINE

CAPSULE; ORAL

OLANZAPINE AND FLUOXETINE HYDROCHLORIDE

>A>	AB	TEVA PHARMS	EQ 25MG BASE;EQ 6MG BASE	A077528 001	Jun 19, 2012	Jun	NEWA
>A>	AB		EQ 25MG BASE;EQ 12MG BASE	A077528 002	Jun 19, 2012	Jun	NEWA
>A>	AB		EQ 50MG BASE;EQ 6MG BASE	A077528 003	Jun 19, 2012	Jun	NEWA
>A>	AB		EQ 50MG BASE;EQ 12MG BASE	A077528 004	Jun 19, 2012	Jun	NEWA

SYMBYAX

LILLY

>D>			EQ 25MG BASE;EQ 6MG BASE	N021520 002	Dec 24, 2003	Jun	CFTG
>A>	AB		EQ 25MG BASE;EQ 6MG BASE	N021520 002	Dec 24, 2003	Jun	CFTG
>D>			EQ 25MG BASE;EQ 12MG BASE	N021520 004	Dec 24, 2003	Jun	CFTG
>A>	AB		EQ 25MG BASE;EQ 12MG BASE	N021520 004	Dec 24, 2003	Jun	CFTG
>D>	+		EQ 50MG BASE;EQ 6MG BASE	N021520 003	Dec 24, 2003	Jun	CFTG
>A>	AB	+	EQ 50MG BASE;EQ 6MG BASE	N021520 003	Dec 24, 2003	Jun	CFTG
>D>			EQ 50MG BASE;EQ 12MG BASE	N021520 005	Dec 24, 2003	Jun	CFTG
>A>	AB		EQ 50MG BASE;EQ 12MG BASE	N021520 005	Dec 24, 2003	Jun	CFTG

FLURANDRENOLIDE

CREAM; TOPICAL

CORDRAN SP

WATSON PHARMS

0.05%

N012806 002 Apr CMFD

FLUTAMIDE

CAPSULE; ORAL

FLUTAMIDE

AB	+	IVAX SUB TEVA PHARMS	125MG	A075780 001	Sep 19, 2001	Mar	CRLD
AB		SANDOZ INC	125MG	A075818 001	Sep 18, 2001	Mar	CRLD

FLUTICASONE PROPIONATE

CREAM; TOPICAL

CUTIVATE

AB	+	FOUGERA PHARMS	0.05%	N019958 001	Dec 18, 1990	Jan	CAHN
----	---	----------------	-------	-------------	--------------	-----	------

FLUTICASONE PROPIONATE

AB		FOUGERA PHARMS	0.05%	A076451 001	May 14, 2004	Jan	CAHN
>D>	AB	NESHER PHARMS	0.05%	A076865 001	Sep 10, 2004	Jun	DISC
>A>	@		0.05%	A076865 001	Sep 10, 2004	Jun	DISC

OINTMENT; TOPICAL

FLUTICASONE PROPIONATE

AB		FOUGERA PHARMS	0.005%	A076300 001	May 14, 2004	Jan	CAHN
----	--	----------------	--------	-------------	--------------	-----	------

FLUVASTATIN SODIUM

CAPSULE; ORAL

FLUVASTATIN SODIUM

AB	MYLAN PHARMS INC	EQ 20MG BASE	A090595 001	Apr 11, 2012	Mar	NEWA
AB		EQ 40MG BASE	A090595 002	Apr 11, 2012	Mar	NEWA
AB	TEVA PHARMS	EQ 20MG BASE	A078407 001	Jun 12, 2012	May	NEWA
AB		EQ 40MG BASE	A078407 002	Jun 12, 2012	May	NEWA
LESCOL						
AB	NOVARTIS	EQ 20MG BASE	N020261 001	Dec 31, 1993	Mar	CFTG
AB	+	EQ 40MG BASE	N020261 002	Dec 31, 1993	Mar	CFTG

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

LUVOX CR

>D>	JAZZ	100MG	N022033 001	Feb 28, 2008	Jun	CAHN
>D>	+	150MG	N022033 002	Feb 28, 2008	Jun	CAHN
>A>	JAZZ PHARMS	100MG	N022033 001	Feb 28, 2008	Jun	CAHN
>A>	+	150MG	N022033 002	Feb 28, 2008	Jun	CAHN

FORMOTEROL FUMARATE; MOMETASONE FUROATE

AEROSOL, METERED; INHALATION

DULERA

>A>	+	MERCK SHARP DOHME	0.005MG/INH;0.1MG/INH	N022518 001	Jun 22, 2010	Jun	CAHN
>A>	+		0.005MG/INH;0.2MG/INH	N022518 002	Jun 22, 2010	Jun	CAHN
>D>	+	SCHERING	0.005MG/INH;0.1MG/INH	N022518 001	Jun 22, 2010	Jun	CAHN
>D>	+		0.005MG/INH;0.2MG/INH	N022518 002	Jun 22, 2010	Jun	CAHN

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

@ RANBAXY LABS LTD

@

@

MONOPRIL

@ BRISTOL MYERS SQUIBB

@

@

@

10MG

20MG

40MG

10MG

20MG

40MG

A076580 001 Apr 23, 2004 Apr DISC

A076580 002 Apr 23, 2004 Apr DISC

A076580 003 Apr 23, 2004 Apr DISC

N019915 002 May 16, 1991 Mar DISC

N019915 003 May 16, 1991 Mar DISC

N019915 004 Mar 28, 1995 Mar DISC

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

FOSPHENYTOIN SODIUM

@ TEVA PARENTERAL

EQ 50MG PHENYTOIN NA/ML

A076886 001 Aug 06, 2007 Mar DISC

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

>D>	AP	HOSPIRA	10MG/ML	A070578 001	Jul 08, 1987	Jun	DISC
>A>	@		10MG/ML	A070578 001	Jul 08, 1987	Jun	DISC

GABAPENTIN

SOLUTION; ORAL

GABAPENTIN

>A>	AA	ACELLA PHARMS LLC	250MG/5ML	A076403 001	May 01, 2012	Jun	CAHN
>A>	AA	AMNEAL PHARMS	250MG/5ML	A202024 001	Mar 23, 2012	Mar	NEWA
>D>	AA	KIEL	250MG/5ML	A076403 001	May 01, 2012	Jun	CAHN

SOLUTION; ORAL							
GABAPENTIN							
AA	KIEL	250MG/5ML	A076403	001	May 01, 2012	Apr	NEWA

GANCICLOVIR

CAPSULE; ORAL

GANCICLOVIR

@ RANBAXY LABS LTD

250MG

A076457 001 Jun 27, 2003 Apr DISC

@

500MG

A076457 002 Jun 27, 2003 Apr DISC

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION

GEMCITABINE HYDROCHLORIDE

+ HOSPIRA INC

200MG/5.26ML (38MG/ML)

N200795 001 Aug 04, 2011 Apr CTNA

+

1GM/26.3ML (38MG/ML)

N200795 002 Aug 04, 2011 Apr CTNA

+

2GM/52.6ML (38MG/ML)

N200795 003 Aug 04, 2011 Apr CTNA

GLIMEPIRIDE

TABLET; ORAL

GLIMEPIRIDE

>A> AB AUROBINDO PHARMA LTD

1MG

A202759 001 Jun 29, 2012 Jun NEWA

>A> AB

2MG

A202759 002 Jun 29, 2012 Jun NEWA

>A> AB

4MG

A202759 003 Jun 29, 2012 Jun NEWA

>A> AB

MICRO LABS USA

1MG

A091220 001 Jun 29, 2012 Jun NEWA

>A> AB

2MG

A091220 002 Jun 29, 2012 Jun NEWA

>A> AB

3MG

A091220 003 Jun 29, 2012 Jun NEWA

>A> AB

4MG

A091220 004 Jun 29, 2012 Jun NEWA

>A> AB

6MG

A091220 005 Jun 29, 2012 Jun NEWA

>A> AB

8MG

A091220 006 Jun 29, 2012 Jun NEWA

@ RANBAXY LABS LTD

1MG

A076875 001 Oct 06, 2005 Apr DISC

@

2MG

A076875 002 Oct 06, 2005 Apr DISC

@

4MG

A076875 003 Oct 06, 2005 Apr DISC

@

8MG

A076875 004 Oct 06, 2005 Apr DISC

GLYCOPYRROLATE

TABLET; ORAL

GLYCOPYRROLATE

AA NEXGEN PHARMA

1.5MG

A091522 001 Mar 12, 2012 Feb NEWA

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

AP CIPLA LTD

EQ 0.1MG BASE/ML (EQ 0.1MG
BASE/ML)

A078262 001 Dec 31, 2007 Mar CAHN

AP

EQ 1MG BASE/ML (EQ 1MG BASE/ML)

A078258 001 Jun 30, 2008 Mar CAHN

AP

EQ 4MG BASE/4ML (EQ 1MG BASE/ML)

A078258 002 Jun 30, 2008 Mar CAHN

GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE

AP + APP PHARMS LLC

EQ 1MG BASE/ML (EQ 1MG BASE/ML)

A078096 001 Jun 30, 2008 Apr CRLD

@ TEVA PARENTERAL

EQ 1MG BASE/ML (EQ 1MG BASE/ML)

A077165 001 Dec 31, 2007 Apr DISC

GRISEOFULVIN, MICROCRYSTALLINE

SUSPENSION; ORAL

GRIFULVIN V

AB + VALEANT PHARM NORTH

125MG/5ML

A062483 001 Jan 26, 1984 Feb CAHN

HALOBETASOL PROPIONATE

CREAM; TOPICAL

HALOBETASOL PROPIONATE

AB	FOUGERA PHARMS	0.05%	A077001 001	Dec 16, 2004	Jan	CAHN
----	----------------	-------	-------------	--------------	-----	------

OINTMENT; TOPICAL

HALOBETASOL PROPIONATE

>D>	@ ACTAVIS MID ATLANTIC	0.05%	A077109 001	Jun 14, 2005	Jun	CAHN
-----	------------------------	-------	-------------	--------------	-----	------

AB	FOUGERA PHARMS	0.05%	A076903 001	Dec 16, 2004	Jan	CAHN
----	----------------	-------	-------------	--------------	-----	------

>A>	@ VENUS PHARMS	0.05%	A077109 001	Jun 14, 2005	Jun	CAHN
-----	----------------	-------	-------------	--------------	-----	------

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER

@ BAXTER HLTHCARE	2,000 UNITS/100ML	N018814 002	Jul 09, 1985	Mar	DISC
-------------------	-------------------	-------------	--------------	-----	------

HEPARIN SODIUM 20,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER

@ BAXTER HLTHCARE	4,000 UNITS/100ML	N018814 001	Oct 31, 1983	Mar	DISC
-------------------	-------------------	-------------	--------------	-----	------

HEPARIN SODIUM 25,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER

@ BAXTER HLTHCARE	5,000 UNITS/100ML	N018814 003	Jul 09, 1985	Mar	DISC
-------------------	-------------------	-------------	--------------	-----	------

@	10,000 UNITS/100ML	N018814 004	Jul 02, 1987	Mar	DISC
---	--------------------	-------------	--------------	-----	------

HEXAMINOLEVULINATE HYDROCHLORIDE

FOR SOLUTION; INTRAVESICAL

CYSVIEW KIT

+	PHOTOCURE ASA	100MG/VIAL	N022555 001	May 28, 2010	May	CAHN
---	---------------	------------	-------------	--------------	-----	------

HYALURONIDASE

INJECTABLE; INJECTION

HYDASE

>D>						
-----	--	--	--	--	--	--

>D>	+	AKORN INC	150 UNITS/ML	N021716 001	Oct 25, 2005	Jun DISC
-----	---	-----------	--------------	-------------	--------------	----------

>A>	@		150 UNITS/ML	N021716 001	Oct 25, 2005	Jun DISC
-----	---	--	--------------	-------------	--------------	----------

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDROCHLOROTHIAZIDE

AB	LANNETT HOLDINGS INC	12.5MG	A091662 001	Jan 27, 2012	Jan	NEWA
----	----------------------	--------	-------------	--------------	-----	------

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

AVALIDE

AB	+	SANOFI AVENTIS	12.5MG;150MG	N020758 002	Sep 30, 1997	Mar CFTG
----	---	----------------	--------------	-------------	--------------	----------

AB	+		12.5MG;300MG	N020758 003	Aug 31, 1998	Mar CFTG
----	---	--	--------------	-------------	--------------	----------

	+		12.5MG;300MG	N020758 003	Aug 31, 1998	Feb CRLD
--	---	--	--------------	-------------	--------------	----------

IRBESARTAN AND HYDROCHLOROTHIAZIDE

AB	TEVA	12.5MG;150MG	A077369 001	Mar 30, 2012	Mar	NEWA
----	------	--------------	-------------	--------------	-----	------

AB		12.5MG;300MG	A077369 002	Mar 30, 2012	Mar	NEWA
----	--	--------------	-------------	--------------	-----	------

@		25MG;300MG	A077369 003	Mar 30, 2012	Apr	DISC
---	--	------------	-------------	--------------	-----	------

		25MG;300MG	A077369 003	Mar 30, 2012	Mar	NEWA
--	--	------------	-------------	--------------	-----	------

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

AB	ALEMBIC LTD	12.5MG;50MG	A091617 001	Feb 17, 2012	Feb	NEWA
----	-------------	-------------	-------------	--------------	-----	------

AB		12.5MG;100MG	A091617 002	Feb 17, 2012	Feb	NEWA
----	--	--------------	-------------	--------------	-----	------

AB		25MG;100MG	A091617 003	Feb 17, 2012	Feb	NEWA
----	--	------------	-------------	--------------	-----	------

HYDROCHLOROTHIAZIDE; METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

DUTOPROL

ASTRAZENECA	12.5MG;EQ 25MG TARTRATE	N021956 001	Aug 28, 2006	Jan	CMFD
	12.5MG;EQ 50MG TARTRATE	N021956 002	Aug 28, 2006	Jan	CMFD
+	12.5MG;EQ 100MG TARTRATE	N021956 003	Aug 28, 2006	Apr	CRLD
	12.5MG;EQ 100MG TARTRATE	N021956 003	Aug 28, 2006	Jan	CMFD

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET; ORAL

METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE

AB	MYLAN	50MG;100MG	A076792 003	Aug 20, 2004	Jan	CTEC
AB	SUN PHARM INDS	25MG;50MG	A090654 001	Jan 19, 2012	Jan	NEWA
AB		25MG;100MG	A090654 002	Jan 19, 2012	Jan	NEWA
AB		50MG;100MG	A090654 003	Jan 19, 2012	Jan	NEWA

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

@ PADDOCK LLC	12.5MG;7.5MG	A090096 001	Sep 25, 2008	Jan	DISC
@	12.5MG;15MG	A090096 002	Sep 25, 2008	Jan	DISC
@	25MG;15MG	A090096 003	Sep 25, 2008	Jan	DISC

HYDROCORTISONE

CREAM; TOPICAL

NUTRACORT

>D>	@ CORIA	0.5%	A080442 002		Jun	CAHN
>D>	@	1%	A080442 003		Jun	CAHN
>A>	@ DOW PHARM	0.5%	A080442 002		Jun	CAHN
>A>	@	1%	A080442 003		Jun	CAHN

LOTION; TOPICAL

CETACORT

>D>	@ CORIA	0.5%	A080426 002		Jun	CAHN
>D>	@	1%	A080426 001		Jun	CAHN
>A>	@ DOW PHARM	0.5%	A080426 002		Jun	CAHN
>A>	@	1%	A080426 001		Jun	CAHN

HYDROCORTISONE

AT	+	FOUGERA PHARMS	2.5%	A040351 001	Jul 25, 2000	Jan	CAHN
		NUTRACORT					
>D>		@ CORIA	0.5%	A080443 002		Jun	CAHN
>D>	AT		1%	A080443 003		Jun	CAHN
>D>	AT		2.5%	A087644 001	Aug 24, 1982	Jun	CAHN
>A>		@ DOW PHARM	0.5%	A080443 002		Jun	CAHN
>A>	AT		1%	A080443 003		Jun	CAHN
>A>	AT		2.5%	A087644 001	Aug 24, 1982	Jun	CAHN

OINTMENT; TOPICAL

HYDROCORTISONE

AT	+	FOUGERA PHARMS	1%	A080692 001		Jan	CAHN
----	---	----------------	----	-------------	--	-----	------

HYDROCORTISONE ACETATE; UREA

CREAM; TOPICAL

CARMOL HC

AT		FOUGERA PHARMS	1%;10%	A080505 001		Jan	CAHN
----	--	----------------	--------	-------------	--	-----	------

HYDROCORTISONE BUTYRATE

CREAM; TOPICAL

LOCOID

>A>	AB	+	PRECISION DERMAT	0.1%	N018514	001	Mar 31, 1982	Jun	CAHN
-----	----	---	------------------	------	---------	-----	--------------	-----	------

>D>	AB	+	TRIAx PHARMS LLC	0.1%	N018514	001	Mar 31, 1982	Jun	CAHN
-----	----	---	------------------	------	---------	-----	--------------	-----	------

LOCOID LIPOCREAM

>A>		+	PRECISION DERMAT	0.1%	N020769	001	Sep 08, 1997	Jun	CAHN
-----	--	---	------------------	------	---------	-----	--------------	-----	------

>D>		+	TRIAx PHARMS LLC	0.1%	N020769	001	Sep 08, 1997	Jun	CAHN
-----	--	---	------------------	------	---------	-----	--------------	-----	------

LOTION; TOPICAL

LOCOID

		+	PRECISION DERMAT	0.1%	N022076	001	May 18, 2007	May	CAHN
--	--	---	------------------	------	---------	-----	--------------	-----	------

OINTMENT; TOPICAL

LOCOID

	AB	+	PRECISION DERMAT	0.1%	N018652	001	Oct 29, 1982	May	CAHN
--	----	---	------------------	------	---------	-----	--------------	-----	------

SOLUTION; TOPICAL

LOCOID

>A>	AT	+	PRECISION DERMAT	0.1%	N019116	001	Feb 25, 1987	Jun	CAHN
-----	----	---	------------------	------	---------	-----	--------------	-----	------

>D>	AT	+	TRIAx PHARMS LLC	0.1%	N019116	001	Feb 25, 1987	Jun	CAHN
-----	----	---	------------------	------	---------	-----	--------------	-----	------

HYDROCORTISONE VALERATE

CREAM; TOPICAL

HYDROCORTISONE VALERATE

	AB	+	TARO	0.2%	A075042	001	Aug 25, 1998	Mar	CRLD
--	----	---	------	------	---------	-----	--------------	-----	------

WESTCORT

			@ RANBAXY	0.2%	N017950	001		Mar	DISC
--	--	--	-----------	------	---------	-----	--	-----	------

OINTMENT; TOPICAL

HYDROCORTISONE VALERATE

	AB		FOUGERA PHARMS	0.2%	A075085	001	Jul 31, 2001	Jan	CAHN
--	----	--	----------------	------	---------	-----	--------------	-----	------

HYDROFLUMETHIAZIDE

TABLET; ORAL

SALURON

	AB	+	SHIRE LLC	50MG	N011949	001		Jan	CAHN
--	----	---	-----------	------	---------	-----	--	-----	------

HYDROMORPHONE HYDROCHLORIDE

TABLET; ORAL

HYDROMORPHONE HYDROCHLORIDE

>D>	AB		NESHER PHARMS	2MG	A077311	001	Nov 09, 2005	Jun	DISC
-----	----	--	---------------	-----	---------	-----	--------------	-----	------

>A>			@	2MG	A077311	001	Nov 09, 2005	Jun	DISC
-----	--	--	---	-----	---------	-----	--------------	-----	------

>D>	AB			4MG	A077311	002	Nov 09, 2005	Jun	DISC
-----	----	--	--	-----	---------	-----	--------------	-----	------

>A>			@	4MG	A077311	002	Nov 09, 2005	Jun	DISC
-----	--	--	---	-----	---------	-----	--------------	-----	------

>D>	AB			8MG	A077311	003	Nov 09, 2005	Jun	DISC
-----	----	--	--	-----	---------	-----	--------------	-----	------

>A>			@	8MG	A077311	003	Nov 09, 2005	Jun	DISC
-----	--	--	---	-----	---------	-----	--------------	-----	------

HYDROXYZINE HYDROCHLORIDE

SYRUP; ORAL

HYDROXYZINE HYDROCHLORIDE

			@ STI PHARMA LLC	10MG/5ML	A086880	001		Feb	CAHN
--	--	--	------------------	----------	---------	-----	--	-----	------

IBANDRONATE SODIUM

TABLET; ORAL

BONIVA

	AB	+	HOFFMANN LA ROCHE	EQ 150MG BASE	N021455	002	Mar 24, 2005	Mar	CFTG
--	----	---	-------------------	---------------	---------	-----	--------------	-----	------

IBANDRONATE SODIUM

	AB		APOTEX INC	EQ 150MG BASE	A078948	001	Mar 19, 2012	Mar	NEWA
--	----	--	------------	---------------	---------	-----	--------------	-----	------

TABLET; ORAL

IBANDRONATE SODIUM

AB	DR REDDYS LABS LTD	EQ 150MG BASE	A078997	001	Apr 30, 2012	Apr	NEWA
AB	MYLAN PHARMS INC	EQ 150MG BASE	A078995	001	Mar 19, 2012	Mar	NEWA
AB	ORCHID HLTHCARE	EQ 150MG BASE	A078998	001	Mar 19, 2012	Mar	NEWA
AB	WATSON LABS INC	EQ 150MG BASE	A079003	001	Mar 20, 2012	Mar	NEWA

IBUPROFEN

TABLET; ORAL

IBUPROFEN

>D>	AB	NORTHSTAR HLTHCARE	400MG	A078132	001	Sep 10, 2007	Jun	DISC
>A>		@	400MG	A078132	001	Sep 10, 2007	Jun	DISC
>D>	AB		600MG	A078132	002	Sep 10, 2007	Jun	DISC
>A>		@	600MG	A078132	002	Sep 10, 2007	Jun	DISC
>D>	AB		800MG	A078132	003	Sep 10, 2007	Jun	DISC
>A>		@	800MG	A078132	003	Sep 10, 2007	Jun	DISC
>D>	AB	OHM LABS	400MG	A070818	001	Dec 26, 1985	Jun	DISC
>A>		@	400MG	A070818	001	Dec 26, 1985	Jun	DISC

IBUPROFEN LYSINE

INJECTABLE; INTRAVENOUS

NEOPROFEN

+	LUNDBECK LLC	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N021903	001	Apr 13, 2006	Mar	CAHN
---	--------------	------------------------------------	---------	-----	--------------	-----	------

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

IDARUBICIN HYDROCHLORIDE

@	TEVA PARENTERAL	5MG/VIAL	A065037	003	May 01, 2002	Mar	DISC
@		10MG/VIAL	A065037	002	May 01, 2002	Mar	DISC
@		20MG/VIAL	A065037	001	May 01, 2002	Mar	DISC

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL

IMIPRAMINE HYDROCHLORIDE

AB	PROSAM LABS	10MG	A040753	001	Feb 28, 2008	Feb	CMFD
AB		25MG	A040752	001	Feb 28, 2008	Feb	CMFD
AB		50MG	A040751	001	Feb 28, 2008	Feb	CMFD

IMIQUIMOD

CREAM; TOPICAL

IMIQUIMOD

AB	APOTEX INC	5%	A091308	001	Apr 06, 2012	Mar	NEWA
AB	FOUGERA PHARMS	5%	A078548	001	Feb 25, 2010	Jan	CAHN
AB	GLENMARK GENERICS	5%	A201994	001	Mar 06, 2012	Feb	NEWA

INDOMETHACIN SODIUM

INJECTABLE; INJECTION

INDOCIN

AP	+	LUNDBECK LLC	EQ 1MG BASE/VIAL	N018878	001	Jan 30, 1985	Mar	CAHN
----	---	--------------	------------------	---------	-----	--------------	-----	------

INGENOL MEBUTATE

GEL; TOPICAL

PICATO

		LEO PHARMA AS	0.015%	N202833	001	Jan 23, 2012	Jan	NEWA
	+		0.05%	N202833	002	Jan 23, 2012	Jan	NEWA

INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT

INJECTABLE; INJECTION

>D>		HUMALOG MIX 50/50 PEN								
>D>	+	LILLY	50 UNITS/ML;50 UNITS/ML	N021018	003	Dec 22,	1999	Jun	DISC	
>A>	@		50 UNITS/ML;50 UNITS/ML	N021018	003	Dec 22,	1999	Jun	DISC	
>D>		HUMALOG MIX 75/25 PEN								
>D>	+	LILLY	75 UNITS/ML;25 UNITS/ML	N021017	003	Dec 22,	1999	Jun	DISC	
>A>	@		75 UNITS/ML;25 UNITS/ML	N021017	003	Dec 22,	1999	Jun	DISC	

INSULIN LISPRO RECOMBINANT

INJECTABLE; INJECTION

>D>		HUMALOG PEN								
>D>	+	LILLY	100 UNITS/ML	N020563	002	Aug 06,	1998	Jun	DISC	
>A>	@		100 UNITS/ML	N020563	002	Aug 06,	1998	Jun	DISC	

IRBESARTAN

TABLET; ORAL

AVAPRO

AB		SANOFI AVENTIS US	75MG	N020757	001	Sep 30,	1997	Mar	CFTG	
AB			150MG	N020757	002	Sep 30,	1997	Mar	CFTG	
AB	+		300MG	N020757	003	Sep 30,	1997	Mar	CFTG	

IRBESARTAN

AB		TEVA PHARMS	75MG	A077159	001	Mar 30,	2012	Mar	NEWA	
AB			150MG	A077159	002	Mar 30,	2012	Mar	NEWA	
AB			300MG	A077159	003	Mar 30,	2012	Mar	NEWA	

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

IRINOTECAN HYDROCHLORIDE

AP		CIPLA LTD	40MG/2ML (20MG/ML)	A077219	001	Feb 20,	2008	Mar	CAHN	
AP			100MG/5ML (20MG/ML)	A077219	002	Feb 20,	2008	Mar	CAHN	
AP		EMCURE PHARMS LTD	40MG/2ML (20MG/ML)	A200771	001	Feb 14,	2012	Jan	NEWA	
AP			100MG/5ML (20MG/ML)	A200771	002	Feb 14,	2012	Jan	NEWA	
AP		HISUN PHARM HANGZHOU	40MG/2ML (20MG/ML)	A090016	001	Jan 28,	2009	Mar	CAHN	
AP			100MG/5ML (20MG/ML)	A090016	002	Jan 28,	2009	Mar	CAHN	
>A>	AP	TEVA PARENTERAL	40MG/2ML (20MG/ML)	A090101	002	Feb 27,	2008	Jun	NEWA	
>A>	AP		100MG/5ML (20MG/ML)	A090101	003	Feb 27,	2008	Jun	NEWA	
>D>	@		500MG/25ML (20MG/ML)	A090101	001	Nov 26,	2008	Jun	CMFD	
>A>	AP		500MG/25ML (20MG/ML)	A090101	001	Nov 26,	2008	Jun	CMFD	
	@		500MG/25ML (20MG/ML)	A090101	001	Nov 26,	2008	Mar	DISC	

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE; ORAL

ISOSORBIDE MONONITRATE

>A>	AB	ALKERMES GAINESVILLE	60MG	A075041	001	Sep 22,	1998	Jun	CAHN	
>D>	AB	ELAN PHARM	60MG	A075041	001	Sep 22,	1998	Jun	CAHN	
	@	SKYEPHARMA AG	60MG	A075166	001	Oct 07,	1999	Jan	DISC	

ISOTRETINOIN

CAPSULE; ORAL

ABSORICA

CIPHER

10MG	N021951	001	May 25,	2012	May	NEWA	
20MG	N021951	002	May 25,	2012	May	NEWA	
30MG	N021951	003	May 25,	2012	May	NEWA	
40MG	N021951	004	May 25,	2012	May	NEWA	

CAPSULE; ORAL

MYORISAN

AB	DOUGLAS PHARMS	10MG	A076485 001	Jan 19, 2012	Jan	NEWA
AB		20MG	A076485 002	Jan 19, 2012	Jan	NEWA
AB		40MG	A076485 003	Jan 19, 2012	Jan	NEWA

IVACAFTOR

TABLET; ORAL

KALYDECO

+	VERTEX PHARMS	150MG	N203188 001	Jan 31, 2012	Jan	NEWA
---	---------------	-------	-------------	--------------	-----	------

IVERMECTIN

LOTION; TOPICAL

SKLICE

+	SANOFI PASTEUR	0.5%	N202736 001	Feb 07, 2012	Feb	NEWA
---	----------------	------	-------------	--------------	-----	------

KETOCONAZOLE

CREAM; TOPICAL

KETOCONAZOLE

AB	FOUGERA PHARMS	2%	A076294 001	Apr 28, 2004	Jan	CAHN
----	----------------	----	-------------	--------------	-----	------

KETOPROFEN

CAPSULE, EXTENDED RELEASE; ORAL

KETOPROFEN

>A>	AB	ALKERMES GAINESVILLE	200MG	A074879 001	Dec 10, 1997	Jun	CAHN
>D>	AB	ELAN PHARM	200MG	A074879 001	Dec 10, 1997	Jun	CAHN

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION

LABETALOL HYDROCHLORIDE

AP	GLAND PHARMA LTD	5MG/ML	A090699 001	Apr 03, 2012	Mar	NEWA
----	------------------	--------	-------------	--------------	-----	------

TABLET; ORAL

LABETALOL HYDROCHLORIDE

>A>	AB	PAR FORM	100MG	A200908 001	Jul 10, 2012	Jun	NEWA
>A>	AB		200MG	A200908 002	Jul 10, 2012	Jun	NEWA
>A>	AB		300MG	A200908 003	Jul 10, 2012	Jun	NEWA

LACTULOSE

FOR SOLUTION; ORAL

LACTULOSE

>A>	+	CUMBERLAND PHARMS	10GM/PACKET	A074712 001	Dec 10, 1997	Jun	CAHN
>A>	+		20GM/PACKET	A074712 002	Dec 10, 1997	Jun	CAHN
>D>	+	INALCO	10GM/PACKET	A074712 001	Dec 10, 1997	Jun	CAHN
>D>	+		20GM/PACKET	A074712 002	Dec 10, 1997	Jun	CAHN

SOLUTION; ORAL

LACTULOSE

AA	FRESENIUS KABI	10GM/15ML	A090503 001	Jan 25, 2012	Jan	NEWA
----	----------------	-----------	-------------	--------------	-----	------

SOLUTION; ORAL, RECTAL

LACTULOSE

AA	FRESENIUS KABI	10GM/15ML	A090502 001	Jan 25, 2012	Jan	NEWA
----	----------------	-----------	-------------	--------------	-----	------

LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL

LAMIVUDINE AND ZIDOVUDINE

AB	AUROBINDO PHARMA LTD	150MG;300MG	A202418 001	May 15, 2012	Apr	NEWA
AB	LUPIN LTD	150MG;300MG	A090246 001	May 15, 2012	Apr	NEWA

LAMOTRIGINE

TABLET; ORAL

LAMOTRIGINE

AB	GLENMARK GENERICS	25MG	A090169 001	May 12, 2012	Apr	NEWA
AB		100MG	A090169 002	May 12, 2012	Apr	NEWA
AB		150MG	A090169 003	May 12, 2012	Apr	NEWA
AB		200MG	A090169 004	May 12, 2012	Apr	NEWA

LANREOTIDE ACETATE

INJECTABLE; SUBCUTANEOUS

SOMATULINE DEPOT

+	IPSEN INC	EQ 60MG BASE	N022074 001	Aug 30, 2007	Apr	CAHN
+		EQ 90MG BASE	N022074 002	Aug 30, 2007	Apr	CAHN
+		EQ 120MG BASE	N022074 003	Aug 30, 2007	Apr	CAHN
+	IPSEN PHARMA	EQ 60MG BASE	N022074 001	Aug 30, 2007	May	CAHN
+		EQ 90MG BASE	N022074 002	Aug 30, 2007	May	CAHN
+		EQ 120MG BASE	N022074 003	Aug 30, 2007	May	CAHN

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

PREVACID

AB	TAKEDA PHARMS USA	15MG	N020406 001	May 10, 1995	Mar	CAHN
AB	+	30MG	N020406 002	May 10, 1995	Mar	CAHN

TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING; ORAL

LANSOPRAZOLE

@	TEVA PHARMS	15MG	A078730 001	Oct 15, 2010	Mar	DISC
@		30MG	A078730 002	Oct 15, 2010	Mar	DISC

PREVACID

	TAKEDA PHARMS USA	15MG	N021428 001	Aug 30, 2002	Mar	CTEC
+		30MG	N021428 002	Aug 30, 2002	Mar	CTEC

LANTHANUM CARBONATE

TABLET, CHEWABLE; ORAL

FOSRENOL

@	SHIRE LLC	EQ 250MG BASE	N021468 001	Oct 26, 2004	Feb	CAHN
		EQ 500MG BASE	N021468 002	Oct 26, 2004	Feb	CAHN
		EQ 750MG BASE	N021468 003	Nov 23, 2005	Feb	CAHN
+		EQ 1GM BASE	N021468 004	Nov 23, 2005	Feb	CAHN

LETROZOLE

TABLET; ORAL

LETROZOLE

AB	APOTEX INC	2.5MG	A091303 001	Apr 19, 2012	Apr	NEWA
----	------------	-------	-------------	--------------	-----	------

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION

LEUCOVORIN CALCIUM

@	TEVA PARENTERAL	EQ 50MG BASE/VIAL	A081278 001	Sep 28, 1993	Mar	DISC
---	-----------------	-------------------	-------------	--------------	-----	------

LEUPROLIDE ACETATE

INJECTABLE; INJECTION

LUPRON DEPOT

+	ABBOTT ENDOCRINE	3.75MG/VIAL	N020011 001	Oct 22, 1990	May	CAHN
+		7.5MG/VIAL	N019732 001	Jan 26, 1989	May	CAHN
+		11.25MG/VIAL	N020708 001	Mar 07, 1997	May	CAHN

LEVETIRACETAM

INJECTABLE; IV (INFUSION)

LEVETIRACETAM

AP	APP PHARMS LLC	500MG/5ML (100MG/ML)	A090813 001	May 26, 2010	May	CAHN
AP	HOSPIRA INC	500MG/ML (100MG/ML)	A202869 001	Apr 06, 2012	Mar	NEWA
AP	PHARMAFORCE	500MG/5ML (100MG/ML)	A202143 001	Jan 31, 2012	Jan	NEWA

SOLUTION; ORAL

LEVETIRACETAM

AA	HI-TECH PHARMACAL	100MG/ML	A090601 001	Feb 28, 2012	Feb	NEWA
AA	VINTAGE PHARMS	100MG/ML	A090079 001	Apr 11, 2012	Mar	NEWA

TABLET; ORAL

LEVETIRACETAM

AB	WATSON LABS INC	250MG	A078797 002	Jan 15, 2009	Apr	NEWA
AB		500MG	A078797 003	Jan 15, 2009	Apr	NEWA
AB		750MG	A078797 004	Jan 15, 2009	Apr	NEWA

TABLET, EXTENDED RELEASE; ORAL

LEVETIRACETAM

AB	BOCA PHARMA	500MG	A201464 001	May 25, 2012	May	NEWA
AB		750MG	A201464 002	May 25, 2012	May	NEWA
AB	TORRENT PHARMS LTD	500MG	A091338 001	May 29, 2012	May	NEWA
AB		750MG	A091338 002	May 29, 2012	May	NEWA

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

>A>	AB	HETERO LABS LTD III	5MG	A091264 001	Jun 29, 2012	Jun	NEWA
-----	----	---------------------	-----	-------------	--------------	-----	------

LEVOFLOXACIN

TABLET; ORAL

LEVOFLOXACIN

AB	CIPLA LTD	250MG	A076890 001	Mar 30, 2012	Mar	NEWA
AB		500MG	A076890 002	Mar 30, 2012	Mar	NEWA
AB		750MG	A076890 003	Mar 30, 2012	Mar	NEWA
AB	MACLEODS PHARMS LTD	250MG	A200839 001	Mar 22, 2012	Mar	NEWA
AB		500MG	A200839 002	Mar 22, 2012	Mar	NEWA
AB		750MG	A200839 003	Mar 22, 2012	Mar	NEWA
AB	ORCHID HLTHCARE	250MG	A202200 001	Jan 30, 2012	Jan	NEWA
AB		500MG	A202200 002	Jan 30, 2012	Jan	NEWA
AB		750MG	A202200 003	Jan 30, 2012	Jan	NEWA

LEVOLEUCOVORIN CALCIUM

SOLUTION; IV (INFUSION)

FUSILEV

>D>	+	SPECTRUM PHARMS	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	N020140 003	Apr 29, 2011	Jun	DISC
>A>	@		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	N020140 003	Apr 29, 2011	Jun	DISC

LEVONORGESTREL

TABLET; ORAL

LEVONORGESTREL

>A>	AB	WATSON LABS INC	1.5MG	A200670 001	Jul 12, 2012	Jun	NEWA
		PLAN B					
		@ TEVA BRANDED PHARM	0.75MG	N021045 001	Jul 28, 1999	May	CAHN
AB	+		0.75MG	N021045 002	Aug 24, 2006	May	CAHN

		TABLET; ORAL							
		PLAN B ONE-STEP							
>D>		+ DURAMED	1.5MG	N021998	001	Jul 10, 2009	Jun	CFTG	
>A>	AB	+	1.5MG	N021998	001	Jul 10, 2009	Jun	CFTG	
		<u>LIDOCAINE HYDROCHLORIDE</u>							
		INJECTABLE; INJECTION							
		XYLOCAINE DENTAL							
		@ DENTSPLY PHARM	2%	N021380	001		May	DISC	
		<u>LIDOCAINE; PRILOCAINE</u>							
		CREAM; TOPICAL							
		LIDOCAINE AND PRILOCAINE							
	AB	FOUGERA PHARMS	2.5%;2.5%	A076453	001	Aug 18, 2003	Jan	CAHN	
		<u>LIDOCAINE; TETRACAINE</u>							
		CREAM; TOPICAL							
>D>		LIDOCAINE AND TETRACAINE							
>D>		+ GALDERMA LABS LP	7%;7%	N021717	001	Jun 29, 2006	Jun	CTNA	
>A>		PLIAGLIS							
>A>		+ GALDERMA LABS LP	7%;7%	N021717	001	Jun 29, 2006	Jun	CTNA	
		<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE</u>							
		TABLET; ORAL							
		JENTADUETO							
		BOEHRINGER INGELHEIM	2.5MG;500MG	N201281	001	Jan 30, 2012	Jan	NEWA	
			2.5MG;850MG	N201281	002	Jan 30, 2012	Jan	NEWA	
		+	2.5MG;1GM	N201281	003	Jan 30, 2012	Jan	NEWA	
		<u>LINEZOLID</u>							
		INJECTABLE; INJECTION							
>A>		LINEZOLID							
>A>	AP	TEVA PHARMS	200MG/100ML	A200222	001	Jun 22, 2012	Jun	NEWA	
		ZYVOX							
>D>		+ PHARMACIA AND UPJOHN	200MG/100ML	N021131	001	Apr 18, 2000	Jun	CFTG	
>A>	AP	+	200MG/100ML	N021131	001	Apr 18, 2000	Jun	CFTG	
		<u>LITHIUM CARBONATE</u>							
		TABLET, EXTENDED RELEASE; ORAL							
		LITHIUM CARBONATE							
>A>	AB	MYLAN PHARMS INC	300MG	A202288	001	Jun 29, 2012	Jun	NEWA	
		<u>LOMUSTINE</u>							
		CAPSULE; ORAL							
		CEENU							
>D>		@ BRISTOL MYERS SQUIBB	10MG	N017588	001		Jun	CMFD	
>A>			10MG	N017588	001		Jun	CMFD	
		@	10MG	N017588	001		May	DISC	
>D>		@	40MG	N017588	002		Jun	CMFD	
>A>			40MG	N017588	002		Jun	CMFD	
		@	40MG	N017588	002		May	DISC	
>D>		@	100MG	N017588	003		Jun	CMFD	
>A>		+	100MG	N017588	003		Jun	CMFD	
		@	100MG	N017588	003		May	DISC	

LORAZEPAM

CONCENTRATE; ORAL

LORAZEPAM

AA	HI-TECH PHARMA CO	2MG/ML	A200169 001	Jan 30, 2012	Jan	NEWA
----	-------------------	--------	-------------	--------------	-----	------

INJECTABLE; INJECTION

LORAZEPAM

>D>	AP	BEDFORD	2MG/ML	A077076 001	Jul 13, 2005	Jun	DISC
>A>		@	2MG/ML	A077076 001	Jul 13, 2005	Jun	DISC
>D>	AP		4MG/ML	A077076 002	Jul 13, 2005	Jun	DISC
>A>		@	4MG/ML	A077076 002	Jul 13, 2005	Jun	DISC
>D>	AP	HOSPIRA	2MG/ML	A074300 001	Apr 12, 1994	Jun	DISC
>A>		@	2MG/ML	A074300 001	Apr 12, 1994	Jun	DISC

>A> LORCASERIN HYDROCHLORIDE

>A> TABLET; ORAL

>A> BELVIQ

>A>	+	ARENA PHARMS INC	10MG	N022529 001	Jun 27, 2012	Jun	NEWA
-----	---	------------------	------	-------------	--------------	-----	------

LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM

AB	MACLEODS PHARMS LTD	25MG	A202230 001	May 30, 2012	May	NEWA
AB		50MG	A202230 002	May 30, 2012	May	NEWA
AB		100MG	A202230 003	May 30, 2012	May	NEWA

LUCINACTANT

SUSPENSION; INTRATRACHEAL

SURFAXIN

+	DISCOVERY LABS	8.5ML	N021746 001	Mar 06, 2012	Apr	NEWA
---	----------------	-------	-------------	--------------	-----	------

LURASIDONE HYDROCHLORIDE

TABLET; ORAL

LATUDA

	SUNOVION PHARMS INC	20MG	N200603 003	Dec 07, 2011	Apr	NEWA
+		40MG	N200603 001	Oct 28, 2010	Apr	CRLD
		80MG	N200603 002	Oct 28, 2010	Apr	CRLD
		120MG	N200603 004	Apr 26, 2012	Apr	NEWA

LUTROPIN ALFA

INJECTABLE; SUBCUTANEOUS

LUVERIS

>D>							
>D>	+	EMD SERONO	75 IU/VIAL	N021322 001	Oct 08, 2004	Jun	DISC
>A>		@	75 IU/VIAL	N021322 001	Oct 08, 2004	Jun	DISC

MAFENIDE ACETATE

CREAM; TOPICAL

SULFAMYLON

>A>	+	MYLAN LLC	EQ 85MG BASE/GM	N016763 001		Jun	CAHN
>D>	+	UDL LABS	EQ 85MG BASE/GM	N016763 001		Jun	CAHN

FOR SOLUTION; TOPICAL

SULFAMYLON

>A>	+	MYLAN LLC	5%	N019832 003	Jun 05, 1998	Jun	CAHN
>D>	+	UDL LABS	5%	N019832 003	Jun 05, 1998	Jun	CAHN

>D> MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE

>D> TABLET; ORAL

>D> MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE

>D>	SANTARUS	343MG;20MG;750MG	N022456 001	Dec 04, 2009	Jun	DISC
>A>	@	343MG;20MG;750MG	N022456 001	Dec 04, 2009	Jun	DISC
>D>	+	343MG;40MG;750MG	N022456 002	Dec 04, 2009	Jun	DISC
>A>	@	343MG;40MG;750MG	N022456 002	Dec 04, 2009	Jun	DISC

MAGNESIUM SULFATE

INJECTABLE; INJECTION

MAGNESIUM SULFATE IN PLASTIC CONTAINER

HOSPIRA	20GM/500ML (40MG/ML)	N020309 004	Jan 18, 1995	Jan	NEWA
	40GM/1000ML (40MG/ML)	N020309 005	Jan 18, 1995	Jan	NEWA

MALATHION

LOTION; TOPICAL

MALATHION

AT	MYLAN PHARMS INC	0.5%	A078743 001	Mar 06, 2009	Feb	CAHN
AT	SUVEN LIFE	0.5%	A091559 001	May 23, 2012	May	NEWA

MANNITOL

POWDER; INHALATION

ARIDOL KIT

+	PHARMAXIS LTD	N/A, 5MG, 10MG, 20MG, 40MG	N022368 001	Oct 05, 2010	May	CAHN
---	---------------	----------------------------	-------------	--------------	-----	------

MECASERMIN RECOMBINANT

INJECTABLE; SUBCUTANEOUS

INCRELEX

+	IPSEN INC	40MG/4ML (10MG/ML)	N021839 001	Aug 30, 2005	May	CAHN
---	-----------	--------------------	-------------	--------------	-----	------

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

MECLIZINE HYDROCHLORIDE

AA	EPIC PHARMA LLC	12.5MG	A200294 001	Apr 13, 2012	Mar	NEWA
AA		25MG	A200294 002	Apr 13, 2012	Mar	NEWA

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION

MEDROXYPROGESTERONE ACETATE

@	TEVA PARENTERAL	150MG/ML	A076552 001	Oct 27, 2004	Apr	DISC
---	-----------------	----------	-------------	--------------	-----	------

MEMANTINE HYDROCHLORIDE

TABLET; ORAL

MEMANTINE HYDROCHLORIDE

	@ ORCHID HLTHCARE	5MG	A090044 001	Mar 12, 2012	Mar	DISC
AB		5MG	A090044 001	Mar 12, 2012	Feb	NEWA
	@	10MG	A090044 002	Mar 12, 2012	Mar	DISC
AB		10MG	A090044 002	Mar 12, 2012	Feb	NEWA
	NAMENDA					
	FOREST LABS	5MG	N021487 001	Oct 16, 2003	Mar	CTEC
AB		5MG	N021487 001	Oct 16, 2003	Feb	CTEC
	+	10MG	N021487 002	Oct 16, 2003	Mar	CTEC
AB	+	10MG	N021487 002	Oct 16, 2003	Feb	CTEC

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

POLOCAINE

@ DENTSPLY PHARM 3%

A088653 001 Aug 21, 1984 May DISC

MEQUINOL; TRETINOIN

SOLUTION; TOPICAL

SOLAGE

>D>

>D> + AQUA PHARMS 2%;0.01%

N020922 001 Dec 10, 1999 Jun DISC

>A> @ 2%;0.01%

N020922 001 Dec 10, 1999 Jun DISC

MESALAMINE

SUPPOSITORY; RECTAL

ROWASA

@ MEDA PHARMS 500MG

N019919 001 Dec 18, 1990 Jan CAHN

MESNA

INJECTABLE; INTRAVENOUS

MESNA

AP MYLAN INSTITUTIONAL 100MG/ML

A076488 001 Mar 08, 2012 Feb NEWA

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE

AB MARKSANS PHARMA 500MG

A090888 001 Mar 12, 2012 Feb NEWA

AB 850MG

A090888 002 Mar 12, 2012 Feb NEWA

AB 1GM

A090888 003 Mar 12, 2012 Feb NEWA

TABLET, EXTENDED RELEASE; ORAL

METFORMIN HYDROCHLORIDE

AB1 INVENTIA HLTHCARE 500MG

A201991 001 Jan 18, 2012 Jan NEWA

@ RANBAXY LABS LTD 500MG

A076413 001 Jun 18, 2004 Apr DISC

@ 750MG

A077211 001 Jun 29, 2005 Apr DISC

METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

KOMBIGLYZE XR

BRISTOL MYERS SQUIBB 500MG;EQ 5MG BASE

N200678 001 Nov 05, 2010 Apr CAIN

1GM;EQ 2.5MG BASE

N200678 003 Nov 05, 2010 Apr CAIN

+ 1GM;EQ 5MG BASE

N200678 002 Nov 05, 2010 Apr CAIN

METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE

TABLET; ORAL

JANUMET

MERCK SHARP DOHME 500MG;EQ 50MG BASE

N022044 001 Mar 30, 2007 May CAHN

+ 1GM;EQ 50MG BASE

N022044 002 Mar 30, 2007 May CAHN

TABLET, EXTENDED RELEASE; ORAL

JANUMET XR

MERCK SHARP DOHME 500MG;EQ 50MG BASE

N202270 001 Feb 02, 2012 Feb NEWA

1GM;EQ 50MG BASE

N202270 002 Feb 02, 2012 Feb NEWA

+ 1GM;EQ 100MG BASE

N202270 003 Feb 02, 2012 Feb NEWA

METHIMAZOLE

TABLET; ORAL

METHIMAZOLE

AB BOCA PHARMA 5MG

A202068 001 Mar 07, 2012 Feb NEWA

TABLET; ORAL

METHIMAZOLE

AB	BOCA PHARMA	10MG	A202068 002	Mar 07, 2012	Feb	NEWA
----	-------------	------	-------------	--------------	-----	------

METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL

AA	SOLCO HLTHCARE	500MG	A086989 001		Mar	CMFD
----	----------------	-------	-------------	--	-----	------

AA		750MG	A086988 001		Mar	CMFD
----	--	-------	-------------	--	-----	------

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE PRESERVATIVE FREE

AP	APP PHARMS LLC	EQ 1GM BASE/VIAL	A040266 001	Feb 26, 1999	Jan	CMFD
----	----------------	------------------	-------------	--------------	-----	------

AP	PHARMACHEMIE BV	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A200171 001	Feb 27, 2012	Feb	NEWA
----	-----------------	-------------------------------------	-------------	--------------	-----	------

METHOTREXATE SODIUM

AP	+ BEDFORD	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A089341 001	Sep 16, 1986	Feb	CTEC
----	-----------	-------------------------------------	-------------	--------------	-----	------

METHOTREXATE SODIUM PRESERVATIVE FREE

AP	+ MYLAN INSTITUTIONAL	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A040767 001	Apr 30, 2007	Feb	CAHN
----	-----------------------	------------------------------------	-------------	--------------	-----	------

AP	ONCO THERAPIES LTD	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A201529 001	Mar 29, 2012	Mar	NEWA
----	--------------------	------------------------------------	-------------	--------------	-----	------

AP		EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A201529 002	Mar 29, 2012	Mar	NEWA
----	--	-------------------------------------	-------------	--------------	-----	------

AP		EQ 200MG BASE/8ML (EQ 25MG BASE/ML)	A201529 003	Mar 29, 2012	Mar	NEWA
----	--	-------------------------------------	-------------	--------------	-----	------

AP		EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A201529 004	Mar 29, 2012	Mar	NEWA
----	--	--------------------------------------	-------------	--------------	-----	------

AP		EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A201530 001	Mar 29, 2012	Mar	NEWA
----	--	------------------------------------	-------------	--------------	-----	------

METHYCLOTHIAZIDE

TABLET; ORAL

ENDURON

@ ABBOTT LABS PHARM

2.5MG

N012524 001

Mar DISC

@

5MG

N012524 004

Mar DISC

METHYCLOTHIAZIDE

AB	+ MYLAN PHARMS INC	5MG	A087672 001	Aug 17, 1982	Mar	CRLD
----	--------------------	-----	-------------	--------------	-----	------

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION

METHYLDOPATE HYDROCHLORIDE

@ TEVA PARENTERAL

50MG/ML

A072974 001 Nov 22, 1991 Mar DISC

METHYLNALTREXONE BROMIDE

INJECTABLE; SUBCUTANEOUS

RELISTOR

SALIX PHARMS

8MG/0.4ML

N021964 002 Sep 27, 2010 May CAHN

>A>	+	12MG/0.6ML (12MG/0.6ML)	N021964 003	Apr 24, 2008	Jun	NEWA
-----	---	-------------------------	-------------	--------------	-----	------

SOLUTION; SUBCUTANEOUS

RELISTOR

	+	SALIX PHARMS	12MG/0.6ML (12MG/0.6ML)	N021964 001	Apr 24, 2008	May	CAHN
--	---	--------------	-------------------------	-------------	--------------	-----	------

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

METHYLPHENIDATE HYDROCHLORIDE

>A>	AB	BARR LABS INC	20MG	A079031 001	Jul 13, 2012	Jun	NEWA
-----	----	---------------	------	-------------	--------------	-----	------

CAPSULE, EXTENDED RELEASE; ORAL

METHYLPHENIDATE HYDROCHLORIDE

>A>	AB	BARR LABS INC	30MG	A079031	002	Jul 13, 2012	Jun	NEWA
>A>	AB		40MG	A079031	003	Jul 13, 2012	Jun	NEWA

TABLET; ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB	SUN PHARM INDS INC	5MG	A090710	001	Mar 15, 2012	Feb	NEWA
AB		10MG	A090710	002	Mar 15, 2012	Feb	NEWA
AB		20MG	A090710	003	Mar 15, 2012	Feb	NEWA

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

METHYLPREDNISOLONE SODIUM SUCCINATE

>D>	AP	BEDFORD LABS	EQ 40MG BASE/VIAL	A040662	001	Feb 21, 2007	Jun	DISC
>A>	@		EQ 40MG BASE/VIAL	A040662	001	Feb 21, 2007	Jun	DISC
>D>	AP		EQ 125MG BASE/VIAL	A040641	002	Feb 21, 2007	Jun	DISC
>A>	@		EQ 125MG BASE/VIAL	A040641	002	Feb 21, 2007	Jun	DISC
>D>	AP		EQ 500MG BASE/VIAL	A040709	001	Feb 21, 2007	Jun	DISC
>D>	AP		EQ 500MG BASE/VIAL	A040641	003	Feb 21, 2007	Jun	DISC
>A>	@		EQ 500MG BASE/VIAL	A040709	001	Feb 21, 2007	Jun	DISC
>A>	@		EQ 500MG BASE/VIAL	A040641	003	Feb 21, 2007	Jun	DISC
>D>	AP		EQ 1GM BASE/VIAL	A040709	002	Feb 21, 2007	Jun	DISC
>D>	AP		EQ 1GM BASE/VIAL	A040641	004	Feb 21, 2007	Jun	DISC
>A>	@		EQ 1GM BASE/VIAL	A040641	004	Feb 21, 2007	Jun	DISC
>A>	@		EQ 1GM BASE/VIAL	A040709	002	Feb 21, 2007	Jun	DISC
	@	TEVA PARENTERAL	EQ 125MG BASE/VIAL	A081266	001	Nov 30, 1992	Mar	DISC

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

METOCLOPRAMIDE HYDROCHLORIDE

@	TEVA PARENTERAL	EQ 5MG BASE/ML	A073135	001	Nov 27, 1991	Jan	DISC
---	-----------------	----------------	---------	-----	--------------	-----	------

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

METOPROLOL SUCCINATE

>D>	AB	NESHER PHARMS	EQ 100MG TARTRATE	A076640	002	May 18, 2007	Jun	DISC
>A>	@		EQ 100MG TARTRATE	A076640	002	May 18, 2007	Jun	DISC
>D>	AB		EQ 200MG TARTRATE	A076640	001	May 18, 2007	Jun	DISC
>A>	@		EQ 200MG TARTRATE	A076640	001	May 18, 2007	Jun	DISC

METRONIDAZOLE

CREAM; TOPICAL

METRONIDAZOLE

AB	FOUGERA PHARMS	0.75%	A076408	001	May 28, 2004	Jan	CAHN
	NORITATE						
+	VALEANT INTL	1%	N020743	001	Sep 26, 1997	Apr	CAHN

GEL; TOPICAL

METRONIDAZOLE

AB	FOUGERA PHARMS	0.75%	A077018	001	Jun 06, 2006	Jan	CAHN
----	----------------	-------	---------	-----	--------------	-----	------

LOTION; TOPICAL

METRONIDAZOLE

AB	FOUGERA PHARMS	0.75%	A077197	001	May 24, 2006	Jan	CAHN
----	----------------	-------	---------	-----	--------------	-----	------

METYRAPONE

CAPSULE; ORAL

METOPIRONE

>A>	+	HRA PHARMA	250MG	N012911 002	Aug 09, 1996	Jun	CAHN
>D>	+	NOVARTIS	250MG	N012911 002	Aug 09, 1996	Jun	CAHN

TABLET; ORAL

METOPIRONE

>A>	@	HRA PHARMA	250MG	N012911 001		Jun	CAHN
>D>	@	NOVARTIS	250MG	N012911 001		Jun	CAHN

METYROSINE

CAPSULE; ORAL

DEMSEER

+	BIOVAIL TECHNOLOGIES	250MG	N017871 001		May	CAHN
---	----------------------	-------	-------------	--	-----	------

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE

AP		GLAND PHARMA LTD	EQ 1MG BASE/ML	A090696 001	Feb 29, 2012	Feb	NEWA
AP			EQ 5MG BASE/ML	A090850 001	Jan 25, 2012	Jan	NEWA

MIDODRINE HYDROCHLORIDE

TABLET; ORAL

PROAMATINE

AB		SHIRE LLC	2.5MG	N019815 001	Sep 06, 1996	Jan	CAHN
AB	+		5MG	N019815 002	Sep 06, 1996	Jan	CAHN
AB			10MG	N019815 003	Mar 20, 2002	Jan	CAHN

MIFEPRISTONE

TABLET; ORAL

KORLYM

+	CORCEPT THERAP	300MG	N202107 001	Feb 17, 2012	Feb	NEWA
---	----------------	-------	-------------	--------------	-----	------

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL

MINOCIN

AB		PRECISION DERMAT	EQ 50MG BASE	N050649 001	May 31, 1990	May	CAHN
	@		EQ 75MG BASE	N050649 003	Feb 12, 2001	May	CAHN
AB			EQ 100MG BASE	N050649 002	May 31, 1990	May	CAHN

INJECTABLE; INJECTION

MINOCIN

+	PRECISION DERMAT	EQ 100MG BASE/VIAL	N050444 001		May	CAHN
---	------------------	--------------------	-------------	--	-----	------

SUSPENSION; ORAL

MINOCIN

@	PRECISION DERMAT	EQ 50MG BASE/5ML	N050445 001		May	CAHN
---	------------------	------------------	-------------	--	-----	------

>A> MIRABEGRON

>A> TABLET, EXTENDED RELEASE; ORAL

>A> MYRBETRIQ

>A>		APGDI	25MG	N202611 001	Jun 28, 2012	Jun	NEWA
-----	--	-------	------	-------------	--------------	-----	------

>A>	+		50MG	N202611 002	Jun 28, 2012	Jun	NEWA
-----	---	--	------	-------------	--------------	-----	------

MITOMYCIN

FOR SOLUTION; TOPICAL

MITOSOL

+	MOBIUS THERAP	0.2MG/VIAL	N022572	001	Feb 07, 2012	Feb	NEWA
---	---------------	------------	---------	-----	--------------	-----	------

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION

MITOXANTRONE HYDROCHLORIDE

>D>	AP	FRESENIUS KABI ONCOL	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A078606	001	May 14, 2008	Jun	DISC
>A>		@	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A078606	001	May 14, 2008	Jun	DISC
>D>	AP		EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)	A078606	002	May 14, 2008	Jun	DISC
>A>		@	EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)	A078606	002	May 14, 2008	Jun	DISC
>D>	AP		EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	A078606	003	May 14, 2008	Jun	DISC
>A>		@	EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	A078606	003	May 14, 2008	Jun	DISC

MIVACURIUM CHLORIDE

INJECTABLE; INJECTION

MIVACURIUM CHLORIDE

>D>		@ PISGAH LABS	EQ 2MG BASE/ML	A078562	001	Apr 30, 2009	Jun	CAHN
>A>		@ STRIDES ARCOLAB LTD	EQ 2MG BASE/ML	A078562	001	Apr 30, 2009	Jun	CAHN

MODAFINIL

TABLET; ORAL

MODAFINIL

>A>								
>A>	AB	MYLAN PHARMS INC	100MG	A076594	001	Jul 16, 2012	Jun	NEWA
>A>	AB		200MG	A076594	002	Jul 16, 2012	Jun	NEWA
		PROVIGIL						
>D>		CEPHALON	100MG	N020717	001	Dec 24, 1998	Jun	CFTG
>A>	AB		100MG	N020717	001	Dec 24, 1998	Jun	CFTG
>D>		+	200MG	N020717	002	Dec 24, 1998	Jun	CFTG
>A>	AB	+	200MG	N020717	002	Dec 24, 1998	Jun	CFTG

MOMETASONE FUROATE

CREAM; TOPICAL

ELOCON

>A>	AB	+	MERCK SHARP DOHME	0.1%	N019625	001	May 06, 1987	Jun	CAHN
>D>	AB	+	SCHERING	0.1%	N019625	001	May 06, 1987	Jun	CAHN
			MOMETASONE FUROATE						
	AB		FOUGERA PHARMS	0.1%	A076171	001	Apr 08, 2005	Jan	CAHN
			LOTION; TOPICAL						
			MOMETASONE FUROATE						
	AB		FOUGERA PHARMS	0.1%	A075919	001	Nov 29, 2007	Jan	CAHN
			OINTMENT; TOPICAL						
			ELOCON						
	AB	+	MERCK SHARP DOHME	0.1%	N019543	001	Apr 30, 1987	May	CAHN
			MOMETASONE FUROATE						
	AB		FOUGERA PHARMS	0.1%	A077061	001	Mar 28, 2005	Jan	CAHN

MORPHINE SULFATE

INJECTABLE; INJECTION

DURAMORPH PF

>D>	AP	+	BAXTER HLTHCARE	0.5MG/ML	N018565 001	Sep 18, 1984	Jun	CAHN
>D>	AP	+		1MG/ML	N018565 002	Sep 18, 1984	Jun	CAHN
>A>	AP	+	HIKMA MAPLE	0.5MG/ML	N018565 001	Sep 18, 1984	Jun	CAHN
>A>	AP	+		1MG/ML	N018565 002	Sep 18, 1984	Jun	CAHN

INFUMORPH

>D>	+	BAXTER HLTHCARE	10MG/ML	N018565 003	Jul 19, 1991	Jun	CAHN
>D>	+		25MG/ML	N018565 004	Jul 19, 1991	Jun	CAHN
>A>	+	HIKMA MAPLE	10MG/ML	N018565 003	Jul 19, 1991	Jun	CAHN
>A>	+		25MG/ML	N018565 004	Jul 19, 1991	Jun	CAHN

INJECTABLE, LIPOSOMAL; EPIDURAL

DEPODUR

	@	PACIRA PHARMS INC	10MG/ML (10MG/ML)	N021671 001	May 18, 2004	May	CAHN
	@		15MG/1.5ML (10MG/ML)	N021671 002	May 18, 2004	May	CAHN
	@		20MG/2ML (10MG/ML)	N021671 003	May 18, 2004	May	CAHN

TABLET, EXTENDED RELEASE; ORAL

MORPHINE SULFATE

AB		RANBAXY LABS LTD	15MG	A078761 001	May 11, 2012	Apr	NEWA
AB			30MG	A078761 002	May 11, 2012	Apr	NEWA
AB			60MG	A078761 003	May 11, 2012	Apr	NEWA
AB			100MG	A078761 004	May 11, 2012	Apr	NEWA
AB			200MG	A078761 005	May 11, 2012	Apr	NEWA

ORAMORPH SR

	@	XANODYNE PHARMS INC	15MG	N019977 004	Nov 23, 1994	May	DISC
	@		30MG	N019977 001	Aug 15, 1991	May	DISC
	@		60MG	N019977 002	Aug 15, 1991	May	DISC
	@		100MG	N019977 003	Aug 15, 1991	May	DISC

MUPIROCIIN

OINTMENT; TOPICAL

MUPIROCIIN

AB		FOUGERA PHARMS	2%	A065192 001	Nov 30, 2005	Jan	CAHN
----	--	----------------	----	-------------	--------------	-----	------

NABUMETONE

TABLET; ORAL

NABUMETONE

AB		PROSAM LABS	500MG	A079093 001	Feb 27, 2009	Feb	CMFD
AB			750MG	A079093 002	Feb 27, 2009	Feb	CMFD

NAFTIFINE HYDROCHLORIDE

CREAM; TOPICAL

NAFTIN

	+	MERZ PHARMS	2%	N019599 002	Jan 13, 2012	Jan	NEWA
--	---	-------------	----	-------------	--------------	-----	------

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE

>D>	@	BAXTER HLTHCARE	0.4MG/ML	A070299 001	Sep 24, 1986	Jun	CAHN
>D>	@		0.4MG/ML	A070298 001	Sep 24, 1986	Jun	CAHN
>D>	@		0.4MG/ML	A070496 001	Sep 24, 1986	Jun	CAHN
>A>	@	HIKMA MAPLE	0.4MG/ML	A070496 001	Sep 24, 1986	Jun	CAHN
>A>	@		0.4MG/ML	A070299 001	Sep 24, 1986	Jun	CAHN
>A>	@		0.4MG/ML	A070298 001	Sep 24, 1986	Jun	CAHN

INJECTABLE; INJECTION

NALOXONE HYDROCHLORIDE

>D>	@	BAXTER HLTHCARE	0.02MG/ML	A071272	001	May 24, 1988	Jun	CAHN	
>D>	@		1MG/ML	A071273	001	May 24, 1988	Jun	CAHN	
>D>	@		1MG/ML	A071274	001	May 24, 1988	Jun	CAHN	
>D>	@		1MG/ML	A071287	001	May 24, 1988	Jun	CAHN	
>A>	@	HIKMA MAPLE	0.02MG/ML	A071272	001	May 24, 1988	Jun	CAHN	
>A>	@		1MG/ML	A071273	001	May 24, 1988	Jun	CAHN	
>A>	@		1MG/ML	A071274	001	May 24, 1988	Jun	CAHN	
>A>	@		1MG/ML	A071287	001	May 24, 1988	Jun	CAHN	
>D>	AP	+	HOSPIRA	0.4MG/ML	A070254	001	Jan 07, 1987	Jun	DISC
>A>	@		0.4MG/ML	A070254	001	Jan 07, 1987	Jun	DISC	

NALTREXONE HYDROCHLORIDE

TABLET; ORAL

NALTREXONE HYDROCHLORIDE

AB		SUN PHARMA GLOBAL	50MG	A090356	001	Feb 24, 2012	Feb	NEWA
----	--	-------------------	------	---------	-----	--------------	-----	------

NAPROXEN SODIUM

TABLET; ORAL

ANAPROX

AB		HOFFMANN LA ROCHE	EQ 250MG BASE	N018164	001		May	CAHN
----	--	-------------------	---------------	---------	-----	--	-----	------

ANAPROX DS

AB	+	HOFFMANN LA ROCHE	EQ 500MG BASE	N018164	003	Sep 30, 1987	May	CAHN
----	---	-------------------	---------------	---------	-----	--------------	-----	------

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

TABLET; ORAL

TREXIMET

+	SMITHKLINE BEECHAM	500MG;EQ 85MG BASE	N021926	001	Apr 15, 2008	May	CAHN
---	--------------------	--------------------	---------	-----	--------------	-----	------

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL

NARATRIPTAN

AB		MYLAN PHARMS INC	EQ 1MG BASE	A202431	001	May 31, 2012	May	NEWA
AB			EQ 2.5MG BASE	A202431	002	May 31, 2012	May	NEWA
AB		ORCHID HLTHCARE	EQ 1MG BASE	A091441	001	Apr 30, 2012	Apr	NEWA
AB			EQ 2.5MG BASE	A091441	002	Apr 30, 2012	Apr	NEWA

NEVIRAPINE

SUSPENSION; ORAL

NEVIRAPINE

AA		AUROBINDO	50MG/5ML	A077702	001	May 22, 2012	May	NEWA
----	--	-----------	----------	---------	-----	--------------	-----	------

VIRAMUNE

AA	+	BOEHRINGER INGELHEIM	50MG/5ML	N020933	001	Sep 11, 1998	May	CFTG
----	---	----------------------	----------	---------	-----	--------------	-----	------

TABLET; ORAL

NEVIRAPINE

AB		APOTEX INC	200MG	A203021	001	May 22, 2012	May	NEWA
AB		AUROBINDO	200MG	A077521	001	May 22, 2012	May	NEWA
AB		CIPLA	200MG	A077956	001	May 22, 2012	May	NEWA
AB		HETERO LABS LTD III	200MG	A078584	001	May 22, 2012	May	NEWA
AB		MICRO LABS LTD	200MG	A203080	001	May 22, 2012	May	NEWA
AB		MYLAN LABS	200MG	A078864	001	May 22, 2012	May	NEWA
AB		MYLAN PHARMS INC	200MG	A202523	001	May 22, 2012	May	NEWA
AB		PRINSTON INC	200MG	A078644	001	May 22, 2012	May	NEWA
AB		SCIEGEN PHARMS INC	200MG	A203176	001	May 22, 2012	May	NEWA
AB		STRIDES	200MG	A078195	001	May 22, 2012	May	NEWA

TABLET; ORAL

VIRAMUNE

AB	+	BOEHRINGER INGELHEIM	200MG	N020636	001	Jun 21, 1996	May	CFTG
----	---	----------------------	-------	---------	-----	--------------	-----	------

NIFEDIPINE

TABLET, EXTENDED RELEASE; ORAL

NIFEDIPINE

AB1		ACTAVIS	90MG	A077899	003	May 25, 2012	May	NEWA
-----	--	---------	------	---------	-----	--------------	-----	------

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

@ RANBAXY LABS LTD 75MG;25MG

A076951	001	Mar 30, 2005	Apr	DISC
---------	-----	--------------	-----	------

NITROGLYCERIN

OINTMENT; INTRA-ANAL

RECTIV

+ APTALIS PHARMA 0.4%

N021359	001	Jun 21, 2011	Jan	CAHN
---------	-----	--------------	-----	------

NIZATIDINE

CAPSULE; ORAL

AXID

@ SMITHKLINE BEECHAM 150MG

N019508	001	Apr 12, 1988	Mar	DISC
---------	-----	--------------	-----	------

@ 300MG

N019508	002	Apr 12, 1988	Mar	DISC
---------	-----	--------------	-----	------

NIZATIDINE

@ MYLAN PHARMS INC 150MG

A075934	001	Jul 09, 2002	Apr	DISC
---------	-----	--------------	-----	------

AB + 300MG

A075806	002	Jul 05, 2002	Apr	CRLD
---------	-----	--------------	-----	------

@ 300MG

A075934	002	Jul 09, 2002	Apr	DISC
---------	-----	--------------	-----	------

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

NOREPINEPHRINE BITARTRATE

AP CLARIS LIFESCIENCES EQ 1MG BASE/ML

A040859	001	Mar 27, 2012	May	CAHN
---------	-----	--------------	-----	------

AP SINTETICA EQ 1MG BASE/ML

A040859	001	Mar 27, 2012	Mar	NEWA
---------	-----	--------------	-----	------

NYSTATIN

CREAM; TOPICAL

NYSTATIN

AT FOUGERA PHARMS 100,000 UNITS/GM

A062129	001		Jan	CAHN
---------	-----	--	-----	------

OINTMENT; TOPICAL

NYSTATIN

AT + FOUGERA PHARMS 100,000 UNITS/GM

A062124	002	Sep 23, 1982	Jan	CAHN
---------	-----	--------------	-----	------

POWDER; TOPICAL

NYSTATIN

>D> AT NESHER PHARMS 100,000 UNITS/GM

A065321	001	Aug 18, 2006	Jun	DISC
---------	-----	--------------	-----	------

>A> @ 100,000 UNITS/GM

A065321	001	Aug 18, 2006	Jun	DISC
---------	-----	--------------	-----	------

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

MYKACET

>D> @ ACTAVIS MID ATLANTIC 100,000 UNITS/GM;0.1%

A062367	001	May 28, 1985	Jun	CAHN
---------	-----	--------------	-----	------

>A> @ G AND W LABS INC 100,000 UNITS/GM;0.1%

A062367	001	May 28, 1985	Jun	CAHN
---------	-----	--------------	-----	------

OINTMENT; TOPICAL

MYKACET

>D> @ ACTAVIS MID ATLANTIC 100,000 UNITS/GM;0.1%

A062733	001	Mar 09, 1987	Jun	CAHN
---------	-----	--------------	-----	------

>A> @ G AND W LABS INC 100,000 UNITS/GM;0.1%

A062733	001	Mar 09, 1987	Jun	CAHN
---------	-----	--------------	-----	------

OFLOXACIN

TABLET; ORAL

OFLOXACIN

@ RANBAXY LABS LTD

200MG

A076220 001 Sep 02, 2003 Apr DISC

@

300MG

A076220 002 Sep 02, 2003 Apr DISC

@

400MG

A076220 003 Sep 02, 2003 Apr DISC

OLANZAPINE

INJECTABLE; INTRAMUSCULAR

OLANZAPINE

AP PHARMAFORCE

10MG/VIAL

A201741 001 Mar 20, 2012 Mar NEWA

AP SANDOZ INC

10MG/VIAL

A201588 001 Oct 24, 2011 Mar CAHN

TABLET; ORAL

OLANZAPINE

AB APOTEX INC

2.5MG

A090798 001 Apr 23, 2012 Apr NEWA

AB

5MG

A090798 002 Apr 23, 2012 Apr NEWA

AB

7.5MG

A090798 003 Apr 23, 2012 Apr NEWA

AB

10MG

A090798 004 Apr 23, 2012 Apr NEWA

AB

15MG

A090798 005 Apr 23, 2012 Apr NEWA

AB

20MG

A090798 006 Apr 23, 2012 Apr NEWA

AB AUROBINDO PHARMA LTD

2.5MG

A202050 001 Apr 23, 2012 Apr NEWA

AB

5MG

A202050 002 Apr 23, 2012 Apr NEWA

AB

7.5MG

A202050 003 Apr 23, 2012 Apr NEWA

AB

10MG

A202050 004 Apr 23, 2012 Apr NEWA

AB

15MG

A202050 005 Apr 23, 2012 Apr NEWA

AB

20MG

A202050 006 Apr 23, 2012 Apr NEWA

AB DR REDDYS LABS LTD

2.5MG

A076255 001 Apr 23, 2012 Apr NEWA

AB

5MG

A076255 002 Apr 23, 2012 Apr NEWA

AB

7.5MG

A076255 003 Apr 23, 2012 Apr NEWA

AB

10MG

A076255 004 Apr 23, 2012 Apr NEWA

AB

15MG

A076133 001 Apr 23, 2012 Apr NEWA

AB MYLAN

2.5MG

A076866 001 Apr 23, 2012 Apr NEWA

AB

5MG

A076866 002 Apr 23, 2012 Apr NEWA

AB

7.5MG

A076866 003 Apr 23, 2012 Apr NEWA

AB

10MG

A076866 004 Apr 23, 2012 Apr NEWA

AB

15MG

A076866 005 Apr 23, 2012 Apr NEWA

AB

20MG

A076866 006 Apr 23, 2012 Apr NEWA

AB ORCHID HLTHCARE

2.5MG

A202287 001 Apr 23, 2012 Apr NEWA

AB

5MG

A202287 002 Apr 23, 2012 Apr NEWA

AB

7.5MG

A202287 003 Apr 23, 2012 Apr NEWA

AB

10MG

A202287 004 Apr 23, 2012 Apr NEWA

AB

15MG

A202287 005 Apr 23, 2012 Apr NEWA

AB

20MG

A202287 006 Apr 23, 2012 Apr NEWA

AB SUN PHARM INDS

2.5MG

A091038 001 Apr 23, 2012 Apr NEWA

AB

5MG

A091038 002 Apr 23, 2012 Apr NEWA

AB

7.5MG

A091038 003 Apr 23, 2012 Apr NEWA

AB

10MG

A091038 004 Apr 23, 2012 Apr NEWA

AB

15MG

A091038 005 Apr 23, 2012 Apr NEWA

AB

20MG

A091038 006 Apr 23, 2012 Apr NEWA

AB TORRENT PHARMS LTD

2.5MG

A091434 001 Apr 23, 2012 Apr NEWA

AB

5MG

A091434 002 Apr 23, 2012 Apr NEWA

AB

7.5MG

A091434 003 Apr 23, 2012 Apr NEWA

AB

10MG

A091434 004 Apr 23, 2012 Apr NEWA

AB

15MG

A091434 005 Apr 23, 2012 Apr NEWA

AB

20MG

A091434 006 Apr 23, 2012 Apr NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

OLANZAPINE

AB	BARR LABS INC	5MG	A077243 001	Jan 30, 2012	Jan	NEWA
AB		10MG	A077243 002	Jan 30, 2012	Jan	NEWA
AB		15MG	A077243 003	Jan 30, 2012	Jan	NEWA
AB		20MG	A077243 004	Jan 30, 2012	Jan	NEWA
AB	SUN PHARM INDS	5MG	A090881 001	Feb 28, 2012	Feb	NEWA
AB		10MG	A090881 002	Feb 28, 2012	Feb	NEWA
AB		15MG	A090881 003	Feb 28, 2012	Feb	NEWA
AB		20MG	A090881 004	Feb 28, 2012	Feb	NEWA

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

OMEPRAZOLE

AB	DR REDDYS LABS LTD	10MG	A078490 002	Mar 16, 2009	Apr	NEWA
AB		20MG	A078490 003	Mar 16, 2009	Apr	NEWA

ONDANSETRON

TABLET, ORALLY DISINTEGRATING; ORAL

ONDANSETRON

>D>	AB	NESHER PHARMS	4MG	A077717 001	Jun 25, 2007	Jun	DISC
>A>		@	4MG	A077717 001	Jun 25, 2007	Jun	DISC
>D>	AB		8MG	A077717 002	Jun 25, 2007	Jun	DISC
>A>		@	8MG	A077717 002	Jun 25, 2007	Jun	DISC

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

ONDANSETRON HYDROCHLORIDE

>D>	AP	BAXTER HLTHCARE	EQ 2MG BASE/ML	A077365 001	Dec 26, 2006	Jun	CAHN
>A>	AP	GLAND PHARMA LTD	EQ 2MG BASE/ML	A090648 001	Jun 15, 2012	Jun	NEWA
>A>	AP	HIKMA MAPLE	EQ 2MG BASE/ML	A077365 001	Dec 26, 2006	Jun	CAHN
		ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE					
>D>	AP	BAXTER HLTHCARE	EQ 2MG BASE/ML	A077541 001	Dec 26, 2006	Jun	CAHN
>A>	AP	HIKMA MAPLE	EQ 2MG BASE/ML	A077541 001	Dec 26, 2006	Jun	CAHN

OSELTAMIVIR PHOSPHATE

FOR SUSPENSION; ORAL

TAMIFLU

+	ROCHE	EQ 6MG BASE/ML	N021246 002	Mar 21, 2011	Jan	CRLD
---	-------	----------------	-------------	--------------	-----	------

OXACILLIN SODIUM

INJECTABLE; INJECTION

OXACILLIN SODIUM

AP	SAGENT PHARMS	EQ 1GM BASE/VIAL	A091246 001	Mar 30, 2012	Mar	NEWA
AP		EQ 2GM BASE/VIAL	A091246 002	Mar 30, 2012	Mar	NEWA
AP		EQ 10GM BASE/VIAL	A091245 001	Mar 30, 2012	Mar	NEWA

OXALIPLATIN

INJECTABLE; IV (INFUSION)

OXALIPLATIN

AP	+	TEVA PHARMS	50MG/10ML (5MG/ML)	N022160 001	Aug 07, 2009	Mar	CRLD
AP	+		100MG/20ML (5MG/ML)	N022160 002	Aug 07, 2009	Mar	CRLD

OXICONAZOLE NITRATE

CREAM; TOPICAL

OXISTAT

+	FOUGERA PHARMS	EQ 1% BASE	N019828 001	Dec 30, 1988	Jan	CAHN
---	----------------	------------	-------------	--------------	-----	------

OXTRIPHYLLINE

TABLET, EXTENDED RELEASE; ORAL

CHOLEDYL SA

>D>	+	WARNER CHILCOTT	400MG	A087863 001	May 24, 1983	Jun	CAHN
>D>	+		600MG	A086742 001		Jun	CAHN
>A>	+	WARNER CHILCOTT LLC	400MG	A087863 001	May 24, 1983	Jun	CAHN
>A>	+		600MG	A086742 001		Jun	CAHN

OXYBUTYNIN

GEL, METERED; TRANSDERMAL

ANTUROL

+	ARROW INTL	3%	N202513 001	Dec 07, 2011	Apr	CAHN
+	WATSON LABS INC	3%	N202513 001	Dec 07, 2011	Feb	CAHN

OXYBUTYNIN CHLORIDE

TABLET; ORAL

DITROPAN

@ JANSSEN PHARMS 5MG

N017577 001		Mar	DISC
-------------	--	-----	------

OXYBUTYNIN CHLORIDE

AB	+	VINTAGE PHARMS	5MG	A075079 001	Oct 31, 1997	Mar	CRLD
----	---	----------------	-----	-------------	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

OXYBUTYNIN CHLORIDE

AB		MYLAN PHARMS INC	15MG	A076644 002	May 10, 2007	Mar	NEWA
----	--	------------------	------	-------------	--------------	-----	------

OXYCODONE HYDROCHLORIDE

SOLUTION; ORAL

OXYCODONE HYDROCHLORIDE

+	VISTAPHARM	5MG/5ML	N201194 001	Jan 12, 2012	Jan	NEWA
---	------------	---------	-------------	--------------	-----	------

TABLET; ORAL

OXYCODONE HYDROCHLORIDE

AB		MALLINCKRODT INC	5MG	A076758 003	Mar 19, 2007	Apr	NEWA
----	--	------------------	-----	-------------	--------------	-----	------

OXYMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

OPANA ER

@ ENDO PHARMS 5MG

N021610 001	Jun 22, 2006	May	DISC
-------------	--------------	-----	------

@ 10MG

N021610 002	Jun 22, 2006	May	DISC
-------------	--------------	-----	------

@ 20MG

N021610 003	Jun 22, 2006	May	DISC
-------------	--------------	-----	------

@ 30MG

N021610 007	Feb 29, 2008	May	DISC
-------------	--------------	-----	------

@ 40MG

N021610 004	Jun 22, 2006	May	DISC
-------------	--------------	-----	------

OXYMORPHONE HYDROCHLORIDE

IMPAX LABS 5MG

A079087 001	Jun 14, 2010	May	CTEC
-------------	--------------	-----	------

10MG

A079087 003	Jun 14, 2010	May	CTEC
-------------	--------------	-----	------

20MG

A079087 005	Jun 14, 2010	May	CTEC
-------------	--------------	-----	------

30MG

A079087 006	Jul 22, 2010	May	CTEC
-------------	--------------	-----	------

40MG

A079087 007	Jun 14, 2010	May	CTEC
-------------	--------------	-----	------

OXYTOCIN

INJECTABLE; INJECTION

OXYTOCIN

@ TEVA PARENTERAL

10USP UNITS/ML (10USP UNITS/ML)

A077453 001 Jan 24, 2008 Jan DISC

@

100USP UNITS/10ML (10USP
UNITS/ML)

A077453 002 Jan 24, 2008 Mar DISC

PACLITAXEL

INJECTABLE; INJECTION

TAXOL

@ CORDEN PHARMA

6MG/ML

N020262 001 Dec 29, 1992 Mar CAHN

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

AREDIA

@ NOVARTIS

30MG/VIAL

N020036 001 Oct 31, 1991 Mar DISC

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

CAPSULE, DELAYED RELEASE; ORAL

CREON

>A>

ABBOTT LABS

15,000USP UNITS;3,000USP
UNITS;9,500USP UNITS

N020725 004 Jul 12, 2011 Jun NEWA

30,000USP UNITS;6,000USP
UNITS;19,000USP UNITS

N020725 001 Apr 30, 2009 Feb CAHN

60,000USP UNITS;12,000USP
UNITS;38,000USP UNITS

N020725 002 Apr 30, 2009 Feb CAHN

+

120,000USP UNITS;24,000USP
UNITS;76,000USP UNITS

N020725 003 Apr 30, 2009 Feb CAHN

PERTZYE

DIGESTIVE CARE INC

30,250USP/UNITS;8,000USP/UNITS;28
,750USP/UNITS

N022175 001 May 17, 2012 May NEWA

+

60,500USP/UNITS;16,000USP/UNITS;5
7,500USP/UNITS

N022175 002 May 17, 2012 May NEWA

ULTRESA

APTALIS PHARMA US

27,600USP UNITS;13,800USP
UNITS;27,600USP UNITS

N022222 001 Mar 01, 2012 Mar NEWA

41,400USP UNITS;20,700USP
UNITS;41,400USP UNITS

N022222 002 Mar 01, 2012 Mar NEWA

+

46,000USP UNITS;23,000USP
UNITS;46,000USP UNITS

N022222 003 Mar 01, 2012 Mar NEWA

ZENPEP

APTALIS PHARMA US

16,000USP UNITS;3,000USP
UNITS;10,000USP UNITS

N022210 005 Jun 15, 2011 Apr NEWA

109,000USP UNITS;20,000USP
UNITS;68,000USP UNITS

N022210 004 Aug 27, 2009 Apr CRLD

+

136,000USP UNITS;25,000USP
UNITS;85,000USP UNITS

N022210 006 Jul 13, 2011 Apr NEWA

TABLET; ORAL

VIOKACE

APTALIS PHARMA US

39,150USP UNITS;10,440USP
UNITS;39,150USP UNITS

N022542 001 Mar 01, 2012 Mar NEWA

+

78,300USP UNITS;20,880USP
UNITS;78,300USP UNITS

N022542 002 Mar 01, 2012 Mar NEWA

PANTOPRAZOLE SODIUM

TABLET, DELAYED RELEASE; ORAL

PANTOPRAZOLE SODIUM

AB APOTEX INC

EQ 20MG BASE

A090807 001 May 02, 2012 Apr NEWA

AB

EQ 40MG BASE

A090807 002 May 02, 2012 Apr NEWA

AB

MACLEODS PHARMS LTD

EQ 20MG BASE

A200821 001 Feb 16, 2012 Jan NEWA

AB

EQ 40MG BASE

A200821 002 Feb 16, 2012 Jan NEWA

TABLET, DELAYED RELEASE; ORAL

PANTOPRAZOLE SODIUM

AB	RANBAXY LABS LTD	EQ 20MG BASE	A200794 001	May 02, 2012	Apr	NEWA
AB		EQ 40MG BASE	A200794 002	May 02, 2012	Apr	NEWA

PAROXETINE HYDROCHLORIDE

TABLET; ORAL

PAROXETINE HYDROCHLORIDE

AB	ACTAVIS ELIZABETH	EQ 10MG BASE	A076968 001	Jun 21, 2010	Feb	CMFD
AB		EQ 20MG BASE	A076968 002	Jun 21, 2010	Feb	CMFD
AB		EQ 30MG BASE	A076968 003	Jun 21, 2010	Feb	CMFD
AB		EQ 40MG BASE	A076968 004	Jun 21, 2010	Feb	CMFD

PEGAPTANIB SODIUM

INJECTABLE; INTRAVITREAL

MACUGEN

+	VALEANT PHARMS LLC	EQ 0.3MG ACID/0.09ML	N021756 001	Dec 17, 2004	May	CAHN
---	--------------------	----------------------	-------------	--------------	-----	------

PEGINESATIDE ACETATE

SOLUTION; INTRAVENOUS, SUBCUTANEOUS

OMONTYS

+	AFFYMAX	EQ 10MG BASE/ML (EQ 10MG BASE/ML)	N202799 007	Mar 27, 2012	Mar	NEWA
+		EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N202799 008	Mar 27, 2012	Mar	NEWA

OMONTYS PRESERVATIVE FREE

+	AFFYMAX	EQ 1MG BASE/0.5ML (EQ 1MG BASE/0.5ML)	N202799 001	Mar 27, 2012	Mar	NEWA
+		EQ 2MG BASE/0.5ML (EQ 2MG BASE/0.5ML)	N202799 002	Mar 27, 2012	Mar	NEWA
+		EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)	N202799 003	Mar 27, 2012	Mar	NEWA
+		EQ 4MG BASE/0.5ML (EQ 4MG BASE/0.5ML)	N202799 004	Mar 27, 2012	Mar	NEWA
+		EQ 5MG BASE/0.5ML (EQ 5MG BASE/0.5ML)	N202799 005	Mar 27, 2012	Mar	NEWA
+		EQ 6MG BASE/0.5ML (EQ 6MG BASE/0.5ML)	N202799 006	Mar 27, 2012	Mar	NEWA

PENTOBARBITAL SODIUM

INJECTABLE; INJECTION

NEMBUTAL SODIUM

+	OAK PHARMS	50MG/ML	A083246 001		Feb	CAHN
---	------------	---------	-------------	--	-----	------

PERINDOPRIL ERBUMINE

TABLET; ORAL

ACEON

AB	XOMA	2MG	N020184 001	Dec 30, 1993	Jan	CAHN
AB		4MG	N020184 002	Dec 30, 1993	Jan	CAHN
AB	+	8MG	N020184 003	Dec 30, 1993	Jan	CAHN

PERMETHRIN

CREAM; TOPICAL

ELIMITE

AB	+	RENAISSANCE PHARMA	5%	N019855 001	Aug 25, 1989	May	CAHN
----	---	--------------------	----	-------------	--------------	-----	------

PHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE; ORAL

DIBENZYLINE

>D>	+	WELLSPRING PHARM	10MG	N008708 001		Jun	CFTG
-----	---	------------------	------	-------------	--	-----	------

CAPSULE; ORAL									
DIBENZYLINE									
>A>	AB	+	WELLSPRING PHARM	10MG	N008708 001		Jun	CFTG	
>A>			PHENOXYBENZAMINE HYDROCHLORIDE						
>A>	AB		ROXANE	10MG	A201050 001	Jul 16, 2012	Jun	NEWA	
<u>PHENTERMINE HYDROCHLORIDE</u>									
CAPSULE; ORAL									
PHENTERMINE HYDROCHLORIDE									
AA			LANNETT	15MG	A087022 002	Jan 20, 2012	Feb	NEWA	
TABLET; ORAL									
PHENTERMINE HYDROCHLORIDE									
			@ SANDOZ INC	30MG	A088605 001	Sep 28, 1987	Feb	DISC	
TABLET, ORALLY DISINTEGRATING; ORAL									
SUPRENZA									
			CITIUS PHARMS	30MG	N202088 002	Jun 13, 2011	Apr	CRLD	
		+		37.5MG	N202088 003	Mar 27, 2012	Apr	CRLD	
				37.5MG	N202088 003	Mar 27, 2012	Mar	NEWA	
<u>PHENTERMINE RESIN COMPLEX</u>									
CAPSULE, EXTENDED RELEASE; ORAL									
PHENTERMINE RESIN COMPLEX									
		+	LANNETT HOLDINGS INC	EQ 15MG BASE	A040872 001	Jul 28, 2011	Jan	CRLD	
		+		EQ 30MG BASE	A040872 002	Jul 28, 2011	Jan	CRLD	
<u>PHENYTOIN SODIUM</u>									
INJECTABLE; INJECTION									
PHENYTOIN SODIUM									
>D>	AP	+	BAXTER HLTHCARE	50MG/ML	A084307 001		Jun	CAHN	
>A>	AP	+	HIKMA MAPLE	50MG/ML	A084307 001		Jun	CAHN	
<u>PHYTONADIONE</u>									
INJECTABLE; INJECTION									
PHYTONADIONE									
BP		+	INTL MEDICATION	1MG/0.5ML	A083722 001		Feb	CRLD	
TABLET; ORAL									
MEPHYTON									
>D>		+	BIOVAIL TECHNOLOGIES	5MG	N010104 003		Jun	CAHN	
>A>		+	VALEANT PHARMS	5MG	N010104 003		Jun	CAHN	
<u>PINDOLOL</u>									
TABLET; ORAL									
PINDOLOL									
			@ MYLAN PHARMS INC	5MG	A074013 001	Sep 24, 1992	May	CAHN	
			@	10MG	A074018 001	Sep 24, 1992	May	CAHN	
<u>PIOGLITAZONE HYDROCHLORIDE</u>									
TABLET; ORAL									
ACTOS									
			TAKEDA PHARMS USA	EQ 15MG BASE	N021073 001	Jul 15, 1999	Mar	CAHN	
				EQ 30MG BASE	N021073 002	Jul 15, 1999	Mar	CAHN	
		+		EQ 45MG BASE	N021073 003	Jul 15, 1999	Mar	CAHN	

POTASSIUM CHLORIDE

TABLET, EXTENDED RELEASE; ORAL

K+10

	@ FUTURE PAK	10MEQ	A070999 001	Oct 22, 1987	Mar	DISC
	KAON CL-10					
	@ SAVAGE LABS	10MEQ	N017046 002		Mar	DISC
	KLOR-CON M20					
AB +	UPSHER SMITH LABS	20MEQ	A074726 001	Nov 20, 1998	Mar	CRLD
	KLOTRIX					
	@ APOTHECON	10MEQ	N017850 001		Mar	DISC
	POTASSIUM CHLORIDE					
	@ NESHER PHARMS	20MEQ	A076044 001	Apr 05, 2002	Mar	DISC
	@ SCHERING	10MEQ	N019439 002	Jun 13, 1986	Mar	DISC
	@	20MEQ	N019439 001	Jun 13, 1986	Mar	DISC

POTASSIUM CITRATE

FOR SOLUTION; ORAL

POTASSIUM CITRATE

	@ NOVA K	10MEQ/PACKET	N019647 002	Oct 13, 1988	Feb	CAHN
	@	20MEQ/PACKET	N019647 001	Oct 13, 1988	Feb	CAHN

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

AB	APOTEX INC	0.125MG	A090151 001	Apr 30, 2012	Apr	NEWA
AB		0.25MG	A090151 002	Apr 30, 2012	Apr	NEWA
AB		0.5MG	A090151 003	Apr 30, 2012	Apr	NEWA
AB		0.75MG	A090151 006	Apr 30, 2012	Apr	NEWA
AB		1MG	A090151 004	Apr 30, 2012	Apr	NEWA
AB		1.5MG	A090151 005	Apr 30, 2012	Apr	NEWA

PRAVASTATIN SODIUM

TABLET; ORAL

PRAVASTATIN SODIUM

>D>	AB	PLIVA HRVATSKA DOO	10MG	A077730 001	Nov 21, 2006	Jun	DISC
>A>		@	10MG	A077730 001	Nov 21, 2006	Jun	DISC
>D>	AB		20MG	A077730 002	Nov 21, 2006	Jun	DISC
>A>		@	20MG	A077730 002	Nov 21, 2006	Jun	DISC
>D>			30MG	A077730 003	Nov 21, 2006	Jun	DISC
>A>		@	30MG	A077730 003	Nov 21, 2006	Jun	DISC
>D>	AB		40MG	A077730 005	Nov 21, 2006	Jun	DISC
>A>		@	40MG	A077730 005	Nov 21, 2006	Jun	DISC
		@ RANBAXY LABS LTD	10MG	A076445 001	Apr 23, 2007	Apr	DISC
		@	20MG	A076445 002	Apr 23, 2007	Apr	DISC
		@	40MG	A076445 003	Apr 23, 2007	Apr	DISC
		@	80MG	A076445 004	Apr 23, 2007	Apr	DISC

PREDNICARBATE

CREAM; TOPICAL

PREDNICARBATE

AB	FOUGERA PHARMS	0.1%	A077287 001	Sep 19, 2006	Jan	CAHN
----	----------------	------	-------------	--------------	-----	------

OINTMENT; TOPICAL

PREDNICARBATE

AB	FOUGERA PHARMS	0.1%	A077236 001	Mar 09, 2007	Jan	CAHN
----	----------------	------	-------------	--------------	-----	------

PREDNISOLONE

SYRUP; ORAL

PREDNISOLONE

>D>	AA	+	NESHER PHARMS	5MG/5ML	A040423	001	Oct 22,	2001	Jun	DISC
>A>			@	5MG/5ML	A040423	001	Oct 22,	2001	Jun	DISC
>D>	AA	+		15MG/5ML	A040364	001	Apr 10,	2002	Jun	DISC
>A>			@	15MG/5ML	A040364	001	Apr 10,	2002	Jun	DISC

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL

PREDNISOLONE SODIUM PHOSPHATE

>D>	AA		NESHER PHARMS	EQ 5MG BASE/5ML	A076982	001	May 24,	2005	Jun	DISC
>A>			@	EQ 5MG BASE/5ML	A076982	001	May 24,	2005	Jun	DISC

PREGABALIN

CAPSULE; ORAL

LYRICA

>D>			PF PRISM	25MG	N021446	001	Dec 30,	2004	Jun	CFTG
>A>	AB			25MG	N021446	001	Dec 30,	2004	Jun	CFTG
				25MG	N021446	001	Dec 30,	2004	Jan	CAHN
>D>				50MG	N021446	002	Dec 30,	2004	Jun	CFTG
>A>	AB			50MG	N021446	002	Dec 30,	2004	Jun	CFTG
				50MG	N021446	002	Dec 30,	2004	Jan	CAHN
>D>				75MG	N021446	003	Dec 30,	2004	Jun	CFTG
>A>	AB			75MG	N021446	003	Dec 30,	2004	Jun	CFTG
				75MG	N021446	003	Dec 30,	2004	Jan	CAHN
				100MG	N021446	004	Dec 30,	2004	Jan	CAHN
>D>				150MG	N021446	005	Dec 30,	2004	Jun	CFTG
>A>	AB			150MG	N021446	005	Dec 30,	2004	Jun	CFTG
				150MG	N021446	005	Dec 30,	2004	Jan	CAHN
>D>				200MG	N021446	006	Dec 30,	2004	Jun	CFTG
>A>	AB			200MG	N021446	006	Dec 30,	2004	Jun	CFTG
				200MG	N021446	006	Dec 30,	2004	Jan	CAHN
>D>				225MG	N021446	007	Dec 30,	2004	Jun	CFTG
>A>	AB			225MG	N021446	007	Dec 30,	2004	Jun	CFTG
				225MG	N021446	007	Dec 30,	2004	Jan	CAHN
>D>		+		300MG	N021446	008	Dec 30,	2004	Jun	CFTG
>A>	AB	+		300MG	N021446	008	Dec 30,	2004	Jun	CFTG
		+		300MG	N021446	008	Dec 30,	2004	Jan	CAHN
>A>			PREGABALIN							
>A>	AB		LUPIN LTD	25MG	A091040	001	Jul 03,	2012	Jun	NEWA
>A>	AB			50MG	A091040	002	Jul 03,	2012	Jun	NEWA
>A>	AB			75MG	A091040	003	Jul 03,	2012	Jun	NEWA
>A>	AB			100MG	A091040	004	Jul 03,	2012	Jun	NEWA
>A>	AB			150MG	A091040	005	Jul 03,	2012	Jun	NEWA
>A>	AB			200MG	A091040	006	Jul 03,	2012	Jun	NEWA
>A>	AB			225MG	A091040	007	Jul 03,	2012	Jun	NEWA
>A>	AB			300MG	A091040	008	Jul 03,	2012	Jun	NEWA
>A>	AB		TEVA PHARMS	25MG	A091219	001	Jul 03,	2012	Jun	NEWA
>A>	AB			50MG	A091219	002	Jul 03,	2012	Jun	NEWA
>A>	AB			75MG	A091224	001	Jul 03,	2012	Jun	NEWA
>A>	AB			100MG	A091224	002	Jul 03,	2012	Jun	NEWA
>A>	AB			150MG	A091224	003	Jul 03,	2012	Jun	NEWA
>A>	AB			200MG	A091224	004	Jul 03,	2012	Jun	NEWA
>A>	AB			225MG	A091224	005	Jul 03,	2012	Jun	NEWA

CAPSULE; ORAL

>A> PREGABALIN

>A>	AB	TEVA PHARMS	300MG	A091224	006	Jul 03, 2012	Jun	NEWA
>A>	AB	WATSON LABS INC	25MG	A091221	001	Jul 03, 2012	Jun	NEWA
>A>	AB		50MG	A091221	002	Jul 03, 2012	Jun	NEWA
>A>	AB		75MG	A091221	003	Jul 03, 2012	Jun	NEWA
>A>	AB		100MG	A091221	004	Jul 03, 2012	Jun	NEWA
>A>	AB		150MG	A091221	005	Jul 03, 2012	Jun	NEWA
>A>	AB		200MG	A091221	006	Jul 03, 2012	Jun	NEWA
>A>	AB		225MG	A091221	007	Jul 03, 2012	Jun	NEWA
>A>	AB		300MG	A091221	008	Jul 03, 2012	Jun	NEWA

SOLUTION; ORAL

LYRICA

+	PF PRISM	20MG/ML	N022488	001	Jan 04, 2010	Jan	CAHN
---	----------	---------	---------	-----	--------------	-----	------

PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CITANEST PLAIN DENTAL

@	DENTSPLY PHARM	4%	N021382	001		May	DISC
---	----------------	----	---------	-----	--	-----	------

PRILOCAINE HYDROCHLORIDE

+	SEPTODONT INC	4%	A079235	001	Sep 29, 2010	May	CRLD
---	---------------	----	---------	-----	--------------	-----	------

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

PROCAINAMIDE HYDROCHLORIDE

>D>	@	BAXTER HLTHCARE	100MG/ML	A089029	001	Apr 17, 1986	Jun	CAHN
>D>	@		500MG/ML	A089030	001	Apr 17, 1986	Jun	CAHN
>A>	@	HIKMA MAPLE	100MG/ML	A089029	001	Apr 17, 1986	Jun	CAHN
>A>	@		500MG/ML	A089030	001	Apr 17, 1986	Jun	CAHN

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION

PROCHLORPERAZINE EDISYLATE

>D>	@	BAXTER HLTHCARE	EQ 5MG BASE/ML	A089523	001	May 03, 1988	Jun	CAHN
>D>	AP	+	EQ 5MG BASE/ML	A089903	001	Aug 29, 1989	Jun	CAHN
>A>	@	HIKMA MAPLE	EQ 5MG BASE/ML	A089523	001	May 03, 1988	Jun	CAHN
>A>	AP	+	EQ 5MG BASE/ML	A089903	001	Aug 29, 1989	Jun	CAHN

PROGESTERONE

CAPSULE; ORAL

PROGESTERONE

AB	TEVA PHARMS	100MG	A202121	001	Feb 29, 2012	Feb	NEWA
AB		200MG	A202121	002	Feb 29, 2012	Feb	NEWA
	PROMETRIUM						
AB	ABBOTT LABS	100MG	N019781	001	May 14, 1998	Feb	CFTG
AB	+	200MG	N019781	002	Oct 15, 1999	Feb	CFTG

PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE

>A>	AA	TRIS PHARMA INC	6.25MG/5ML	A091675	001	Jun 28, 2012	Jun	NEWA
-----	----	-----------------	------------	---------	-----	--------------	-----	------

PROPAPENONE HYDROCHLORIDE

TABLET; ORAL

PROPAPENONE HYDROCHLORIDE

>D>	AB	NESHER PHARMS	150MG	A076193	001	Feb 07, 2002	Jun	DISC
-----	----	---------------	-------	---------	-----	--------------	-----	------

TABLET; ORAL

PROPAFENONE HYDROCHLORIDE

>A>		@ NESHER PHARMS	150MG	A076193 001	Feb 07, 2002	Jun	DISC
>D>	AB		225MG	A076193 002	Feb 07, 2002	Jun	DISC
>A>		@	225MG	A076193 002	Feb 07, 2002	Jun	DISC
>D>	AB		300MG	A076193 003	Feb 07, 2002	Jun	DISC
>A>		@	300MG	A076193 003	Feb 07, 2002	Jun	DISC

PYRIDOSTIGMINE BROMIDE

TABLET; ORAL

MESTINON

>D>	AB	+	VALEANT PHARM INTL	60MG	N009829 002		Jun	CAHN
>A>	AB	+	VALEANT PHARMS LLC	60MG	N009829 002		Jun	CAHN

TABLET, EXTENDED RELEASE; ORAL

MESTINON

>D>		+	VALEANT PHARM INTL	180MG	N011665 001		Jun	CAHN
>A>		+	VALEANT PHARMS LLC	180MG	N011665 001		Jun	CAHN

QUETIAPINE FUMARATE

TABLET; ORAL

QUETIAPINE FUMARATE

AB		ACCORD HLTHCARE INC	EQ 25MG BASE	A202152 001	Mar 27, 2012	Mar	NEWA
AB			EQ 50MG BASE	A202152 002	Mar 27, 2012	Mar	NEWA
AB			EQ 100MG BASE	A202152 003	Mar 27, 2012	Mar	NEWA
AB			EQ 200MG BASE	A202152 004	Mar 27, 2012	Mar	NEWA
AB			EQ 300MG BASE	A202152 005	Mar 27, 2012	Mar	NEWA
AB			EQ 400MG BASE	A202152 006	Mar 27, 2012	Mar	NEWA
AB		APOTEX INC	EQ 25MG BASE	A090960 001	Mar 27, 2012	Mar	NEWA
AB			EQ 50MG BASE	A090960 002	Mar 27, 2012	Mar	NEWA
AB			EQ 100MG BASE	A090960 003	Mar 27, 2012	Mar	NEWA
AB			EQ 200MG BASE	A090960 004	Mar 27, 2012	Mar	NEWA
AB			EQ 300MG BASE	A090960 005	Mar 27, 2012	Mar	NEWA
AB			EQ 400MG BASE	A090960 006	Mar 27, 2012	Mar	NEWA
AB		AUROBINDO PHARMA LTD	EQ 25MG BASE	A091388 001	Mar 27, 2012	Mar	NEWA
AB			EQ 50MG BASE	A091388 002	Mar 27, 2012	Mar	NEWA
AB			EQ 100MG BASE	A091388 003	Mar 27, 2012	Mar	NEWA
AB			EQ 150MG BASE	A091388 004	Mar 27, 2012	Mar	NEWA
AB			EQ 200MG BASE	A091388 005	Mar 27, 2012	Mar	NEWA
AB			EQ 300MG BASE	A091388 006	Mar 27, 2012	Mar	NEWA
AB			EQ 400MG BASE	A091388 007	Mar 27, 2012	Mar	NEWA
AB		DR REDDYS LABS LTD	EQ 25MG BASE	A077380 001	Mar 27, 2012	Mar	NEWA
AB			EQ 50MG BASE	A077380 002	Mar 27, 2012	Mar	NEWA
AB			EQ 100MG BASE	A077380 003	Mar 27, 2012	Mar	NEWA
AB			EQ 150MG BASE	A077380 004	Mar 27, 2012	Mar	NEWA
AB			EQ 200MG BASE	A077380 005	Mar 27, 2012	Mar	NEWA
AB			EQ 300MG BASE	A077380 006	Mar 27, 2012	Mar	NEWA
AB			EQ 400MG BASE	A077380 007	Mar 27, 2012	Mar	NEWA
AB		LUPIN LTD	EQ 25MG BASE	A201109 001	Mar 27, 2012	Mar	NEWA
AB			EQ 50MG BASE	A201109 002	Mar 27, 2012	Mar	NEWA
AB			EQ 100MG BASE	A201109 003	Mar 27, 2012	Mar	NEWA
AB			EQ 200MG BASE	A201109 004	Mar 27, 2012	Mar	NEWA
AB			EQ 300MG BASE	A201109 005	Mar 27, 2012	Mar	NEWA
AB			EQ 400MG BASE	A201109 006	Mar 27, 2012	Mar	NEWA
AB		MYLAN PHARMS INC	EQ 25MG BASE	A090323 001	Mar 27, 2012	Mar	NEWA
AB		ROXANE	EQ 25MG BASE	A090120 001	Mar 27, 2012	Mar	NEWA
AB			EQ 50MG BASE	A090749 001	Mar 27, 2012	Mar	NEWA

TABLET; ORAL

QUETIAPINE FUMARATE

AB	ROXANE	EQ 100MG BASE	A090749 002	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A090749 003	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A090749 004	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A090749 005	Mar 27, 2012	Mar	NEWA
AB	SUN PHARMA GLOBAL	EQ 25MG BASE	A201190 001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A201190 002	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A201190 003	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A201190 004	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A201190 005	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A201190 006	Mar 27, 2012	Mar	NEWA
AB	TEVA PHARMS	EQ 25MG BASE	A077745 001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A077745 002	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A077745 003	Mar 27, 2012	Mar	NEWA
AB		EQ 150MG BASE	A077745 004	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A077745 005	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A077745 006	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A077745 007	Mar 27, 2012	Mar	NEWA
AB	TORRENT PHARMS LTD	EQ 25MG BASE	A200363 001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A200363 002	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A200363 003	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A200363 004	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A200363 005	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A200363 006	Mar 27, 2012	Mar	NEWA
SEROQUEL						
AB	+ ASTRAZENECA	EQ 25MG BASE	N020639 001	Sep 26, 1997	Mar	CFTG
AB		EQ 50MG BASE	N020639 007	Oct 04, 2005	Mar	CFTG
AB		EQ 100MG BASE	N020639 002	Sep 26, 1997	Mar	CFTG
AB		EQ 200MG BASE	N020639 003	Sep 26, 1997	Mar	CFTG
AB	+	EQ 300MG BASE	N020639 005	Jul 26, 2000	Mar	CFTG
AB		EQ 400MG BASE	N020639 006	Oct 04, 2005	Mar	CFTG

RAMIPRIL

CAPSULE; ORAL

RAMIPRIL

@ RANBAXY LABS LTD

5MG

A078849 001 Mar 06, 2009 Apr DISC

@

10MG

A078849 002 Mar 06, 2009 Apr DISC

TABLET; ORAL

ALTACE

@ KING PFIZER

1.25MG

N022021 001 Feb 27, 2007 Jan DISC

@

2.5MG

N022021 002 Feb 27, 2007 Jan DISC

@

5MG

N022021 003 Feb 27, 2007 Jan DISC

@

10MG

N022021 004 Feb 27, 2007 Jan DISC

RANITIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

ZANTAC

AP	+ COVIS PHARMA	EQ 25MG BASE/ML	N019090 001	Oct 19, 1984	Mar	CAHN
	ZANTAC IN PLASTIC CONTAINER					
	+ COVIS PHARMA	EQ 1MG BASE/ML	N019593 002	Sep 27, 1991	Mar	CAHN
	@	EQ 50MG BASE/100ML	N019593 001	Dec 17, 1986	Mar	CAHN

RIFAMPIN

CAPSULE; ORAL

RIMACTANE

AB	PROSAM LABS	300MG	N050429 001		Feb	CMFD
----	-------------	-------	-------------	--	-----	------

RILPIVIRINE HYDROCHLORIDE

TABLET; ORAL

EDURANT

+	JANSSEN PRODS	EQ 25MG BASE	N202022 001	May 20, 2011	Feb	CAHN
---	---------------	--------------	-------------	--------------	-----	------

RISEDRONATE SODIUM

TABLET; ORAL

ACTONEL

>D>	AB	WARNER CHILCOTT	5MG	N020835 002	Apr 14, 2000	Jun	CAHN
>D>	AB		30MG	N020835 001	Mar 27, 1998	Jun	CAHN
>D>	AB	+	35MG	N020835 003	May 25, 2002	Jun	CAHN
>D>		@	75MG	N020835 004	Apr 16, 2007	Jun	CAHN
>D>		+	150MG	N020835 005	Apr 22, 2008	Jun	CAHN
>A>	AB	WARNER CHILCOTT LLC	5MG	N020835 002	Apr 14, 2000	Jun	CAHN
>A>	AB		30MG	N020835 001	Mar 27, 1998	Jun	CAHN
>A>	AB	+	35MG	N020835 003	May 25, 2002	Jun	CAHN
>A>		@	75MG	N020835 004	Apr 16, 2007	Jun	CAHN
>A>		+	150MG	N020835 005	Apr 22, 2008	Jun	CAHN

TABLET, DELAYED RELEASE; ORAL

ATELVIA

>D>	+	WARNER CHILCOTT	35MG	N022560 001	Oct 08, 2010	Jun	CAHN
>A>	+	WARNER CHILCOTT LLC	35MG	N022560 001	Oct 08, 2010	Jun	CAHN

RISPERIDONE

TABLET; ORAL

RISPERIDONE

AB	PROSAM LABS	0.25MG	A078071 001	Jun 17, 2009	Feb	CMFD
AB		0.5MG	A078071 002	Jun 17, 2009	Feb	CMFD
AB		1MG	A078071 003	Jun 17, 2009	Feb	CMFD
AB		2MG	A078071 004	Jun 17, 2009	Feb	CMFD
AB		3MG	A078071 005	Jun 17, 2009	Feb	CMFD
AB		4MG	A078071 006	Jun 17, 2009	Feb	CMFD

TABLET, ORALLY DISINTEGRATING; ORAL

RISPERIDONE

AB	TEVA	0.5MG	A076908 001	Mar 12, 2012	Feb	NEWA
AB		1MG	A076908 002	Mar 12, 2012	Feb	NEWA
AB		2MG	A076908 003	Mar 12, 2012	Feb	NEWA

RIVASTIGMINE TARTRATE

CAPSULE; ORAL

RIVASTIGMINE TARTRATE

AB	ALEMBIC PHARMS LTD	EQ 1.5MG BASE	A091689 001	Jun 12, 2012	May	NEWA
AB		EQ 3MG BASE	A091689 002	Jun 12, 2012	May	NEWA
AB		EQ 4.5MG BASE	A091689 003	Jun 12, 2012	May	NEWA
AB		EQ 6MG BASE	A091689 004	Jun 12, 2012	May	NEWA

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

ROPINIROLE HYDROCHLORIDE

AB	APOTEX	EQ 0.25MG BASE	A079165 001	Feb 07, 2012	Jan	NEWA
----	--------	----------------	-------------	--------------	-----	------

TABLET; ORAL

ROPINIROLE HYDROCHLORIDE

AB	APOTEX	EQ 0.5MG BASE	A079165 002	Feb 07, 2012	Jan	NEWA
AB		EQ 1MG BASE	A079165 003	Feb 07, 2012	Jan	NEWA
AB		EQ 2MG BASE	A079165 004	Feb 07, 2012	Jan	NEWA
AB		EQ 3MG BASE	A079165 005	Feb 07, 2012	Jan	NEWA
AB		EQ 4MG BASE	A079165 006	Feb 07, 2012	Jan	NEWA
AB		EQ 5MG BASE	A079165 007	Feb 07, 2012	Jan	NEWA

TABLET, EXTENDED RELEASE; ORAL

REQUIP XL

AB	+ SMITHKLINE BEECHAM	EQ 2MG BASE	N022008 001	Jun 13, 2008	Apr	CFTG
AB		EQ 4MG BASE	N022008 003	Jun 13, 2008	Apr	CFTG
AB		EQ 6MG BASE	N022008 006	Apr 10, 2009	Apr	CFTG
AB		EQ 8MG BASE	N022008 004	Jun 13, 2008	Apr	CFTG
AB		EQ 12MG BASE	N022008 005	Oct 31, 2008	Apr	CFTG

ROPINIROLE HYDROCHLORIDE

AB	ACTAVIS	EQ 2MG BASE	A090869 001	May 17, 2012	Apr	NEWA
AB		EQ 4MG BASE	A090869 002	May 17, 2012	Apr	NEWA
AB		EQ 6MG BASE	A090869 003	May 17, 2012	Apr	NEWA
AB		EQ 8MG BASE	A090869 004	May 17, 2012	Apr	NEWA
AB		EQ 12MG BASE	A090869 005	May 17, 2012	Apr	NEWA
AB	DR REDDYS LABS LTD	EQ 2MG BASE	A201576 001	Jun 06, 2012	May	NEWA
AB		EQ 4MG BASE	A201576 002	Jun 06, 2012	May	NEWA
AB		EQ 6MG BASE	A201576 003	Jun 06, 2012	May	NEWA
AB		EQ 8MG BASE	A201576 004	Jun 06, 2012	May	NEWA
AB		EQ 12MG BASE	A201576 005	Jun 06, 2012	May	NEWA
AB	SANDOZ INC	EQ 2MG BASE	A201047 001	Jun 06, 2012	May	NEWA
AB		EQ 4MG BASE	A201047 003	Jun 06, 2012	May	NEWA
AB		EQ 6MG BASE	A201047 004	Jun 06, 2012	May	NEWA
AB		EQ 8MG BASE	A201047 005	Jun 06, 2012	May	NEWA
AB		EQ 12MG BASE	A201047 006	Jun 06, 2012	May	NEWA
AB	WATSON LABS INC	EQ 2MG BASE	A200431 001	Jun 06, 2012	May	NEWA
AB		EQ 4MG BASE	A200431 002	Jun 06, 2012	May	NEWA
AB		EQ 6MG BASE	A200431 003	Jun 06, 2012	May	NEWA
AB		EQ 8MG BASE	A200431 004	Jun 06, 2012	May	NEWA
AB		EQ 12MG BASE	A200431 005	Jun 06, 2012	May	NEWA

ROTIGOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL

NEUPRO

	UCB INC	1MG/24HR	N021829 004	Apr 02, 2012	Apr	NEWA
		2MG/24HR	N021829 001	May 09, 2007	Apr	CMFD
		3MG/24HR	N021829 005	Apr 02, 2012	Apr	NEWA
		4MG/24HR	N021829 002	May 09, 2007	Apr	CMFD
		6MG/24HR	N021829 003	May 09, 2007	Apr	CMFD
+		8MG/24HR	N021829 006	Apr 02, 2012	Apr	NEWA

SERTACONAZOLE NITRATE

CREAM; TOPICAL

ERTACZO

+	VALEANT INTL	2%	N021385 001	Dec 10, 2003	Jan	CAHN
---	--------------	----	-------------	--------------	-----	------

SERTRALINE HYDROCHLORIDE

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

AB	PROSAM LABS	EQ 25MG BASE	A078175 001	Jul 21, 2010	Feb	CMFD
----	-------------	--------------	-------------	--------------	-----	------

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

AB	PROSAM LABS	EQ 50MG BASE	A078175 002	Jul 21, 2010	Feb	CMFD
AB		EQ 100MG BASE	A078175 003	Jul 21, 2010	Feb	CMFD

SILVER SULFADIAZINE

CREAM; TOPICAL

THERMAZENE

>D>	AB	COVIDIEN	1%	N018810 001	Dec 23, 1985	Jun	CAHN
>A>	AB	THEPHARMANETWORK LLC	1%	N018810 001	Dec 23, 1985	Jun	CAHN

SIMVASTATIN

TABLET; ORAL

SIMVASTATIN

AB	PROSAM LABS	5MG	A078735 001	Aug 30, 2010	Feb	CMFD
AB		10MG	A078735 002	Aug 30, 2010	Feb	CMFD
AB		20MG	A078735 003	Aug 30, 2010	Feb	CMFD
AB		40MG	A078735 004	Aug 30, 2010	Feb	CMFD
AB		80MG	A078735 005	Aug 30, 2010	Feb	CMFD

SITAGLIPTIN PHOSPHATE

TABLET; ORAL

JANUVIA

	MERCK SHARP DOHME	EQ 25MG BASE	N021995 001	Oct 16, 2006	May	CAHN
		EQ 50MG BASE	N021995 002	Oct 16, 2006	May	CAHN
+		EQ 100MG BASE	N021995 003	Oct 16, 2006	May	CAHN

SODIUM BICARBONATE; TARTARIC ACID

GRANULE, EFFERVESCENT; ORAL

BAROS

@ MALLINCKRODT INC	460MG/GM; 420MG/GM	N018509 001	Aug 07, 1985	Jan	CAHN
--------------------	--------------------	-------------	--------------	-----	------

SODIUM CHLORIDE

INJECTABLE; INJECTION

SODIUM CHLORIDE 0.9%

AP	HIKMA (MAPLE)	9MG/ML	A201850 001	Jan 20, 2012	Jan	NEWA
	SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	MEDEFIL	9MG/ML	N202832 001	Jan 06, 2012	Jan	NEWA

SODIUM CHROMATE CR-51

INJECTABLE; INJECTION

CHROMITOPES SODIUM

>D>	CHROMITOPES SODIUM					
>D>	BRACCO	200uCi/ML	N013993 001		Jun	DISC
>A>	@	200uCi/ML	N013993 001		Jun	DISC

SODIUM FERRIC GLUCONATE COMPLEX

INJECTABLE; INJECTION

SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE

AB	HIKMA PHARMS	62.5MG/5ML	A078215 001	Mar 31, 2011	May	CAHN
----	--------------	------------	-------------	--------------	-----	------

SODIUM IODIDE I-123

CAPSULE; ORAL

SODIUM IODIDE I 123

@ GE HEALTHCARE	100uCi	N017630 001		May	DISC
-----------------	--------	-------------	--	-----	------

SODIUM IODIDE I-131

CAPSULE; ORAL

SODIUM IODIDE I-131

JUBILANT DRAXIMAGE

9-100mCi

N021305 006 May 19, 2005 Feb CAHN

@

2-200mCi

N021305 004 Nov 18, 2004 Jan DISC

SOLUTION; ORAL

HICON

@ JUBILANT DRAXIMAGE

1-250mCi/0.25ML

N021305 002 Jan 24, 2003 Feb DISC

@

1-500mCi/0.5ML

N021305 003 Jan 24, 2003 Feb DISC

@

1-1000mCi/ML

N021305 005 Apr 04, 2006 Feb DISC

+

250-1000mCi

N021305 007 Dec 05, 2011 Jan NEWA

SODIUM NITRITE

SOLUTION; INTRAVENOUS

SODIUM NITRITE

+ HOPE PHARMS

300MG/10ML (30MG/ML)

N203922 001 Feb 14, 2012 Feb NEWA

SODIUM OXYBATE

SOLUTION; ORAL

XYREM

>D>

+ JAZZ

500MG/ML

N021196 001 Jul 17, 2002 Jun CAHN

>A>

+ JAZZ PHARMS

500MG/ML

N021196 001 Jul 17, 2002 Jun CAHN

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

>D> AA

CITRUSPHRMA

454GM/BOT

A040909 001 Dec 03, 2008 Jun DISC

>A>

@

454GM/BOT

A040909 001 Dec 03, 2008 Jun DISC

SODIUM THIOSULFATE

SOLUTION; INTRAVENOUS

SODIUM THIOSULFATE

+ HOPE PHARMS

12.5GM/50ML (250MG/ML)

N203923 001 Feb 14, 2012 Feb NEWA

SOTALOL HYDROCHLORIDE

TABLET; ORAL

SOTALOL HYDROCHLORIDE

>D> AB2

AMNEAL PHARM

80MG

A077070 001 Nov 04, 2005 Jun CAHN

>D> AB2

120MG

A077070 002 Nov 04, 2005 Jun CAHN

>D> AB2

160MG

A077070 003 Nov 04, 2005 Jun CAHN

>A> AB2

EPIC PHARMA INC

80MG

A077070 001 Nov 04, 2005 Jun CAHN

>A> AB2

120MG

A077070 002 Nov 04, 2005 Jun CAHN

>A> AB2

160MG

A077070 003 Nov 04, 2005 Jun CAHN

SPINOSAD

SUSPENSION; TOPICAL

NATROBA

+ PARAPRO LLC

0.9%

N022408 001 Jan 18, 2011 May CAHN

SUCCIMER

CAPSULE; ORAL

CHEMET

+ LUNDBECK LLC

100MG

N019998 002 Jan 30, 1991 Mar CAHN

SULFACETAMIDE SODIUM

LOTION; TOPICAL

SULFACETAMIDE SODIUM

AB	FOUGERA PHARMS	10%	A077015 001	Nov 17, 2006	Jan	CAHN
----	----------------	-----	-------------	--------------	-----	------

SULFANILAMIDE

CREAM; VAGINAL

AVC

>D>	+	JAZZ PHARMS COMMERCL	15%	N006530 003	Jan 27, 1987	Jun	CAHN
	+		15%	N006530 003	Jan 27, 1987	Mar	CAHN
>A>	+	JAZZ PHARMS III	15%	N006530 003	Jan 27, 1987	Jun	CAHN

SUPPOSITORY; VAGINAL

AVC

>D>	@	JAZZ PHARMS COMMERCL	1.05GM	N006530 004	Jan 27, 1987	Jun	CAHN
	@		1.05GM	N006530 004	Jan 27, 1987	Mar	CAHN
>A>	@	JAZZ PHARMS III	1.05GM	N006530 004	Jan 27, 1987	Jun	CAHN

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS

ALSUMA

>D>	+	MERIDIAN MEDCL	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N022377 001	Jun 29, 2010	Jun	CRLD
>A>	BX		EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N022377 001	Jun 29, 2010	Jun	CRLD

SUMATRIPTAN SUCCINATE

AP INJECTALIA

EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)

A090310 001 Aug 11, 2010 Mar CAHN

SUMAVEL DOSEPRO

>D>	+	ZOGENIX INC	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N022239 001	Jul 15, 2009	Jun	CTEC
>A>	BX	+	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N022239 001	Jul 15, 2009	Jun	CTEC

TABLET; ORAL

SUMATRIPTAN SUCCINATE

>A>	AB	APOTEX INC	EQ 25MG BASE	A200263 001	Jun 19, 2012	Jun	NEWA
>A>	AB		EQ 50MG BASE	A200263 002	Jun 19, 2012	Jun	NEWA
>A>	AB		EQ 100MG BASE	A200263 003	Jun 19, 2012	Jun	NEWA

TAFILUPROST

SOLUTION/DROPS; OPHTHALMIC

ZIOPTAN

+	MERCK SHARP DOHME	0.0015%	N202514 001	Feb 10, 2012	Feb	NEWA
---	-------------------	---------	-------------	--------------	-----	------

TALIGLUCERASE ALFA

POWDER; IV (INFUSION)

ELELYSO

+	PFIZER	200 UNITS/VIAL	N022458 001	May 01, 2012	May	NEWA
---	--------	----------------	-------------	--------------	-----	------

TAMOXIFEN CITRATE

TABLET; ORAL

TAMOXIFEN CITRATE

>D>	AB	AEGIS PHARMS	EQ 10MG BASE	A076398 001	Mar 31, 2003	Jun	DISC
>A>	@		EQ 10MG BASE	A076398 001	Mar 31, 2003	Jun	DISC
>D>	AB		EQ 20MG BASE	A076398 002	Mar 31, 2003	Jun	DISC
>A>	@		EQ 20MG BASE	A076398 002	Mar 31, 2003	Jun	DISC

TAZAROTENE

AEROSOL, FOAM; TOPICAL

FABIOR

+	STIEFEL LABS INC	0.1%	N202428 001	May 11, 2012	May	NEWA
---	------------------	------	-------------	--------------	-----	------

TECHNETIUM TC-99M MEDRONATE

INJECTABLE; INJECTION

DRAXIMAGE MDP-10

@ JUBILANT DRAXIMAGE N/A

N018035 001		May	CAHN
-------------	--	-----	------

DRAXIMAGE MDP-25

+	JUBILANT DRAXIMAGE	N/A	N018035 002	Feb 27, 2004	May	CAHN
---	--------------------	-----	-------------	--------------	-----	------

TEMAZEPAM

CAPSULE; ORAL

TEMAZEPAM

>A>	AB	NOVEL LABS INC	7.5MG	A071457 002	Jun 22, 2012	Jun	NEWA
-----	----	----------------	-------	-------------	--------------	-----	------

>A>	AB		22.5MG	A071457 003	Jun 22, 2012	Jun	NEWA
-----	----	--	--------	-------------	--------------	-----	------

TEMOZOLOMIDE

CAPSULE; ORAL

TEMODAR

>A>	AB	MERCK SHARP DOHME	5MG	N021029 001	Aug 11, 1999	Jun	CAHN
-----	----	-------------------	-----	-------------	--------------	-----	------

>A>	AB		20MG	N021029 002	Aug 11, 1999	Jun	CAHN
-----	----	--	------	-------------	--------------	-----	------

>A>	AB		100MG	N021029 003	Aug 11, 1999	Jun	CAHN
-----	----	--	-------	-------------	--------------	-----	------

>A>	AB		140MG	N021029 005	Oct 19, 2006	Jun	CAHN
-----	----	--	-------	-------------	--------------	-----	------

>A>	AB		180MG	N021029 006	Oct 19, 2006	Jun	CAHN
-----	----	--	-------	-------------	--------------	-----	------

>A>	AB	+	250MG	N021029 004	Aug 11, 1999	Jun	CAHN
-----	----	---	-------	-------------	--------------	-----	------

>D>	AB	SCHERING	5MG	N021029 001	Aug 11, 1999	Jun	CAHN
-----	----	----------	-----	-------------	--------------	-----	------

>D>	AB		20MG	N021029 002	Aug 11, 1999	Jun	CAHN
-----	----	--	------	-------------	--------------	-----	------

>D>	AB		100MG	N021029 003	Aug 11, 1999	Jun	CAHN
-----	----	--	-------	-------------	--------------	-----	------

>D>	AB		140MG	N021029 005	Oct 19, 2006	Jun	CAHN
-----	----	--	-------	-------------	--------------	-----	------

>D>	AB		180MG	N021029 006	Oct 19, 2006	Jun	CAHN
-----	----	--	-------	-------------	--------------	-----	------

>D>	AB	+	250MG	N021029 004	Aug 11, 1999	Jun	CAHN
-----	----	---	-------	-------------	--------------	-----	------

POWDER; INTRAVENOUS

TEMODAR

>A>	+	MERCK SHARP DOHME	100MG/VIAL	N022277 001	Feb 27, 2009	Jun	CAHN
-----	---	-------------------	------------	-------------	--------------	-----	------

>D>	+	SCHERING	100MG/VIAL	N022277 001	Feb 27, 2009	Jun	CAHN
-----	---	----------	------------	-------------	--------------	-----	------

TENOFOVIR DISOPROXIL FUMARATE

POWDER; ORAL

VIREAD

+	GILEAD SCIENCES INC	40MG/SC00PFUL	N022577 001	Jan 18, 2012	Jan	NEWA
---	---------------------	---------------	-------------	--------------	-----	------

TABLET; ORAL

VIREAD

GILEAD SCIENCES INC 150MG

N021356 002	Jan 18, 2012	Apr	NEWA
-------------	--------------	-----	------

200MG

N021356 003	Jan 18, 2012	Apr	NEWA
-------------	--------------	-----	------

250MG

N021356 004	Jan 18, 2012	Apr	NEWA
-------------	--------------	-----	------

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

TERAZOSIN HYDROCHLORIDE

@ RANBAXY LABS LTD EQ 1MG BASE

A076021 001	Aug 22, 2002	Apr	DISC
-------------	--------------	-----	------

@ EQ 2MG BASE

A076021 002	Aug 22, 2002	Apr	DISC
-------------	--------------	-----	------

@ EQ 5MG BASE

A076021 003	Aug 22, 2002	Apr	DISC
-------------	--------------	-----	------

@ EQ 10MG BASE

A076021 004	Aug 22, 2002	Apr	DISC
-------------	--------------	-----	------

TERBUTALINE SULFATE

INJECTABLE; INJECTION
 TERBUTALINE SULFATE
 @ TEVA PARENTERAL

1MG/ML

A076853 001 Jul 20, 2004 Jan DISC

TERCONAZOLE

CREAM; VAGINAL
 TERCONAZOLE

AB FOUGERA PHARMS

0.4%

A076712 001 Feb 18, 2005 Jan CAHN

SUPPOSITORY; VAGINAL
 TERCONAZOLE

AB FOUGERA PHARMS

80MG

A076850 001 Jul 12, 2006 Jan CAHN

TESAMORELIN ACETATE

POWDER; SUBCUTANEOUS
 EGRIFTA

>D> + EMD SERONO

EQ 1MG BASE/VIAL

N022505 001 Nov 10, 2010 Jun DISC

>A> @

EQ 1MG BASE/VIAL

N022505 001 Nov 10, 2010 Jun DISC

+

EQ 1MG BASE/VIAL

N022505 001 Nov 10, 2010 May CAHN

>A> +

EQ 2MG BASE/VIAL

N022505 002 Nov 29, 2011 Jun NEWA

TESTOSTERONE

GEL; TRANSDERMAL
 ANDROGEL

BX + ABBOTT LABS

1% (25MG/2.5GM PACKET)

N021015 001 Feb 28, 2000 Feb CPOT

BX + 1% (50MG/5GM PACKET)

N021015 002 Feb 28, 2000 Feb CPOT

TESTIM

BX + AUXILIUM PHARMS

1% (50MG/5GM PACKET)

N021454 001 Oct 31, 2002 Feb CPOT

TESTOSTERONE

TEVA PHARMS

25MG/2.5GM PACKET

N202763 001 Feb 14, 2012 Feb NEWA

50MG/5GM PACKET

N202763 002 Feb 14, 2012 Feb NEWA

GEL, METERED; TRANSDERMAL
 ANDROGEL

>D> + ABBOTT LABS

1% (1.25GM/ACTIVATION)

N021015 003 Sep 26, 2003 Jun CPOT

>A> +

1% (1.25GM/ACTUATION)

N021015 003 Sep 26, 2003 Jun CPOT

PELLET; IMPLANTATION

TESTOPEL

+ ACTIENT PHARMS

75MG

A080911 001

May CAHN

TESTOSTERONE CYPIONATE

INJECTABLE; INJECTION
 TESTOSTERONE CYPIONATE

AO HIKMA FARMACEUTICA

200MG/ML

A091244 001 May 01, 2012 Apr NEWA

AO MYLAN INSTITUTIONAL

200MG/ML

A040652 001 Dec 11, 2006 Feb CAHN

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION
 TESTOSTERONE ENANTHATE

AO MYLAN INSTITUTIONAL

200MG/ML

A040647 001 Oct 05, 2009 Feb CAHN

TETRABENAZINE

TABLET; ORAL
 XENAZINE

VALEANT PHARMS

12.5MG

N021894 001 Aug 15, 2008 Apr CAHN

+

25MG

N021894 002 Aug 15, 2008 Apr CAHN

TETRAHYDROZOLINE HYDROCHLORIDE

SOLUTION; NASAL

TYZINE

+	FOUGERA PHARMS	0.05%	A086576 002	Jan	CAHN
		0.1%	A086576 001	Jan	CAHN

SPRAY; NASAL

TYZINE

+	FOUGERA PHARMS	0.1%	A086576 003	Jan	CAHN
---	----------------	------	-------------	-----	------

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL

THEO-24

UCB INC

		100MG	A087942 001	Aug 22, 1983	May	CTEC
		200MG	A087943 001	Aug 22, 1983	May	CTEC
		300MG	A087944 001	Aug 22, 1983	May	CTEC
+		400MG	A081034 001	Feb 28, 1992	May	CRLD

THEOPHYLLINE

@ INWOOD LABS

@

@

@

		100MG	A040052 001	Feb 14, 1994	May	DISC
		125MG	A040052 002	Feb 14, 1994	May	DISC
		200MG	A040052 003	Feb 14, 1994	May	DISC
		300MG	A040052 004	Feb 14, 1994	May	DISC

INJECTABLE; INJECTION

THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER

@ BAXTER HLTHCARE

@

@

@

@

@

@

		4MG/ML	N018649 007	Jul 26, 1982	Mar	DISC
		40MG/100ML	N018649 001	Jul 26, 1982	Mar	DISC
		80MG/100ML	N018649 002	Jul 26, 1982	Mar	DISC
		160MG/100ML	N018649 003	Jul 26, 1982	Mar	DISC
		200MG/100ML	N018649 004	Jul 26, 1982	Mar	DISC
		320MG/100ML	N018649 006	Nov 13, 1985	Mar	DISC
		400MG/100ML	N018649 005	Jul 26, 1982	Mar	DISC

SOLUTION; ORAL

THEOPHYLLINE

>D>	+	SILARX	80MG/15ML	A091156 001	Apr 13, 2011	Jun	CTEC
>A>	AA	+	80MG/15ML	A091156 001	Apr 13, 2011	Jun	CTEC
>A>	AA	TRIS PHARMA INC	80MG/15ML	A091586 001	Jun 15, 2012	Jun	NEWA

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

THIAMINE HYDROCHLORIDE

>A>	AP	MYLAN INSTITUTIONAL	100MG/ML	A091623 001	Jun 25, 2012	Jun	NEWA
-----	----	---------------------	----------	-------------	--------------	-----	------

TIAGABINE HYDROCHLORIDE

TABLET; ORAL

GABITRIL

@ CEPHALON

@

@

		6MG	N020646 006	Nov 29, 2005	Jan	DISC
		8MG	N020646 007	Nov 29, 2005	Jan	DISC
		10MG	N020646 008	Nov 29, 2005	Jan	DISC

TINIDAZOLE

TABLET; ORAL

TINDAMAX

AB		MISSION PHARMA	250MG	N021618 001	May 17, 2004	Apr	CFTG
AB	+		500MG	N021618 002	May 17, 2004	Apr	CFTG

TINIDAZOLE

AB		NOVEL LABS INC	250MG	A202044 001	Apr 30, 2012	Apr	NEWA
----	--	----------------	-------	-------------	--------------	-----	------

TABLET; ORAL

TINIDAZOLE

AB	NOVEL LABS INC	500MG	A202044 002	Apr 30, 2012	Apr	NEWA
AB	ROXANE	250MG	A201172 001	Apr 30, 2012	Apr	NEWA
AB		500MG	A201172 002	Apr 30, 2012	Apr	NEWA

>D> TINZAPARIN SODIUM

>D> INJECTABLE; INJECTION

>D> INNOHEP

>D>	+	LEO PHARMA AS	20,000 IU/ML	N020484 001	Jul 14, 2000	Jun	DISC
>A>		@	20,000 IU/ML	N020484 001	Jul 14, 2000	Jun	DISC

TIZANIDINE HYDROCHLORIDE

CAPSULE; ORAL

TIZANIDINE HYDROCHLORIDE

AB	APOTEX INC	EQ 2MG BASE	A078868 001	Feb 03, 2012	Jan	NEWA
AB		EQ 4MG BASE	A078868 002	Feb 03, 2012	Jan	NEWA
AB		EQ 6MG BASE	A078868 003	Feb 03, 2012	Jan	NEWA

ZANAFLEX

AB	ACORDA	EQ 2MG BASE	N021447 001	Aug 29, 2002	Jan	CFTG
AB		EQ 4MG BASE	N021447 002	Aug 29, 2002	Jan	CFTG
AB	+	EQ 6MG BASE	N021447 003	Aug 29, 2002	Jan	CFTG

TABLET; ORAL

TIZANIDINE HYDROCHLORIDE

AB	PROSAM LABS	EQ 2MG BASE	A076281 001	Oct 20, 2003	Feb	CMFD
AB		EQ 4MG BASE	A076281 002	Oct 20, 2003	Feb	CMFD
AB	SANDOZ INC	EQ 2MG BASE	A076280 001	Nov 26, 2002	Feb	NEWA

TOLBUTAMIDE

TABLET; ORAL

TOLBUTAMIDE

+	MYLAN PHARMS INC	500MG	A086445 001		Mar	CRLD
	@ WATSON LABS	500MG	A086109 001		Mar	DISC
	@	500MG	A087318 001		Mar	DISC

TOLCAPONE

TABLET; ORAL

TASMAR

+	VALEANT PHARMS LLC	100MG	N020697 001	Jan 29, 1998	May	CAHN
	@	200MG	N020697 002	Jan 29, 1998	May	CAHN

TRAMADOL HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

TRAMADOL HYDROCHLORIDE

>A>	AB2	ACTAVIS	100MG	A091609 001	Jun 27, 2012	Jun	NEWA
>A>	AB2		200MG	A091609 002	Jun 27, 2012	Jun	NEWA
>A>	AB2		300MG	A091609 003	Jun 27, 2012	Jun	NEWA
>A>	AB2	ANCHEN PHARMS	100MG	A200491 001	Jun 27, 2012	Jun	NEWA
>A>	AB2		200MG	A200491 002	Jun 27, 2012	Jun	NEWA
>A>	AB2		300MG	A200491 003	Jun 27, 2012	Jun	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

RYBIX ODT

+	SHIONOGI INC	50MG	N021693 001	May 05, 2005	Mar	CTNA
---	--------------	------	-------------	--------------	-----	------

TRANEXAMIC ACID

INJECTABLE; INJECTION

TRANEXAMIC ACID

AP	APP PHARMS LLC	100MG/ML	A091596 001	Mar 02, 2012	May	CAHN
AP	NEXUS PHARMS	100MG/ML	A091596 001	Mar 02, 2012	Feb	NEWA

TRANLYCYPROMINE SULFATE

TABLET; ORAL

PARNATE

AB	+ COVIS PHARMA	EQ 10MG BASE	N012342 003	Aug 16, 1985	Jan	CAHN
----	----------------	--------------	-------------	--------------	-----	------

TRETINOIN

CREAM; TOPICAL

AVITA

>D>	AB	MYLAN BERTEK	0.025%	N020404 003	Jan 14, 1997	Jun	CAHN
>A>	AB	MYLAN PHARMS INC	0.025%	N020404 003	Jan 14, 1997	Jun	CAHN

RENOVA

	+	VALEANT INTL	0.02%	N021108 001	Aug 31, 2000	Jan	CAHN
AB2	+		0.05%	N019963 001	Dec 29, 1995	Jan	CAHN

RETIN-A

AB	+	VALEANT INTL	0.025%	N019049 001	Sep 16, 1988	Jan	CAHN
AB1	+		0.05%	N017522 001		Jan	CAHN
AB	+		0.1%	N017340 001		Jan	CAHN

TRETINOIN

AB	PRECISION DERMAT	0.025%	A075264 001	Dec 24, 1998	May	CAHN
	+	0.0375%	A090098 001	Mar 22, 2010	May	CAHN
AB1		0.05%	A075265 001	Dec 24, 1998	May	CAHN
AB		0.1%	A075213 001	Dec 24, 1998	May	CAHN
AB2	SUNEVA MEDCL	0.05%	A076498 001	Sep 15, 2005	May	CAHN

GEL; TOPICAL

RETIN-A

AB	+	VALEANT INTL	0.01%	N017955 001		Jan	CAHN
AB	+		0.025%	N017579 002		Jan	CAHN

TRETINOIN

AB	PRECISION DERMAT	0.01%	A075589 001	Jun 11, 2002	May	CAHN
AB		0.025%	A075529 001	Feb 22, 2000	May	CAHN

SOLUTION; TOPICAL

RETIN-A

AT	+	VALEANT INTL	0.05%	N016921 001		Jan	CAHN
----	---	--------------	-------	-------------	--	-----	------

SWAB; TOPICAL

RETIN-A

	@	VALEANT INTL	0.05%	N016921 002		Jan	CAHN
--	---	--------------	-------	-------------	--	-----	------

TRIAMCINOLONE ACETONIDE

AEROSOL, METERED; INHALATION

AZMACORT

	@	ABBOTT	0.1MG/INH	N018117 001	Apr 23, 1982	May	DISC
--	---	--------	-----------	-------------	--------------	-----	------

CREAM; TOPICAL

TRIAMCINOLONE ACETONIDE

AT	FOUGERA PHARMS	0.025%	A085692 001		Jan	CAHN
AT		0.1%	A085692 003		Jan	CAHN
AT	+	0.5%	A085692 002		Jan	CAHN

LOTION; TOPICAL

TRIAMCINOLONE ACETONIDE

AT	FOUGERA PHARMS	0.025%	A040467 001	Apr 21, 2003	Jan	CAHN
----	----------------	--------	-------------	--------------	-----	------

		LOTION; TOPICAL				
		TRIAMCINOLONE ACETONIDE				
AT		FOUGERA PHARMS	0.1%	A040467 002	Apr 21, 2003	Jan CAHN
		OINTMENT; TOPICAL				
		TRIAMCINOLONE ACETONIDE				
AT		FOUGERA PHARMS	0.025%	A085691 001		Jan CAHN
AT			0.1%	A085691 003		Jan CAHN
AT			0.5%	A085691 002		Jan CAHN
		SPRAY, METERED; NASAL				
		TRIAMCINOLONE ACETONIDE				
AB		TEVA PHARMS	0.055MG/SPRAY	A078104 001	Jul 30, 2009	Mar CAHN
<u>TRIMETHOBENZAMIDE HYDROCHLORIDE</u>						
		INJECTABLE; INJECTION				
		TRIMETHOBENZAMIDE HYDROCHLORIDE				
>D>	AP	HOSPIRA	100MG/ML	A088804 001	Apr 03, 1987	Jun DISC
>A>	@		100MG/ML	A088804 001	Apr 03, 1987	Jun DISC
<u>VALACYCLOVIR HYDROCHLORIDE</u>						
		TABLET; ORAL				
		VALACYCLOVIR HYDROCHLORIDE				
AB		JUBILANT ORGANOSYS	EQ 500MG BASE	A201506 001	Apr 03, 2012	Mar NEWA
AB			EQ 1GM BASE	A201506 002	Apr 03, 2012	Mar NEWA
<u>VALGANCICLOVIR HYDROCHLORIDE</u>						
		FOR SOLUTION; ORAL				
		VALCYTE				
	+	HOFFMANN LA ROCHE	50MG/ML	N022257 001	Aug 28, 2009	May CAHN
		TABLET; ORAL				
		VALCYTE				
	+	HOFFMANN LA ROCHE	EQ 450MG BASE	N021304 001	Mar 29, 2001	May CAHN
<u>VANCOMYCIN HYDROCHLORIDE</u>						
		CAPSULE; ORAL				
		VANCOCIN HYDROCHLORIDE				
AB		VIROPHARMA	EQ 125MG BASE	N050606 001	Apr 15, 1986	Mar CFTG
AB	+		EQ 250MG BASE	N050606 002	Apr 15, 1986	Mar CFTG
		VANCOMYCIN HYDROCHLORIDE				
AB		AKORN	EQ 125MG BASE	A065478 001	Apr 09, 2012	Mar NEWA
AB			EQ 250MG BASE	A065478 002	Apr 09, 2012	Mar NEWA
>A>	AB	APP PHARMS LLC	EQ 125MG BASE	A065453 001	Jun 18, 2012	Jun NEWA
>A>	AB		EQ 250MG BASE	A065453 002	Jun 18, 2012	Jun NEWA
AB		STRIDES ARCOLAB LTD	EQ 125MG BASE	A065490 001	Apr 09, 2012	Mar NEWA
AB			EQ 250MG BASE	A065490 002	Apr 09, 2012	Mar NEWA
AB		WATSON LABS	EQ 125MG BASE	A065510 001	Apr 09, 2012	Mar NEWA
AB			EQ 250MG BASE	A065510 002	Apr 09, 2012	Mar NEWA
<u>VANDETANIB</u>						
		TABLET; ORAL				
		CAPRELSA				
		IPR PHARMS INC	100MG	N022405 001	Apr 06, 2011	Feb CTNA
	+		300MG	N022405 002	Apr 06, 2011	Feb CTNA

VARDENAFIL HYDROCHLORIDE

TABLET; ORAL

LEVITRA

AB	BAYER HLTHCARE	2.5MG	N021400 003	Aug 19, 2003	Apr	CFTG
AB		5MG	N021400 001	Aug 19, 2003	Apr	CFTG
AB		10MG	N021400 002	Aug 19, 2003	Apr	CFTG
AB	+	20MG	N021400 004	Aug 19, 2003	Apr	CFTG

VARDENAFIL HYDROCHLORIDE

AB	TEVA PHARMS	2.5MG	A091347 001	May 03, 2012	Apr	NEWA
AB		5MG	A091347 002	May 03, 2012	Apr	NEWA
AB		10MG	A091347 003	May 03, 2012	Apr	NEWA
AB		20MG	A091347 004	May 03, 2012	Apr	NEWA

VECURONIUM BROMIDE

INJECTABLE; INJECTION

VECURONIUM BROMIDE

>D>	AP	+	BEDFORD	10MG/VIAL	A075549 001	Jun 13, 2000	Jun	CRLD
>A>	AP			10MG/VIAL	A075549 001	Jun 13, 2000	Jun	CRLD
>D>	AP	+		20MG/VIAL	A075549 002	Jun 13, 2000	Jun	CRLD
>A>				20MG/VIAL	A075549 002	Jun 13, 2000	Jun	CRLD
>D>	AP		SUN PHARMA GLOBAL	10MG/VIAL	A079001 001	Jun 17, 2009	Jun	CRLD
>A>	AP	+		10MG/VIAL	A079001 001	Jun 17, 2009	Jun	CRLD
>D>	AP			20MG/VIAL	A079001 002	Jun 17, 2009	Jun	CRLD
>A>	AP	+		20MG/VIAL	A079001 002	Jun 17, 2009	Jun	CRLD

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

VENLAFAXINE HYDROCHLORIDE

AB	ANCHEN PHARMS	EQ 37.5MG BASE	A078087 001	Mar 16, 2012	Mar	NEWA
AB		EQ 75MG BASE	A078087 002	Mar 16, 2012	Mar	NEWA
AB		EQ 150MG BASE	A078087 003	Mar 16, 2012	Mar	NEWA

VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CALAN SR

AB	+	PFIZER	120MG	N019152 003	Mar 06, 1991	Feb	CTNA
AB	+		180MG	N019152 002	Dec 15, 1989	Feb	CTNA
AB	+		240MG	N019152 001	Dec 16, 1986	Feb	CTNA

VERAPAMIL HYDROCHLORIDE

AB	APOTEX CORP	120MG	A200878 001	Apr 20, 2012	Apr	NEWA
AB		180MG	A200878 002	Apr 20, 2012	Apr	NEWA
AB		240MG	A200878 003	Apr 20, 2012	Apr	NEWA

VIGABATRIN

FOR SOLUTION; ORAL

SABRIL

+	LUNDBECK LLC	500MG/PACKET	N022006 001	Aug 21, 2009	Apr	CAHN
---	--------------	--------------	-------------	--------------	-----	------

TABLET; ORAL

SABRIL

+	LUNDBECK LLC	500MG	N020427 001	Aug 21, 2009	Apr	CAHN
---	--------------	-------	-------------	--------------	-----	------

VILAZODONE HYDROCHLORIDE

TABLET; ORAL

VIIBRYD

+	FOREST LABS INC	10MG	N022567 001	Jan 21, 2011	Apr	CRLD
---	-----------------	------	-------------	--------------	-----	------

TABLET; ORAL

VIIBRYD

FOREST LABS INC

40MG

N022567 003 Jan 21, 2011 Apr CRLD

VISMODEGIB

CAPSULE; ORAL

ERIVEDGE

+ GENENTECH

150MG

N203388 001 Jan 30, 2012 Jan NEWA

VORICONAZOLE

INJECTABLE; IV (INFUSION)

VFEND

AP + PFIZER

200MG/VIAL

N021267 001 May 24, 2002 May CFTG

VORICONAZOLE

AP SANDOZ INC

200MG/VIAL

A090862 001 May 30, 2012 May NEWA

TABLET; ORAL

VORICONAZOLE

AB TEVA PHARMS

50MG

A091658 001 Apr 06, 2012 Mar NEWA

AB

200MG

A091658 002 Apr 06, 2012 Mar NEWA

ZICONOTIDE

INJECTABLE; INTRATHECAL

PRIALT

>D> @ JAZZ PHARMS COMMERCL 200MCG/2ML (100MCG/ML)

N021060 003 Dec 28, 2004 Jun CAHN

@ 200MCG/2ML (100MCG/ML)

N021060 003 Dec 28, 2004 Mar CAHN

>A> @ JAZZ PHARMS INTL 200MCG/2ML (100MCG/ML)

N021060 003 Dec 28, 2004 Jun CAHN

ZICONOTIDE ACETATE

INJECTABLE; INTRATHECAL

PRIALT

>D> + JAZZ PHARMS COMMERCL 100MCG/1ML (100MCG/ML)

N021060 002 Dec 28, 2004 Jun CAHN

+ 100MCG/1ML (100MCG/ML)

N021060 002 Dec 28, 2004 Mar CAHN

>D> + 500MCG/20ML (25MCG/ML)

N021060 001 Dec 28, 2004 Jun CAHN

>D> + 500MCG/5ML (100MCG/ML)

N021060 004 Dec 28, 2004 Jun CAHN

+ 500MCG/20ML (25MCG/ML)

N021060 001 Dec 28, 2004 Mar CAHN

+ 500MCG/5ML (100MCG/ML)

N021060 004 Dec 28, 2004 Mar CAHN

>A> + JAZZ PHARMS INTL 100MCG/1ML (100MCG/ML)

N021060 002 Dec 28, 2004 Jun CAHN

>A> + 500MCG/5ML (100MCG/ML)

N021060 004 Dec 28, 2004 Jun CAHN

>A> + 500MCG/20ML (25MCG/ML)

N021060 001 Dec 28, 2004 Jun CAHN

ZIDOVUDINE

TABLET; ORAL

ZIDOVUDINE

@ RANBAXY LABS LTD

300MG

A077327 001 Sep 19, 2005 Apr DISC

ZIPRASIDONE HYDROCHLORIDE

CAPSULE; ORAL

GEODON

AB + PFIZER

EQ 20MG BASE

N020825 001 Feb 05, 2001 Feb CFTG

AB EQ 40MG BASE

N020825 002 Feb 05, 2001 Feb CFTG

AB EQ 60MG BASE

N020825 003 Feb 05, 2001 Feb CFTG

AB EQ 80MG BASE

N020825 004 Feb 05, 2001 Feb CFTG

ZIPRASIDONE HYDROCHLORIDE

AB APOTEX CORP EQ 20MG BASE

A077561 001 Mar 02, 2012 Feb NEWA

AB EQ 40MG BASE

A077561 002 Mar 02, 2012 Feb NEWA

AB EQ 60MG BASE

A077561 003 Mar 02, 2012 Feb NEWA

CAPSULE; ORAL

ZIPRASIDONE HYDROCHLORIDE

AB	APOTEX CORP	EQ 80MG BASE	A077561 004	Mar 02, 2012	Feb	NEWA
AB	DR REDDYS LABS INC	EQ 20MG BASE	A077565 001	Mar 02, 2012	Feb	NEWA
AB		EQ 40MG BASE	A077565 002	Mar 02, 2012	Feb	NEWA
AB		EQ 60MG BASE	A077565 003	Mar 02, 2012	Feb	NEWA
AB		EQ 80MG BASE	A077565 004	Mar 02, 2012	Feb	NEWA
AB	LUPIN PHARMS	EQ 20MG BASE	A077560 001	Mar 02, 2012	Feb	NEWA
AB		EQ 40MG BASE	A077560 002	Mar 02, 2012	Feb	NEWA
AB		EQ 60MG BASE	A077560 003	Mar 02, 2012	Feb	NEWA
AB		EQ 80MG BASE	A077560 004	Mar 02, 2012	Feb	NEWA
AB	SANDOZ INC	EQ 20MG BASE	A077562 001	Jun 01, 2012	May	NEWA
AB		EQ 40MG BASE	A077562 002	Jun 01, 2012	May	NEWA
AB		EQ 60MG BASE	A077562 003	Jun 01, 2012	May	NEWA
AB		EQ 80MG BASE	A077562 004	Jun 01, 2012	May	NEWA

OTC DRUG PRODUCT LIST - 32ND EDITION

OTC DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2012

2-1

CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE

TABLET, CHEWABLE; ORAL

PEPCID COMPLETE

+	MCNEIL CONS	800MG;10MG;165MG	N020958	001	Oct 16, 2000	Mar	CAHN
---	-------------	------------------	---------	-----	--------------	-----	------

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SWAB; TOPICAL

CHLORASCUB MAXI SWABSTICK

+	PROF DSPLS	3.15%;70% (5.1ML)	N021524	003	Jun 03, 2005	Mar	CAHN
---	------------	-------------------	---------	-----	--------------	-----	------

CHLORASCUB SWAB

+	PROF DSPLS	3.15%;70% (1ML)	N021524	001	Jun 03, 2005	Mar	CAHN
---	------------	-----------------	---------	-----	--------------	-----	------

CHLORASCUB SWABSTICK

+	PROF DSPLS	3.15%;70% (1.6ML)	N021524	002	Jun 03, 2005	Mar	CAHN
---	------------	-------------------	---------	-----	--------------	-----	------

DEXTROMETHORPHAN POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

DEXTROMETHORPHAN POLISTIREX

	TRIS PHARMA INC	EQ 30MG HBR/5ML	A091135	001	May 25, 2012	May	NEWA
--	-----------------	-----------------	---------	-----	--------------	-----	------

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

CAPSULE; ORAL

IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE

	STRIDES ARCOLAB LTD	25MG;EQ 200MG FREE ACID AND POTASSIUM SALT	A200888	001	Mar 05, 2012	Feb	NEWA
--	---------------------	--	---------	-----	--------------	-----	------

FAMOTIDINE

TABLET, CHEWABLE; ORAL

PEPCID AC

@	MCNEIL CONS	10MG	N020801	001	Sep 24, 1998	Mar	CAHN
---	-------------	------	---------	-----	--------------	-----	------

+		20MG	N020801	002	Dec 17, 2007	Mar	CAHN
---	--	------	---------	-----	--------------	-----	------

TABLET; ORAL

PEPCID AC

	MCNEIL CONS	10MG	N020325	001	Apr 28, 1995	Mar	CAHN
--	-------------	------	---------	-----	--------------	-----	------

+		20MG	N020325	002	Sep 23, 2003	Mar	CAHN
---	--	------	---------	-----	--------------	-----	------

PEPCID AC (GELTAB)

	MCNEIL CONS	10MG	N020902	001	Aug 05, 1999	Mar	CAHN
--	-------------	------	---------	-----	--------------	-----	------

FEXOFENADINE HYDROCHLORIDE

TABLET; ORAL

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

	SUN PHARM INDS	30MG	A091567	002	Feb 06, 2012	Jan	NEWA
--	----------------	------	---------	-----	--------------	-----	------

	WOCKHARDT LTD	30MG	A079112	002	Feb 08, 2012	Jan	NEWA
--	---------------	------	---------	-----	--------------	-----	------

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

	SUN PHARM INDS	30MG	A091567	001	Feb 06, 2012	Jan	NEWA
--	----------------	------	---------	-----	--------------	-----	------

	WOCKHARDT LTD	30MG	A079112	001	Feb 08, 2012	Jan	NEWA
--	---------------	------	---------	-----	--------------	-----	------

FEXOFENADINE HYDROCHLORIDE ALLERGY

	SUN PHARM INDS	60MG	A091567	004	Feb 06, 2012	Jan	NEWA
--	----------------	------	---------	-----	--------------	-----	------

		180MG	A091567	006	Feb 06, 2012	Jan	NEWA
--	--	-------	---------	-----	--------------	-----	------

	WOCKHARDT LTD	60MG	A079112	004	Feb 08, 2012	Jan	NEWA
--	---------------	------	---------	-----	--------------	-----	------

		180MG	A079112	006	Feb 08, 2012	Jan	NEWA
--	--	-------	---------	-----	--------------	-----	------

FEXOFENADINE HYDROCHLORIDE HIVES

	SUN PHARM INDS	60MG	A091567	003	Feb 06, 2012	Jan	NEWA
--	----------------	------	---------	-----	--------------	-----	------

		180MG	A091567	005	Feb 06, 2012	Jan	NEWA
--	--	-------	---------	-----	--------------	-----	------

TABLET; ORAL

FEXOFENADINE HYDROCHLORIDE HIVES

WOCKHARDT LTD

60MG

A079112 003 Feb 08, 2012 Jan NEWA

180MG

A079112 005 Feb 08, 2012 Jan NEWA

IBUPROFEN

CAPSULE; ORAL

IBUPROFEN

ACCUCAPS INDS

EQ 200MG FREE ACID AND POTASSIUM
SALT

A077338 001 Jul 10, 2009 Jan CAHN

>A> IBUPROFEN SODIUM

>A> TABLET; ORAL

>A> ADVIL

>A> + PFIZER CONS HLTHCARE EQ 200MG BASE

N201803 001 Jun 12, 2012 Jun NEWA

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

LANSOPRAZOLE

DR REDDYS LABS LTD

15MG

A202194 001 May 18, 2012 Apr NEWA

PERRIGO R AND D

15MG

A202319 001 May 18, 2012 Apr NEWA

WOCKHARDT LTD

15MG

A202727 001 May 18, 2012 Apr NEWA

PREVACID 24 HR

+ NOVARTIS

15MG

N022327 001 May 18, 2009 Apr CFTG

LEVONORGESTREL

TABLET; ORAL

LEVONORGESTREL

>A> WATSON LABS INC

1.5MG

A200670 001 Jul 12, 2012 Jun NEWA

PLAN B

+ TEVA BRANDED PHARM

0.75MG

N021045 002 Aug 24, 2006 May CAHN

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL

NICOTINE

AVEVA

7MG/24HR

A074612 002 Jul 28, 2003 Apr NEWA

14MG/24HR

A074612 003 Oct 20, 1997 Apr NEWA

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

APOTEX INC

EQ 150MG BASE

A200172 001 May 31, 2012 May NEWA

SHASUN CHEMS

EQ 75MG BASE

A201745 001 Feb 29, 2012 Feb NEWA

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 06 JUNE 2012

NO JUNE 2012 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO JUNE 2012 ADDITIONS

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST - 32ND EDITION

A - 1

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ACETYLCYSTEINE - ACETADOTE</u>						
N021539 001	8148356	May 21, 2026	DP			
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO</u>						
N022320 001	8105618	Dec 23, 2022	U-1078			
	8129362	Jul 18, 2027	U-1078			
<u>ALBUTEROL SULFATE - PROAIR HFA</u>						
N021457 001	6446627	Dec 18, 2017	DP			
	8132712	Sep 07, 2028	DP			
<u>ALENDRONATE SODIUM - BINOSTO</u>						
N202344 001	>A> 7488496	Aug 11, 2023	DS DP			
	>A> 7964212	Mar 06, 2023	DS DP			
<u>ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURNA</u>						
N022217 001	8168616	Jul 05, 2025	DP			
<u>ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURNA</u>						
N022217 002	8168616	Jul 05, 2025	DP			
<u>ALVIMOPAN - ENTEREG</u>						
N021775 001	8112290	Jul 31, 2030	U-1225			
<u>AMBRISENTAN - LETAIRIS</u>						
N022081 001	>A> RE42462	Jul 29, 2018	DS			
<u>AMBRISENTAN - LETAIRIS</u>						
N022081 002	>A> RE42462	Jul 29, 2018	DS			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N022314 001	8101599	May 16, 2023	DP			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N022314 002	8101599	May 16, 2023	DP			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N022314 003	8101599	May 16, 2023	DP			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N022314 004	8101599	May 16, 2023	DP			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N022314 005	8101599	May 16, 2023	DP			
<u>ARFORMOTEROL TARTRATE - BROVANA</u>						
N021912 001	6589508	Apr 03, 2013	U-793			
	6667344	Jun 22, 2021	DP			
	6814953	Jun 22, 2021	U-793			
	8110706	Nov 09, 2021	DP			
<u>ATOVAQUONE; PROGUANIL HYDROCHLORIDE - ATOVAQUONE AND PROGUANIL HYDROCHLORIDE</u>						
A091211 001					PC	Mar 13, 2012
<u>AVANAFIL - STENDRA</u>						
N202276 001	6656935	Sep 13, 2020	DS DP U-155		NCE	Apr 27, 2017
<u>AVANAFIL - STENDRA</u>						
N202276 002	6656935	Sep 13, 2020	DS DP U-155		NCE	Apr 27, 2017

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AVANAFIL - STENDRA</u>						
N202276 003	6656935	Sep 13, 2020	DS DP U-155		NCE	Apr 27, 2017
<u>AXITINIB - INLYTA</u>						
N202324 001	6534524	Jun 30, 2020	DS DP		NCE	Jan 27, 2017
	7141581	Jun 30, 2020	U-1220			
<u>AXITINIB - INLYTA</u>						
N202324 002	6534524	Jun 30, 2020	DS DP		NCE	Jan 27, 2017
	7141581	Jun 30, 2020	U-1220			
<u>AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - DYMISTA</u>						
N202236 001	>A> 8163723	Aug 29, 2023	U-81		NC	May 01, 2015
	>A> 8163723	Aug 29, 2023	U-77			
	>A> 8163723	Aug 29, 2023	U-707			
	>A> 8163723	Aug 29, 2023	U-644			
	8168620	Feb 24, 2026	DP			
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N202331 001	5583141	Dec 10, 2013	DS DP U-3			
	5736555	Jun 25, 2012	DS DP U-3			
	7157584	May 22, 2025	DS			
	7572920	Jan 07, 2025	DP U-3			
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N202331 002	5583141	Dec 10, 2013	DS DP U-3			
	5736555	Jun 25, 2012	DS DP U-3			
	7157584	May 22, 2025	DS			
	7572920	Jan 07, 2025	DP U-3			
<u>BALSALAZIDE DISODIUM - GIAZO</u>						
N022205 001	6197341	Mar 13, 2018	DP U-1229		NDF	Feb 03, 2015
	7452872	Aug 24, 2026	U-1229			
	7625884	Aug 24, 2026	U-1229			
<u>BECLOMETHASONE DIPROPIONATE - QNASL</u>						
N202813 001	5605674	Feb 25, 2014	DP		NP	Mar 23, 2015
	5683677	Nov 04, 2014	DP			
	5776432	Jul 07, 2015	DP			
	7780038	Jan 24, 2027	DP			
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N022249 001					NCE	Mar 20, 2013
					ODE	Mar 20, 2015
					PED	Sep 20, 2015
					PED	Sep 20, 2013
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N022249 002					NCE	Mar 20, 2013
					ODE	Mar 20, 2015
					PED	Sep 20, 2015
					PED	Sep 20, 2013
<u>BIMATOPROST - LATISSE</u>						
N022369 001	8101161	May 25, 2024	U-1218			
	8101161	May 25, 2024	U-1217			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BIVALIRUDIN - ANGIOMAX</u>						
N020873 001	5196404	Dec 15, 2014	DS DP U-1232			
	5196404	Dec 15, 2014	DS DP U-1040			
	5196404*PED	Jun 15, 2015				
<u>BOCEPREVIR - VICTRELIS</u>						
N202258 001	8119602	Mar 17, 2027		U-1233		
	RE43298	Feb 22, 2022	DS DP U-1128			
<u>BORTEZOMIB - VELCADE</u>						
N021602 001					NR	Jan 23, 2015
<u>BRIMONIDINE TARTRATE; TIMOLOL MALEATE - COMBIGAN</u>						
N021398 001	8133890	Apr 19, 2022	U-1235			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N021929 001	8143239	Jan 29, 2023	DP U-1073			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N021929 002	8143239	Jan 29, 2023	DP U-1073			
<u>BUPIVACAINE - EXPAREL</u>						
N022496 001	6132766	Nov 16, 2013	DP			
	>A> 8182835	Sep 18, 2018	DP U-1246			
<u>BUPIVACAINE - EXPAREL</u>						
N022496 002	6132766	Nov 16, 2013	DP			
	>A> 8182835	Sep 18, 2018	DP U-1246			
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N022012 001	6022562	Oct 17, 2015	DP	Y		
	8101209	Sep 11, 2025	DP			
	8101209*PED	Mar 11, 2026				
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N022012 002	6022562	Oct 17, 2015	DP	Y		
	8101209	Sep 11, 2025	DP			
	8101209*PED	Mar 11, 2026				
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N022012 003	6022562	Oct 17, 2015	DP	Y		
	8101209	Sep 11, 2025	DP			
	8101209*PED	Mar 11, 2026				
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N022012 004	6022562	Oct 17, 2015	DP	Y		
	8101209	Sep 11, 2025	DP			
	8101209*PED	Mar 11, 2026				
<u>CHLORHEXIDINE GLUCONATE - CHLORHEXIDINE GLUCONATE</u>						
N021669 001	7717889	Feb 27, 2025	DP U-1022			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CICLESONIDE - ZETONNA</u>						
N022129 001	5482934	Oct 24, 2017	DS DP U-1002		NP	Jan 20, 2015
	5605674	Feb 25, 2014	DP			
	5683677	Nov 04, 2014	DP			
	5775321	Jul 07, 2015	DP			
	6006745	Dec 28, 2016	DP			
	6036942	Apr 30, 2013	DP			
	6120752	May 13, 2018	DP			
	6264923	May 13, 2018	DP			
<u>CLEVIDIPINE BUTYRATE - CLEVIPREX</u>						
N022156 001	5856346	Jan 05, 2021	DS DP U-893			
<u>CLEVIDIPINE BUTYRATE - CLEVIPREX</u>						
N022156 002	5856346	Jan 05, 2021	DS DP U-893			
<u>CLOBETASOL PROPIONATE - CLOBETASOL PROPIONATE</u>						
A078223 001					>A> PC	Jun 30, 2012
<u>CLOBETASOL PROPIONATE - CLOBETASOL PROPIONATE</u>						
A078854 001					>A> PC	Jun 30, 2012
<u>CLOPIDOGREL BISULFATE - CLOPIDOGREL BISULFATE</u>						
A077665 002					PC	Nov 13, 2012
<u>CLOPIDOGREL BISULFATE - CLOPIDOGREL BISULFATE</u>						
A091023 001					PC	Nov 13, 2012
<u>COLCHICINE - COLCRYS</u>						
N022352 001	7964648	Oct 06, 2028	U-1161			
	8097655	Oct 06, 2028	U-1020			
<u>DAPTOMYCIN - CUBICIN</u>						
N021572 002	8129342	Nov 28, 2020	DS DP			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 001	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016	U-935			
	6037157	Jun 26, 2016	U-1209			
	6037157*PED	Dec 26, 2016				
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-903			
	6335460	Aug 25, 2012	DS DP U-744			
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506	Jun 23, 2019	U-1209			
	7470506*PED	Dec 23, 2019				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 002	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016	U-935			
	6037157	Jun 26, 2016	U-1209			
	6037157*PED	Dec 26, 2016				
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-903			
	6335460	Aug 25, 2012	DS DP U-744			
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506	Jun 23, 2019	U-1209			
	7470506*PED	Dec 23, 2019				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 003	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016	U-935			
	6037157	Jun 26, 2016	U-1209			
	6037157*PED	Dec 26, 2016				
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-903			
	6335460	Aug 25, 2012	DS DP U-744			
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506	Jun 23, 2019	U-1209			
	7470506*PED	Dec 23, 2019				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 004	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016	U-935			
	6037157	Jun 26, 2016	U-1209			
	6037157*PED	Dec 26, 2016				
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-903			
	6335460	Aug 25, 2012	DS DP U-744			
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506	Jun 23, 2019	U-1209			
	7470506*PED	Dec 23, 2019				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 005	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016	U-935			
	6037157	Jun 26, 2016	U-1209			
	6037157*PED	Dec 26, 2016				
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-903			
	6335460	Aug 25, 2012	DS DP U-744			
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506	Jun 23, 2019	U-1209			
	7470506*PED	Dec 23, 2019				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N202895 001	5843946	Dec 01, 2015	DP U-1209			
	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016	U-1209			
	6037157*PED	Dec 26, 2016				
	6248775	Aug 13, 2014	DS			
	6248775*PED	Feb 13, 2015				
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-1209			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-1209			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
	RE42889	Oct 19, 2016	DP			
	RE42889*PED	Apr 19, 2017				
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N022201 001	5925730	May 18, 2021	DS DP U-943			
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N022201 002	5925730	May 18, 2021	DS DP U-943			
<u>DESLOMATADINE; PSEUDOEPHEDRINE SULFATE - CLARINEX-D 12 HOUR</u>						
N021313 001	>A> 8187630	Dec 19, 2020	DP U-1017			
<u>DEXAMETHASONE - OZURDEX</u>						
N022315 001	8088407	Oct 20, 2020	DP U-1205			
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N022287 001	8105626	Sep 27, 2026	DP			
	8105626*PED	Mar 27, 2027				
	8173158	Mar 17, 2030	U-951			
	8173158	Mar 17, 2030	U-950			
	8173158	Mar 17, 2030	U-949			
	8173158*PED	Sep 17, 2030				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N022287 002	8105626	Sep 27, 2026	DP			
	8105626*PED	Mar 27, 2027				
	8173158	Mar 17, 2030	U-951			
	8173158	Mar 17, 2030	U-950			
	8173158	Mar 17, 2030	U-949			
	8173158*PED	Sep 17, 2030				
<u>DICLOFENAC POTASSIUM - CAMBIA</u>						
N022165 001	8097651	Jun 16, 2026	DS DP U-436			
<u>DICLOFENAC POTASSIUM - ZIPSOR</u>						
N022202 001	8110606	Feb 24, 2029	U-980			
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N020947 001	>A> 8217078	Jul 10, 2029	U-1248			
<u>DIENOGEST; ESTRADIOL VALERATE - NATAZIA</u>						
N022252 001	8153616	Jan 30, 2028	U-1240		I-648	Mar 14, 2015
<u>DIFLUPREDNATE - DUREZOL</u>						
N022212 001					>A> I-653 >A> ODE	Jun 13, 2015 Jun 13, 2019
<u>DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE - COSOPT PF</u>						
N202667 001					NP	Feb 01, 2015
<u>DOXYCYCLINE - ORACEA</u>						
N050805 001	>A> 8206740	Dec 24, 2025	DP U-925			
<u>DROSPIRENONE; ESTRADIOL - ANGELIQ</u>						
N021355 001					NS	Mar 01, 2015
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N021427 001	>A> 5023269	Jun 11, 2013	DS DP U-882		>A> I-632	Nov 04, 2013
	>A> 5023269	Jun 11, 2013	DS DP U-839		>A> I-617	Nov 19, 2012
	>A> 5023269	Jun 11, 2013	DS DP U-799		>A> PED	May 04, 2014
	>A> 5023269	Jun 11, 2013	DS DP U-797		>A> PED	May 19, 2013
	>A> 5023269	Jun 11, 2013	DS DP U-796			
	>A> 5023269	Jun 11, 2013	DS DP U-795			
	>A> 5023269	Jun 11, 2013	DS DP U-605			
	>A> 5023269	Jun 11, 2013	DS DP U-398			
	>A> 5023269	Jun 11, 2013	DS DP U-1094			
	>A> 5023269*PED	Dec 11, 2013				
	>A> 5508276	Jul 18, 2014	DP			
	>A> 5508276*PED	Jan 18, 2015				
	>A> 6596756	Sep 10, 2019	U-882			
	>A> 6596756*PED	Mar 10, 2020				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N021427 002	>A> 5023269	Jun 11, 2013	DS DP U-882		>A> I-632	Nov 04, 2013
	>A> 5023269	Jun 11, 2013	DS DP U-839		>A> I-617	Nov 19, 2012
	>A> 5023269	Jun 11, 2013	DS DP U-799		>A> PED	May 04, 2014
	>A> 5023269	Jun 11, 2013	DS DP U-797		>A> PED	May 19, 2013
	>A> 5023269	Jun 11, 2013	DS DP U-796			
	>A> 5023269	Jun 11, 2013	DS DP U-795			
	>A> 5023269	Jun 11, 2013	DS DP U-605			
	>A> 5023269	Jun 11, 2013	DS DP U-398			
	>A> 5023269	Jun 11, 2013	DS DP U-1094			
	>A> 5023269*PED	Dec 11, 2013				
	>A> 5508276	Jul 18, 2014	DP			
	>A> 5508276*PED	Jan 18, 2015				
	>A> 6596756	Sep 10, 2019	U-882			
	>A> 6596756*PED	Mar 10, 2020				
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N021427 004	>A> 5023269	Jun 11, 2013	DS DP U-882		>A> I-632	Nov 04, 2013
	>A> 5023269	Jun 11, 2013	DS DP U-839		>A> I-617	Nov 19, 2012
	>A> 5023269	Jun 11, 2013	DS DP U-799		>A> PED	May 04, 2014
	>A> 5023269	Jun 11, 2013	DS DP U-797		>A> PED	May 19, 2013
	>A> 5023269	Jun 11, 2013	DS DP U-796			
	>A> 5023269	Jun 11, 2013	DS DP U-795			
	>A> 5023269	Jun 11, 2013	DS DP U-605			
	>A> 5023269	Jun 11, 2013	DS DP U-398			
	>A> 5023269	Jun 11, 2013	DS DP U-1094			
	>A> 5023269*PED	Dec 11, 2013				
	>A> 5508276	Jul 18, 2014	DP			
	>A> 5508276*PED	Jan 18, 2015				
	>A> 6596756	Sep 10, 2019	U-882			
	>A> 6596756*PED	Mar 10, 2020				
<u>EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA</u>						
N021937 001	>A> 5663169	Sep 02, 2014	U-750			
	>A> 5663169	Sep 02, 2014	U-1170			
	>A> 5811423	Aug 07, 2012	U-750			
	>A> 5811423	Aug 07, 2012	U-1170			
	>A> 5922695	Jul 25, 2017	DS U-750			
	>A> 5922695	Jul 25, 2017	DS U-1170			
	>A> 5935946	Jul 25, 2017	DS DP U-750			
	>A> 5935946	Jul 25, 2017	DS DP U-1170			
	>A> 5977089	Jul 25, 2017	DS DP U-750			
	>A> 5977089	Jul 25, 2017	DS DP U-1170			
	>A> 6043230	Jul 25, 2017	U-750			
	>A> 6043230	Jul 25, 2017	U-1170			
	>A> 6642245	Nov 04, 2020	U-750			
	>A> 6642245	Nov 04, 2020	U-1170			
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE - COMPLERA</u>						
N202123 001	>A> 8080551	Apr 11, 2023	DS DP		NCE	May 20, 2016
	>A> 8101629	Aug 09, 2022	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EPROSARTAN MESYLATE - EPROSARTAN MESYLATE</u>						
A202012 001					PC	Jun 17, 2012
<u>EPROSARTAN MESYLATE - EPROSARTAN MESYLATE</u>						
A202012 002					PC	Jun 17, 2012
<u>ERIBULIN MESYLATE - HALAVEN</u>						
N201532 001	8097648	Jan 22, 2021	U-1096			
<u>ESCITALOPRAM OXALATE - ESCITALOPRAM OXALATE</u>						
A076765 001					PC	Sep 10, 2012
<u>ESCITALOPRAM OXALATE - ESCITALOPRAM OXALATE</u>						
A076765 002					PC	Sep 10, 2012
<u>ESCITALOPRAM OXALATE - ESCITALOPRAM OXALATE</u>						
A076765 003					PC	Sep 10, 2012
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N021957 001	5877192	May 27, 2014	U-773			
	5877192	May 27, 2014	U-729			
	5877192	May 27, 2014	U-1207			
	5877192*PED	Nov 27, 2014				
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N021957 002	5877192	May 27, 2014	U-773			
	5877192	May 27, 2014	U-729			
	5877192	May 27, 2014	U-1207			
	5877192*PED	Nov 27, 2014				
<u>ESZOPICLONE - LUNESTA</u>						
N021476 001	>A> 6319926	Jan 16, 2012	U-620			
	>A> 6319926*PED	Jul 16, 2012				
	>A> 6444673	Feb 14, 2014	DS DP			
	>A> 6444673*PED	Aug 14, 2014				
	>A> 6864257	Aug 30, 2012	U-629			
	>A> 6864257*PED	Mar 02, 2013				
	>A> 7381724	Jan 16, 2012	DS DP U-629			
	>A> 7381724*PED	Jul 16, 2012				
<u>ESZOPICLONE - LUNESTA</u>						
N021476 002	>A> 6319926	Jan 16, 2012	U-620			
	>A> 6319926*PED	Jul 16, 2012				
	>A> 6444673	Feb 14, 2014	DS DP			
	>A> 6444673*PED	Aug 14, 2014				
	>A> 6864257	Aug 30, 2012	U-629			
	>A> 6864257*PED	Mar 02, 2013				
	>A> 7381724	Jan 16, 2012	DS DP U-629			
	>A> 7381724*PED	Jul 16, 2012				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ESZOPICLONE - LUNESTA</u>						
N021476 003	>A> 6319926	Jan 16, 2012	U-620			
	>A> 6319926*PED	Jul 16, 2012				
	>A> 6444673	Feb 14, 2014	DS DP			
	>A> 6444673*PED	Aug 14, 2014				
	>A> 6864257	Aug 30, 2012	U-629			
	>A> 6864257*PED	Mar 02, 2013				
	>A> 7381724	Jan 16, 2012	DS DP U-629			
	>A> 7381724*PED	Jul 16, 2012				
<u>ETONOGESTREL - NEXPLANON</u>						
N021529 002					>A> NP	May 31, 2014
<u>ETRAVIRINE - INTELENCE</u>						
N022187 001	6878717	Nov 05, 2019	U-256		NPP	Mar 26, 2015
	6878717	Nov 05, 2019	U-1237			
	6878717	Nov 05, 2019	U-1016			
	7037917	Dec 13, 2020	DS DP U-256			
	7037917	Dec 13, 2020	DS DP U-1237			
	7037917	Dec 13, 2020	DS DP U-1016			
<u>ETRAVIRINE - INTELENCE</u>						
N022187 002	6878717	Nov 05, 2019	U-256		NPP	Mar 26, 2015
	6878717	Nov 05, 2019	U-1237			
	6878717	Nov 05, 2019	U-1016			
	7037917	Dec 13, 2020	DS DP U-256			
	7037917	Dec 13, 2020	DS DP U-1237			
	7037917	Dec 13, 2020	DS DP U-1016			
<u>ETRAVIRINE - INTELENCE</u>						
N022187 003	6878717	Nov 05, 2019	U-256		NPP	Mar 26, 2015
	6878717	Nov 05, 2019	U-1237		NCE	Jan 18, 2013
	6878717	Nov 05, 2019	U-1016			
	7037917	Dec 13, 2020	DS DP U-1237			
	7887845	Mar 25, 2019	DP			
	8003789	Nov 01, 2019	DS DP			
<u>EVEROLIMUS - AFINITOR</u>						
N022334 001	>A> 5665772	Sep 09, 2019	DS DP		>A> I-650	Apr 26, 2015
	>A> 5665772*PED	Mar 09, 2020			>A> I-638	May 05, 2014
	>A> 6004973	Jul 12, 2016	DP		>A> I-630	Oct 29, 2013
	>A> 6004973*PED	Jan 12, 2017			>A> NCE	Mar 30, 2014
	>A> 7297703	Dec 06, 2019	DP		>A> ODE	Apr 26, 2019
	>A> 7297703*PED	Jun 06, 2020			>A> ODE	May 05, 2018
					>A> ODE	Oct 29, 2017
					>A> PED	Oct 26, 2019
					>A> PED	Nov 05, 2018
					>A> PED	Apr 29, 2018
					>A> PED	Oct 26, 2015
					>A> PED	Nov 05, 2014
					>A> PED	Sep 30, 2014
					>A> PED	Apr 29, 2014

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EVEROLIMUS - AFINITOR</u>						
N022334 002	>A> 5665772	Sep 09, 2019	DS DP		>A> I-650	Apr 26, 2015
	>A> 5665772*PED	Mar 09, 2020			>A> I-638	May 05, 2014
	>A> 6004973	Jul 12, 2016	DP		>A> I-630	Oct 29, 2013
	>A> 6004973*PED	Jan 12, 2017			>A> NCE	Mar 30, 2014
	>A> 7297703	Dec 06, 2019	DP		>A> ODE	Apr 26, 2019
	>A> 7297703*PED	Jun 06, 2020			>A> ODE	May 05, 2018
					>A> ODE	Oct 29, 2017
					>A> PED	Oct 26, 2019
					>A> PED	Nov 05, 2018
					>A> PED	Apr 29, 2018
					>A> PED	Oct 26, 2015
					>A> PED	Nov 05, 2014
					>A> PED	Sep 30, 2014
					>A> PED	Apr 29, 2014
<u>EVEROLIMUS - AFINITOR</u>						
N022334 003	>A> 5665772	Sep 09, 2019	DS DP		>A> I-650	Apr 26, 2015
	>A> 5665772*PED	Mar 09, 2020			>A> I-638	May 05, 2014
	>A> 6004973	Jul 12, 2016	DP		>A> I-630	Oct 29, 2013
	>A> 6004973*PED	Jan 12, 2017			>A> NCE	Mar 30, 2014
	>A> 7297703	Dec 06, 2019	DP		>A> ODE	Apr 26, 2019
	>A> 7297703*PED	Jun 06, 2020			>A> ODE	May 05, 2018
					>A> ODE	Oct 29, 2017
					>A> PED	Oct 26, 2019
					>A> PED	Nov 05, 2018
					>A> PED	Apr 29, 2018
					>A> PED	Oct 26, 2015
					>A> PED	Nov 05, 2014
					>A> PED	Sep 30, 2014
					>A> PED	Apr 29, 2014
<u>EVEROLIMUS - AFINITOR</u>						
N022334 004	>A> 5665772	Sep 09, 2019	DS DP		>A> I-650	Apr 26, 2015
	>A> 5665772*PED	Mar 09, 2020			>A> I-638	May 05, 2014
	>A> 6004973	Jul 12, 2016	DP		>A> I-630	Oct 29, 2013
	>A> 6004973*PED	Jan 12, 2017			>A> NCE	Mar 30, 2014
	>A> 7297703	Dec 06, 2019	DP		>A> ODE	Apr 26, 2019
	>A> 7297703*PED	Jun 06, 2020			>A> ODE	May 05, 2018
					>A> ODE	Oct 29, 2017
					>A> PED	Oct 26, 2019
					>A> PED	Nov 05, 2018
					>A> PED	Apr 29, 2018
					>A> PED	Oct 26, 2015
					>A> PED	Nov 05, 2014
					>A> PED	Sep 30, 2014
					>A> PED	Apr 29, 2014
<u>EVEROLIMUS - ZORTRESS</u>						
N021560 001	>A> 5665772	Sep 09, 2019	DS DP U-1049		>A> NP	Apr 20, 2013
	>A> 5665772*PED	Mar 09, 2020			>A> NCE	Mar 30, 2014
	>A> 6004973	Jul 12, 2016	DP U-1049		>A> PED	Sep 30, 2014
	>A> 6004973*PED	Jan 12, 2017			>A> PED	Oct 20, 2013
	>A> 6239124	Aug 11, 2017	U-1049			
	>A> 6239124*PED	Feb 11, 2018				
	>A> 6440990	Sep 24, 2013	DP U-1049			
	>A> 6440990*PED	Mar 24, 2014				
	>A> 6455518	Jul 29, 2017	U-1049			
	>A> 6455518*PED	Jan 29, 2018				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EVEROLIMUS - ZORTRESS</u>						
N021560 002	>A> 5665772	Sep 09, 2019	DS DP U-1049		>A> NP	Apr 20, 2013
	>A> 5665772*PED	Mar 09, 2020			>A> NCE	Mar 30, 2014
	>A> 6004973	Jul 12, 2016	DP U-1049		>A> PED	Sep 30, 2014
	>A> 6004973*PED	Jan 12, 2017			>A> PED	Oct 20, 2013
	>A> 6239124	Aug 11, 2017	U-1049			
	>A> 6239124*PED	Feb 11, 2018				
	>A> 6440990	Sep 24, 2013	DP U-1049			
	>A> 6440990*PED	Mar 24, 2014				
	>A> 6455518	Jul 29, 2017	U-1049			
	>A> 6455518*PED	Jan 29, 2018				
<u>EVEROLIMUS - ZORTRESS</u>						
N021560 003	>A> 5665772	Sep 09, 2019	DS DP U-1049		>A> NP	Apr 20, 2013
	>A> 5665772*PED	Mar 09, 2020			>A> NCE	Mar 30, 2014
	>A> 6004973	Jul 12, 2016	DP U-1049		>A> PED	Sep 30, 2014
	>A> 6004973*PED	Jan 12, 2017			>A> PED	Oct 20, 2013
	>A> 6239124	Aug 11, 2017	U-1049			
	>A> 6239124*PED	Feb 11, 2018				
	>A> 6440990	Sep 24, 2013	DP U-1049			
	>A> 6440990*PED	Mar 24, 2014				
	>A> 6455518	Jul 29, 2017	U-1049			
	>A> 6455518*PED	Jan 29, 2018				
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N022200 001	5424286	Dec 01, 2016	U-1108		NP	Jan 27, 2015
	6479065	Aug 10, 2020	DP			
	6495164	May 25, 2020	DP			
	6667061	May 25, 2020	DP			
	6824822	Oct 09, 2022	DP			
	6858576	Jan 06, 2017	U-656			
	6872700	Jan 14, 2020	U-654			
	6956026	Jan 07, 2018	U-687			
	7223440	Aug 31, 2021	DP			
	7456254	Jun 30, 2025	DP U-1223			
	7563871	Apr 15, 2024	DP			
	7612176	Apr 13, 2025	DP U-1223			
	7741269	Jan 07, 2018	U-1224			
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
N021773 001					M-113	Oct 19, 2014
					M-111	Oct 19, 2014
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
N021773 002					M-113	Oct 19, 2014
					M-111	Oct 19, 2014
<u>EZETIMIBE - ZETIA</u>						
N021445 001					M-109	Jan 24, 2015
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687 001					M-109	Jan 24, 2015
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687 002					M-109	Jan 24, 2015

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687 003					M-109	Jan 24, 2015
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687 004					M-109	Jan 24, 2015
<u>FAMCICLOVIR - FAMVIR</u>						
N020363 001					M-112	Feb 09, 2015
<u>FAMCICLOVIR - FAMVIR</u>						
N020363 002					M-112	Feb 09, 2015
<u>FAMCICLOVIR - FAMVIR</u>						
N020363 003					M-112	Feb 09, 2015
<u>FENOFIBRATE - FENOGLIDE</u>						
N022118 001	8124125	Oct 01, 2024	DP U-1234			
<u>FENOFIBRATE - FENOGLIDE</u>						
N022118 002	8124125	Oct 01, 2024	DP U-1234			
<u>FENTANYL - SUBSYS</u>						
N202788 001					NP	Jan 04, 2015
<u>FENTANYL - SUBSYS</u>						
N202788 002					NP	Jan 04, 2015
<u>FENTANYL - SUBSYS</u>						
N202788 003					NP	Jan 04, 2015
<u>FENTANYL - SUBSYS</u>						
N202788 004					NP	Jan 04, 2015
<u>FENTANYL - SUBSYS</u>						
N202788 005					NP	Jan 04, 2015
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 001	8092832	Dec 30, 2024	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 002	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 003	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 004	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 005	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N022266 001	7579019	Jan 22, 2020	U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N022266 002	7579019	Jan 22, 2020	U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N022266 003	7579019	Jan 22, 2020	U-767			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FENTANYL CITRATE - ONSOLIS</u>						
N022266 004	7579019	Jan 22, 2020	U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N022266 005	7579019	Jan 22, 2020	U-767			
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N022030 001	8088398	Jun 07, 2027	DP U-913			
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N022030 002	8088398	Jun 07, 2027	DP U-913			
<u>FINGOLIMOD - GILENYA</u>						
N022527 001	6004565	Sep 23, 2017	U-1086			
<u>FLORBETAPIR F-18 - AMYVID</u>						
N202008 001	7687052	Apr 30, 2027	DS DP		NCE	Apr 06, 2017
<u>FLORBETAPIR F-18 - AMYVID</u>						
N202008 002	7687052	Apr 30, 2027	DS DP		NCE	Apr 06, 2017
<u>FLORBETAPIR F-18 - AMYVID</u>						
N202008 003	7687052	Apr 30, 2027	DS DP		NCE	Apr 06, 2017
<u>FLUNISOLIDE - AEROSPAN HFA</u>						
N021247 001	5776433	Jul 07, 2015	DP			
	5980867	Jul 06, 2018	DP			
<u>FOSAMPRENAVIR CALCIUM - LEXIVA</u>						
N021548 001					NPP PED	Apr 27, 2015 Oct 27, 2015
<u>FOSAMPRENAVIR CALCIUM - LEXIVA</u>						
N022116 001					NPP PED	Apr 27, 2015 Oct 27, 2015
<u>FOSAPREPITANT DIMEGLUMINE - EMEND</u>						
N022023 002	5512570	Mar 04, 2014	U-850			
	5538982	Jul 23, 2013	U-850			
	5716942	Feb 10, 2015	U-850			
	7214692	Sep 18, 2012	U-850			
<u>FOSPROPOFOL DISODIUM - LUSEDRA</u>						
N022244 001	6204257	Jul 01, 2022	DS DP U-945			
<u>GABAPENTIN - GRALISE</u>						
N022544 001	>A> 8192756	Oct 25, 2022	DP U-1114			
<u>GABAPENTIN - GRALISE</u>						
N022544 002	>A> 8192756	Oct 25, 2022	DP U-1114			
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N022399 001	>A> 8048917	Nov 06, 2022	DS DP U-1247		>A> I-652	Jun 06, 2015
	8114909	Apr 11, 2026	U-1231			
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N022399 002	>A> 8048917	Nov 06, 2022	DS DP U-1247		>A> I-652	Jun 06, 2015
	8114909	Apr 11, 2026	U-1231			
<u>GADOBENATE DIMEGLUMINE - MULTIHCANCE</u>						
N021357 001					>A> I-654	Jul 06, 2015

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GADOBENATE DIMEGLUMINE - MULTIANCE</u>						
N021357 002					>A> I-654	Jul 06, 2015
<u>GADOBENATE DIMEGLUMINE - MULTIANCE</u>						
N021357 003					>A> I-654	Jul 06, 2015
<u>GADOBENATE DIMEGLUMINE - MULTIANCE</u>						
N021357 004					>A> I-654	Jul 06, 2015
<u>GADOBENATE DIMEGLUMINE - MULTIANCE MULTIPACK</u>						
N021358 001					>A> I-654	Jul 06, 2015
<u>GADOBENATE DIMEGLUMINE - MULTIANCE MULTIPACK</u>						
N021358 002					>A> I-654	Jul 06, 2015
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N021711 001	6676929	May 04, 2020	DP			
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N021711 002	6676929	May 04, 2020	DP			
<u>GADOXETATE DISODIUM - EOVI</u>						
N022090 001	5798092	Aug 25, 2015	DS DP			
	6039931	Nov 13, 2021	U-1239			
<u>GLYCOPYRROLATE - CUVPOSA</u>						
N022571 001					ODE	Jul 28, 2017
<u>HYDROCHLOROTHIAZIDE; IRBESARTAN - IRBESARTAN AND HYDROCHLOROTHIAZIDE</u>						
A077369 001					PC	Sep 26, 2012
<u>HYDROCHLOROTHIAZIDE; IRBESARTAN - IRBESARTAN AND HYDROCHLOROTHIAZIDE</u>						
A077369 002					PC	Sep 26, 2012
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N021588 001					ODE	Dec 19, 2015
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N021588 002					ODE	Dec 19, 2015
<u>INGENOL MEBUTATE - PICATO</u>						
N202833 001	6432452	Aug 19, 2018	DS U-68		NCE	Jan 23, 2017
	6844013	Aug 19, 2018	DS DP U-1221			
	7410656	Aug 19, 2018	DS U-1222			
<u>INGENOL MEBUTATE - PICATO</u>						
N202833 002	6432452	Aug 19, 2018	DS U-68		NCE	Jan 23, 2017
	6844013	Aug 19, 2018	DS DP U-1221			
	7410656	Aug 19, 2018	DS U-1222			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR</u>						
N021536 001					>A> M-117 M-115	May 18, 2015 Apr 06, 2015
<u>IOFLUPANE I-123 - DATSCAN</u>						
N022454 001	5310912	Feb 25, 2013	DS			
<u>IRBESARTAN - IRBESARTAN</u>						
A077159 001					PC	Sep 26, 2012
<u>IRBESARTAN - IRBESARTAN</u>						
A077159 002					PC	Sep 26, 2012

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IRBESARTAN - IRBESARTAN</u>						
A077159 003					PC	Sep 26, 2012
<u>ISOTRETINOIN - ABSORICA</u>						
N021951 001	7435427	Sep 21, 2021	DP		NP	May 25, 2015
<u>ISOTRETINOIN - ABSORICA</u>						
N021951 002	7435427	Sep 21, 2021	DP		NP	May 25, 2015
<u>ISOTRETINOIN - ABSORICA</u>						
N021951 003	7435427	Sep 21, 2021	DP		NP	May 25, 2015
<u>ISOTRETINOIN - ABSORICA</u>						
N021951 004	7435427	Sep 21, 2021	DP		NP	May 25, 2015
<u>IVACAFTOR - KALYDECO</u>						
N203188 001	7495103	May 20, 2027	DS DP		NCE ODE	Jan 31, 2017 Jan 31, 2019
<u>IVERMECTIN - SKLICE</u>						
N202736 001	6103248	May 22, 2018	DP		NP	Feb 07, 2015
<u>IXABEPILONE - IXEMPRA KIT</u>						
N022065 001	RE41911	Sep 28, 2020	DS DP U-961			
	RE41911*PED	Mar 28, 2021				
<u>IXABEPILONE - IXEMPRA KIT</u>						
N022065 002	RE41911	Sep 28, 2020	DS DP U-961			
	RE41911*PED	Mar 28, 2021				
<u>KETOCONAZOLE - EXTINA</u>						
N021738 001	8026238	Oct 19, 2018	DP U-1213			
<u>LAMIVUDINE; ZIDOVUDINE - LAMIVUDINE AND ZIDOVUDINE</u>						
A079081 001					PC	May 15, 2012
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 001	5635517	Oct 04, 2019	DS			U-1211
	6045501	Aug 28, 2018				U-1210
	6281230	Jul 24, 2016			U-1212	
	6315720	Oct 23, 2020			U-1210	
	6555554	Jul 24, 2016	DP			U-1211
	6561976	Aug 28, 2018				U-1210
	6561977	Oct 23, 2020			U-1210	
	6755784	Oct 23, 2020			U-1210	
	6908432	Aug 28, 2018			U-1210	
	7189740	Apr 11, 2023			U-1215	
	7465800	Apr 27, 2027	DS DP			
	7968569	Oct 07, 2023				U-1216
	>A> 8204763	Aug 28, 2018			U-1249	

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 002	5635517	Oct 04, 2019	DS		U-1211	
	6045501	Aug 28, 2018			U-1210	
	6281230	Jul 24, 2016			U-1212	
	6315720	Oct 23, 2020			U-1210	
	6555554	Jul 24, 2016	DP		U-1211	
	6561976	Aug 28, 2018			U-1210	
	6561977	Oct 23, 2020			U-1210	
	6755784	Oct 23, 2020			U-1210	
	6908432	Aug 28, 2018			U-1210	
	7189740	Apr 11, 2023			U-1215	
	7465800	Apr 27, 2027	DS DP			
	7968569	Oct 07, 2023			U-1216	
	>A> 8204763	Aug 28, 2018			U-1249	
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 003	5635517	Oct 04, 2019	DS		U-1211	
	6045501	Aug 28, 2018			U-1210	
	6281230	Jul 24, 2016			U-1212	
	6315720	Oct 23, 2020			U-1210	
	6555554	Jul 24, 2016	DP		U-1211	
	6561976	Aug 28, 2018			U-1210	
	6561977	Oct 23, 2020			U-1210	
	6755784	Oct 23, 2020			U-1210	
	6908432	Aug 28, 2018			U-1210	
	7189740	Apr 11, 2023			U-1215	
	7465800	Apr 27, 2027	DS DP			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023			U-1216	
	>A> 8204763	Aug 28, 2018			U-1249	
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 004	5635517	Oct 04, 2019	DS		U-1211	
	6045501	Aug 28, 2018			U-1210	
	6281230	Jul 24, 2016			U-1212	
	6315720	Oct 23, 2020			U-1210	
	6555554	Jul 24, 2016	DP		U-1211	
	6561976	Aug 28, 2018			U-1210	
	6561977	Oct 23, 2020			U-1210	
	6755784	Oct 23, 2020			U-1210	
	6908432	Aug 28, 2018			U-1210	
	7189740	Apr 11, 2023			U-1215	
	7465800	Apr 27, 2027	DS DP			
	7968569	Oct 07, 2023			U-1216	
	>A> 8204763	Aug 28, 2018			U-1249	

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 005	5635517	Oct 04, 2019	DS		U-1211	
	6045501	Aug 28, 2018			U-1210	
	6281230	Jul 24, 2016			U-1212	
	6315720	Oct 23, 2020			U-1210	
	6555554	Jul 24, 2016	DP		U-1211	
	6561976	Aug 28, 2018			U-1210	
	6561977	Oct 23, 2020			U-1210	
	6755784	Oct 23, 2020			U-1210	
	6908432	Aug 28, 2018			U-1210	
	7119106	Jul 24, 2016	DP			
	7189740	Apr 11, 2023			U-1215	
	7465800	Apr 27, 2027	DS DP			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023			U-1216	
	>A> 8204763	Aug 28, 2018			U-1249	
<u>LINAGLIPTIN - TRADJENTA</u>						
N201280 001	8119648	Aug 12, 2023			U-774	
	>A> 8178541	Aug 12, 2023			U-775	
	>A> 8178541	Aug 12, 2023			U-1245	
	>A> 8178541	Aug 12, 2023			U-1244	
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N201281 001	6303661	Apr 24, 2017			U-802	NCE NC
	6890898	Feb 02, 2019			U-1039	
	7078381	Feb 02, 2019			U-1039	
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019			U-1039	
	8119648	Aug 12, 2023			U-802	
	>A> 8178541	Aug 12, 2023	DP		U-775	
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N201281 002	6303661	Apr 24, 2017			U-802	NCE NC
	6890898	Feb 02, 2019			U-1039	
	7078381	Feb 02, 2019			U-1039	
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019			U-1039	
	8119648	Aug 12, 2023			U-802	
	>A> 8178541	Aug 12, 2023	DP		U-775	
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N201281 003	6303661	Apr 24, 2017			U-802	NCE NC
	6890898	Feb 02, 2019			U-1039	
	7078381	Feb 02, 2019			U-1039	
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019			U-1039	
	8119648	Aug 12, 2023			U-802	
	>A> 8178541	Aug 12, 2023	DP		U-775	
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N022341 001	8114833	Aug 13, 2025	DP		M-115	Apr 06, 2015

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 001	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7713936	Feb 24, 2023	U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 002	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7713936	Feb 24, 2023	U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 003	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7713936	Feb 24, 2023	U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 004	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7671030	Feb 24, 2023	DP U-727			
	7674774	Mar 18, 2023	DP U-842			
	7678771	Mar 25, 2023	DP U-842			
	7687467	Apr 08, 2023	DP U-842			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-842			
	7723305	Feb 24, 2023	DP U-842			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 005	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7713936	Feb 24, 2023	U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 006	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7713936	Feb 24, 2023	U-727			
<u>LORCASERIN HYDROCHLORIDE - BELVIQ</u>						
N022529 001					>A> NCE	Jun 27, 2017
<u>LUBIPROSTONE - AMITIZA</u>						
N021908 001	8097649	Oct 16, 2020	DP			
	8097653	Nov 14, 2022	U-1214			
	8114890	Sep 05, 2020	DP			
<u>LUBIPROSTONE - AMITIZA</u>						
N021908 002	8097649	Oct 16, 2020	DP			
	8114890	Sep 05, 2020	DP			
<u>LUCINACTANT - SURFAXIN</u>						
N021746 001	5407914	Nov 17, 2012	DS DP U-1242			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N200603 001					D-134	Apr 26, 2015
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N200603 002					D-134	Apr 26, 2015
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N200603 003					D-134 NCE	Apr 26, 2015 Oct 28, 2015
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N200603 004					D-134 NCE	Apr 26, 2015 Oct 28, 2015

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N021842 001					M-116	May 17, 2015
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N021842 002					M-116	May 17, 2015
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N202270 001	6303661	Apr 24, 2017	U-1227			
	6340475	Sep 19, 2016	DP			
	6635280	Sep 19, 2016	DP			
	6699871	Jul 26, 2022	DS DP U-1227			
	6890898	Feb 02, 2019	U-1228			
	7078381	Feb 02, 2019	U-1227			
	7125873	Jul 26, 2022	DP U-1227			
	7326708	Apr 11, 2026	DS DP U-1227			
	7459428	Feb 02, 2019	U-1227			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N202270 002	6303661	Apr 24, 2017	U-1227			
	6340475	Sep 19, 2016	DP			
	6635280	Sep 19, 2016	DP			
	6699871	Jul 26, 2022	DS DP U-1227			
	6890898	Feb 02, 2019	U-1228			
	7078381	Feb 02, 2019	U-1227			
	7125873	Jul 26, 2022	DP U-1227			
	7326708	Apr 11, 2026	DS DP U-1227			
	7459428	Feb 02, 2019	U-1227			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N202270 003	6303661	Apr 24, 2017	U-1227			
	6340475	Sep 19, 2016	DP			
	6635280	Sep 19, 2016	DP			
	6699871	Jul 26, 2022	DS DP U-1227			
	6890898	Feb 02, 2019	U-1228			
	7078381	Feb 02, 2019	U-1227			
	7125873	Jul 26, 2022	DP U-1227			
	7326708	Apr 11, 2026	DS DP U-1227			
	7459428	Feb 02, 2019	U-1227			
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N021121 001	8163798	Jul 31, 2017	DP			
	8163798*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N021121 002	8163798	Jul 31, 2017	DP			
	8163798*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N021121 003	8163798	Jul 31, 2017	DP			
	8163798*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N021121 004	8163798	Jul 31, 2017	DP			
	8163798*PED	Jan 31, 2018				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - METHYLPHENIDATE HYDROCHLORIDE</u>						
A078458 001					PC	Jul 01, 2012
<u>METHYLPHENIDATE HYDROCHLORIDE - METHYLPHENIDATE HYDROCHLORIDE</u>						
A078458 002					PC	Jul 01, 2012
<u>METHYLPHENIDATE HYDROCHLORIDE - METHYLPHENIDATE HYDROCHLORIDE</u>						
A078458 003					PC	Jul 01, 2012
<u>MICONAZOLE - ORAVIG</u>						
N022404 001	7651698	Sep 11, 2022	U-1051			
<u>MIFEPRISTONE - KORLYM</u>						
N202107 001					NP	Feb 17, 2015
<u>MINOCYCLINE HYDROCHLORIDE - ARESTIN</u>						
N050781 001	6682348	Mar 29, 2022	DP			
<u>MIRABEGRON - MYRBETRIQ</u>						
N202611 001					>A> NCE	Jun 28, 2017
<u>MIRABEGRON - MYRBETRIQ</u>						
N202611 002					>A> NCE	Jun 28, 2017
<u>MITOMYCIN - MITOSOL</u>						
N022572 001	7806265	Feb 01, 2029	DP		ODE	Feb 07, 2019
	>A> 8186511	Jul 19, 2026	DP			
<u>MOMETASONE FUROATE - ASMANEX TWISTHALER</u>						
N021067 001	8173172	Mar 17, 2018	DP			
	8173172*PED	Sep 17, 2018				
<u>MOMETASONE FUROATE - ASMANEX TWISTHALER</u>						
N021067 002	8173172	Mar 17, 2018	DP			
	8173172*PED	Sep 17, 2018				
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N020829 002					NPP	Mar 26, 2015
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N020830 001					NPP	Mar 26, 2015
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N020830 002					NPP	Mar 26, 2015
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N021409 001					NPP	Mar 26, 2015
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 001	8158156	Jun 19, 2027	U-1241			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 002	8158156	Jun 19, 2027	U-1241			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 003	8158156	Jun 19, 2027	U-1241			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 004	8158156	Jun 19, 2027	U-1241			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 005	8158156	Jun 19, 2027	U-1241			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 006	8158156	Jun 19, 2027	U-1241			
<u>NAFTIFINE HYDROCHLORIDE - NAFTIN</u>						
N019599 002					NS	Jan 13, 2015
<u>NICOTINE - NICODERM CQ</u>						
N020165 004	8075911	May 22, 2021	DP			
<u>NICOTINE - NICODERM CQ</u>						
N020165 005	8075911	May 22, 2021	DP			
<u>NICOTINE - NICODERM CQ</u>						
N020165 006	8075911	May 22, 2021	DP			
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N022068 001	8163904	Aug 23, 2028	DS DP			
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N022068 002	8163904	Aug 23, 2028	DS DP			
<u>NITRIC OXIDE - INOMAX</u>						
N020845 002	5558083	Nov 22, 2013	DP U-1226			
	5558083*PED	May 22, 2014				
	5732693	Dec 13, 2016	DP U-1230			
	5732693*PED	Jun 13, 2017				
	5752504	Dec 13, 2016	DP U-1230			
	5752504*PED	Jun 13, 2017				
<u>NITRIC OXIDE - INOMAX</u>						
N020845 003	5558083	Nov 22, 2013	DP U-1226			
	5558083*PED	May 22, 2014				
	5732693	Dec 13, 2016	DP U-1230			
	5732693*PED	Jun 13, 2017				
	5752504	Dec 13, 2016	DP U-1230			
	5752504*PED	Jun 13, 2017				
<u>NITROGLYCERIN - NITROLINGUAL PUMPSPRAY</u>						
N018705 002	7872049	Mar 14, 2028	DP U-39			
<u>OXCARBAZEPINE - TRILEPTAL</u>						
N021285 001	8119148	Dec 19, 2020	DP U-724			
	8119148*PED	Jun 19, 2021				
<u>OXYBUTYNIN - ANTUROL</u>						
N202513 001	7029694	Apr 26, 2020	DP U-318			
	7179483	Apr 26, 2020	U-318			
	7198801	Jun 25, 2022	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 001	8114383	Oct 10, 2024	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 002	8114383	Oct 10, 2024	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 003	8114383	Oct 10, 2024	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 004	8114383	Oct 10, 2024	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 005	8114383	Oct 10, 2024	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 006	>A> 8114383	Oct 10, 2024	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 007	>A> 8114383	Oct 10, 2024	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 001	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 002	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 003	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 004	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 005	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 006	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 007	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
<u>PACLITAXEL - ABRAXANE</u>						
N021660 001	8138229	Dec 09, 2023	DP U-1092			
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON</u>						
N020725 004					>A> I-625	Apr 30, 2013
					>A> M-93	Jul 29, 2019
					>A> NCE	Apr 30, 2014
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PERTZYE</u>						
N022175 001					NCE	May 17, 2017

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PERTZYE</u>						
N022175 002					NCE	May 17, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ULTRESA</u>						
N022222 001					NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ULTRESA</u>						
N022222 002					NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ULTRESA</u>						
N022222 003					NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - VIOKACE</u>						
N022542 001					NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - VIOKACE</u>						
N022542 002					NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N022210 005					NCE	Aug 27, 2014
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N022210 006					NCE	Aug 27, 2014
<u>PAZOPANIB HYDROCHLORIDE - VOTRIENT</u>						
N022465 001	8114885	Dec 19, 2021	DS DP		I-649 ODE	Apr 26, 2015 Apr 26, 2019
<u>PAZOPANIB HYDROCHLORIDE - VOTRIENT</u>						
N022465 002	8114885	Dec 19, 2021	DS DP		I-649 ODE	Apr 26, 2015 Apr 26, 2019
<u>PEGINESATIDE ACETATE - OMONTYS</u>						
N202799 007	7084245	May 12, 2024	DS DP U-1238			
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS</u>						
N202799 008	7084245	May 12, 2024	DS DP U-1238			
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 001	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 002	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 003	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 004	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 005	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 006	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PHENTERMINE HYDROCHLORIDE - SUPRENZA</u>						
N202088 003	6149938	Jul 23, 2018	DP U-1243			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 001	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 002	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 003	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 004	8133883	Apr 14, 2023	DP U-282			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N050750 001	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N050750 002	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N050750 003	8133883	Apr 14, 2023	DP U-282			
<u>PREDNISOLONE ACETATE - FLO-PRED</u>						
N022067 001	7799331	Oct 11, 2028	DP U-139			
	7799331	Oct 11, 2028	DP U-1068			
<u>PREDNISOLONE ACETATE - FLO-PRED</u>						
N022067 002	7799331	Oct 11, 2028	DP U-139			
	7799331	Oct 11, 2028	DP U-1068			
<u>PREGABALIN - LYRICA</u>						
N021446 001					>A> I-651	Jun 20, 2015
<u>PREGABALIN - LYRICA</u>						
N021446 002					>A> I-651	Jun 20, 2015
<u>PREGABALIN - LYRICA</u>						
N021446 003					>A> I-651	Jun 20, 2015
<u>PREGABALIN - LYRICA</u>						
N021446 004					>A> I-651	Jun 20, 2015
<u>PREGABALIN - LYRICA</u>						
N021446 005					>A> I-651	Jun 20, 2015
<u>PREGABALIN - LYRICA</u>						
N021446 006					>A> I-651	Jun 20, 2015
<u>PREGABALIN - LYRICA</u>						
N021446 007					>A> I-651	Jun 20, 2015
<u>PREGABALIN - LYRICA</u>						
N021446 008					>A> I-651	Jun 20, 2015
<u>PROPRANOLOL HYDROCHLORIDE - INNOPRAN XL</u>						
N021438 001	6500454	Oct 04, 2021	DP			
<u>PROPRANOLOL HYDROCHLORIDE - INNOPRAN XL</u>						
N021438 002	6500454	Oct 04, 2021	DP			
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N022145 001					M-114	Mar 28, 2015
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N203045 001	7169780	Oct 03, 2023	DS DP		M-114	Mar 28, 2015
	7217713	Oct 21, 2022	U-257			
	7435734	Oct 21, 2022	U-257			
	7754731	Mar 11, 2029	DS DP U-257			
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N203045 002	7169780	Oct 03, 2023	DS DP		M-114	Mar 28, 2015
	7217713	Oct 21, 2022	U-257			
	7435734	Oct 21, 2022	U-257			
	7754731	Mar 11, 2029	DS DP U-257			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>REGADENOSON - LEXISCAN</u>						
N022161 001	8106029	Jun 22, 2019	U-1042			
	8106183	Feb 02, 2027	DS			
	8133879	Jun 22, 2019	DP			
	>A> 8183226	Jun 22, 2019	U-116			
<u>RETAPAMULIN - ALTABAX</u>						
N022055 001	>A> RE43390	Apr 12, 2021	DS DP U-805			
<u>RIFAXIMIN - XIFAXAN</u>						
N021361 001	8158644	Jun 19, 2024	DP			
	8158781	Jun 19, 2024	DS			
	>A> 8193196	Sep 02, 2027	DS DP			
<u>RIFAXIMIN - XIFAXAN</u>						
N022554 001	8158644	Jun 19, 2024	DP			
	8158781	Jun 19, 2024	DS			
	>A> 8193196	Sep 02, 2027	DS DP			
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u>						
N202022 001	8080551	Apr 11, 2023	DS DP			
	8101629	Aug 09, 2022	DP			
<u>RIZATRIPTAN BENZOATE - MAXALT</u>						
N020864 001	>A> 5602162	Jan 28, 2012		Y		
	>A> 5602162*PED	Jul 28, 2012				
<u>RIZATRIPTAN BENZOATE - MAXALT</u>						
N020864 002	>A> 5602162	Jan 28, 2012		Y		
	>A> 5602162*PED	Jul 28, 2012				
<u>RIZATRIPTAN BENZOATE - MAXALT-MLT</u>						
N020865 001	>A> 5602162	Jan 28, 2012	U-240	Y		
	>A> 5602162*PED	Jul 28, 2012				
<u>RIZATRIPTAN BENZOATE - MAXALT-MLT</u>						
N020865 002	>A> 5602162	Jan 28, 2012	U-240	Y		
	>A> 5602162*PED	Jul 28, 2012				
<u>ROTIGOTINE - NEUPRO</u>						
N021829 001					I-647 I-646	Apr 02, 2015 Apr 02, 2015
<u>ROTIGOTINE - NEUPRO</u>						
N021829 002					I-647 I-646	Apr 02, 2015 Apr 02, 2015
<u>ROTIGOTINE - NEUPRO</u>						
N021829 003					I-647 I-646	Apr 02, 2015 Apr 02, 2015
<u>ROTIGOTINE - NEUPRO</u>						
N021829 004	6699498	Nov 27, 2020	DP		I-647	Apr 02, 2015
	6884434	Mar 30, 2021	DP		I-646	Apr 02, 2015
	7413747	Mar 18, 2019	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ROTIGOTINE - NEUPRO</u>						
N021829 005	6699498	Nov 27, 2020	DP		I-647	Apr 02, 2015
	6884434	Mar 30, 2021	DP		I-646	Apr 02, 2015
	7413747	Mar 18, 2019	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N021829 006	6699498	Nov 27, 2020	DP		I-647	Apr 02, 2015
	6884434	Mar 30, 2021	DP		I-646	Apr 02, 2015
	7413747	Mar 18, 2019	DP			
<u>SILDENAFIL CITRATE - REVATIO</u>						
N021845 001	5250534	Mar 27, 2012	DS DP		I-598	May 07, 2012
	5250534*PED	Sep 27, 2012			PED	Nov 07, 2012
<u>SILDENAFIL CITRATE - REVATIO</u>						
N022473 001	5250534	Mar 27, 2012	DS DP		NDF	Nov 20, 2012
	5250534*PED	Sep 27, 2012			PED	May 20, 2013
<u>SILDENAFIL CITRATE - VIAGRA</u>						
N020895 001	5250534	Mar 27, 2012				
	5250534*PED	Sep 27, 2012				
	6469012	Oct 22, 2019		U-155		
	6469012*PED	Apr 22, 2020				
<u>SILDENAFIL CITRATE - VIAGRA</u>						
N020895 002	5250534	Mar 27, 2012				
	5250534*PED	Sep 27, 2012				
	6469012	Oct 22, 2019		U-155		
	6469012*PED	Apr 22, 2020				
<u>SILDENAFIL CITRATE - VIAGRA</u>						
N020895 003	5250534	Mar 27, 2012				
	5250534*PED	Sep 27, 2012				
	6469012	Oct 22, 2019		U-155		
	6469012*PED	Apr 22, 2020				
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N202343 001	8168637	Jun 26, 2022	DP U-1188			
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N202343 002	8168637	Jun 26, 2022	DP U-1188			
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N202343 003	8168637	Jun 26, 2022	DP U-1188			
<u>SODIUM NITRITE - SODIUM NITRITE</u>						
N203922 001					ODE	Jan 14, 2018
<u>SODIUM THIOSULFATE - SODIUM THIOSULFATE</u>						
N203923 001					ODE	Jan 14, 2018
<u>SUMATRIPTAN SUCCINATE - SUMAVEL DOSEPRO</u>						
N022239 001	8118771	Aug 10, 2023	DP			
<u>TAFLUPROST - ZIOPTAN</u>						
N202514 001	5886035	Dec 18, 2017	DS DP U-778		NCE	Feb 10, 2017
<u>TALIGLUCERASE ALFA - ELELYSO</u>						
N022458 001					NCE	May 01, 2017

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 001	8114383	Oct 10, 2024	DP			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 002	8114383	Oct 10, 2024	DP			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 003	8114383	Oct 10, 2024	DP			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 004	8114383	Oct 10, 2024	DP			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 005	8114383	Oct 10, 2024	DP			
<u>TAZAROTENE - FABIOR</u>						
N202428 001					NDF	May 11, 2015
<u>TELAVANCIN HYDROCHLORIDE - VIBATIV</u>						
N022110 001	8101575	May 01, 2021	DP			
	8158580	May 01, 2021	DP			
<u>TELAVANCIN HYDROCHLORIDE - VIBATIV</u>						
N022110 002	8101575	May 01, 2021	DP			
	8158580	May 01, 2021	DP			
<u>TELBIVUDINE - TYZEKA</u>						
N022154 001	7858594	Sep 11, 2023	DS DP U-999			
<u>TEMSIROLIMUS - TORISEL</u>						
N022088 001	5362718	Apr 18, 2014	DS DP		M-92	Jul 09, 2013
	5362718*PED	Oct 18, 2014			M-91	Apr 26, 2013
	8026276	Jan 20, 2026	DP		ODE	May 30, 2014
	8026276*PED	Jul 20, 2026			PED	Nov 30, 2014
					PED	Jan 09, 2014
					PED	Oct 26, 2013
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N021356 001					NPP	Jan 18, 2015
					PED	Jul 18, 2015

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TENOFVIR DISOPROXIL FUMARATE - VIREAD						
N021356 002	5922695	Jul 25, 2017	DS U-250		M-95	Oct 01, 2013
	5922695	Jul 25, 2017	DS U-256		NPP	Jan 18, 2015
	5922695	Jul 25, 2017	DS U-999		NPP	Mar 24, 2013
	5922695	Jul 25, 2017	DS U-248		ODE	Mar 24, 2017
	5922695*PED	Jan 25, 2018			PED	Sep 24, 2017
	5935946	Jul 25, 2017	DS DP U-999		PED	Jul 18, 2015
	5935946	Jul 25, 2017	DS DP U-248		PED	Apr 01, 2014
	5935946	Jul 25, 2017	DS DP U-250		PED	Sep 24, 2013
	5935946	Jul 25, 2017	DS DP U-256			
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-999			
	5977089	Jul 25, 2017	DS DP U-248			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-250			
	6043230	Jul 25, 2017	U-256			
	6043230	Jul 25, 2017	U-999			
	6043230*PED	Jan 25, 2018				
TENOFVIR DISOPROXIL FUMARATE - VIREAD						
N021356 003	5922695	Jul 25, 2017	DS U-250		M-95	Oct 01, 2013
	5922695	Jul 25, 2017	DS U-256		NPP	Jan 18, 2015
	5922695	Jul 25, 2017	DS U-999		NPP	Mar 24, 2013
	5922695	Jul 25, 2017	DS U-248		ODE	Mar 24, 2017
	5922695*PED	Jan 25, 2018			PED	Sep 24, 2017
	5935946	Jul 25, 2017	DS DP U-999		PED	Jul 18, 2015
	5935946	Jul 25, 2017	DS DP U-248		PED	Apr 01, 2014
	5935946	Jul 25, 2017	DS DP U-250		PED	Sep 24, 2013
	5935946	Jul 25, 2017	DS DP U-256			
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-999			
	5977089	Jul 25, 2017	DS DP U-248			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-250			
	6043230	Jul 25, 2017	U-256			
	6043230	Jul 25, 2017	U-999			
	6043230*PED	Jan 25, 2018				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N021356 004	5922695	Jul 25, 2017	DS U-250		M-95	Oct 01, 2013
	5922695	Jul 25, 2017	DS U-256		NPP	Jan 18, 2015
	5922695	Jul 25, 2017	DS U-999		NPP	Mar 24, 2013
	5922695	Jul 25, 2017	DS U-248		ODE	Mar 24, 2017
	5922695*PED	Jan 25, 2018			PED	Sep 24, 2017
	5935946	Jul 25, 2017	DS DP U-999		PED	Jul 18, 2015
	5935946	Jul 25, 2017	DS DP U-248		PED	Apr 01, 2014
	5935946	Jul 25, 2017	DS DP U-250		PED	Sep 24, 2013
	5935946	Jul 25, 2017	DS DP U-256			
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-999			
	5977089	Jul 25, 2017	DS DP U-248			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-250			
	6043230	Jul 25, 2017	U-256			
	6043230	Jul 25, 2017	U-999			
	6043230*PED	Jan 25, 2018				
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N022577 001	5922695	Jul 25, 2017	DS U-250		M-95	Oct 01, 2013
	5922695	Jul 25, 2017	DS U-256		NPP	Mar 24, 2013
	5922695	Jul 25, 2017	DS U-999		NDF	Jan 18, 2015
	5922695	Jul 25, 2017	DS U-248		ODE	Mar 24, 2017
	5922695*PED	Jan 25, 2018			PED	Sep 24, 2017
	5935946	Jul 25, 2017	DP U-999	Y	PED	Jul 18, 2015
	5935946	Jul 25, 2017	DP U-248	Y	PED	Apr 01, 2014
	5935946	Jul 25, 2017	DP U-250	Y	PED	Sep 24, 2013
	5935946	Jul 25, 2017	DP U-256	Y		
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-999			
	5977089	Jul 25, 2017	DS DP U-248			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-250			
	6043230	Jul 25, 2017	U-256			
	6043230	Jul 25, 2017	U-999			
	6043230*PED	Jan 25, 2018				
<u>TESAMORELIN ACETATE - EGRIFTA</u>						
N022505 002					>A> NCE	Nov 10, 2015
<u>TESTOSTERONE - TESTIM</u>						
N021454 001	8178518	Apr 21, 2023	DP			
<u>TESTOSTERONE - TESTOSTERONE</u>						
N202763 001					NP	Feb 14, 2015

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>THALIDOMIDE - THALOMID</u>						
N020785 001	8143283	Mar 01, 2013	U-1236			
	>A> 8204763	Aug 28, 2018	U-1249			
<u>THALIDOMIDE - THALOMID</u>						
N020785 002	8143283	Mar 01, 2013	U-1236			
	>A> 8204763	Aug 28, 2018	U-1249			
<u>THALIDOMIDE - THALOMID</u>						
N020785 003	8143283	Mar 01, 2013	U-1236			
	>A> 8204763	Aug 28, 2018	U-1249			
<u>THALIDOMIDE - THALOMID</u>						
N020785 004	8143283	Mar 01, 2013	U-1236			
	>A> 8204763	Aug 28, 2018	U-1249			
<u>TOPIRAMATE - TOPAMAX</u>						
N020505 001					NPP	Jul 15, 2014
<u>TOPIRAMATE - TOPAMAX</u>						
N020505 002					NPP	Jul 15, 2014
<u>TOPIRAMATE - TOPAMAX</u>						
N020505 004					NPP	Jul 15, 2014
<u>TOPIRAMATE - TOPAMAX</u>						
N020505 005					NPP	Jul 15, 2014
<u>TOPIRAMATE - TOPAMAX</u>						
N020844 001					NPP	Jul 15, 2014
<u>TOPIRAMATE - TOPAMAX</u>						
N020844 002					NPP	Jul 15, 2014
<u>TOPOTECAN HYDROCHLORIDE - HYCAMTIN</u>						
N020981 001	8158645	Dec 10, 2024	DP			
<u>TOPOTECAN HYDROCHLORIDE - HYCAMTIN</u>						
N020981 002	8158645	Dec 10, 2024	DP			
<u>TRAMADOL HYDROCHLORIDE - TRAMADOL HYDROCHLORIDE</u>						
A091607 001					PC	Jun 27, 2012
<u>TRAMADOL HYDROCHLORIDE - TRAMADOL HYDROCHLORIDE</u>						
A091607 002					PC	Jun 27, 2012
<u>TRAMADOL HYDROCHLORIDE - TRAMADOL HYDROCHLORIDE</u>						
A091607 003					PC	Jun 27, 2012
<u>TRAZODONE HYDROCHLORIDE - OLEPTRO</u>						
N022411 001	8133893	Mar 13, 2029	DS DP			
<u>TRAZODONE HYDROCHLORIDE - OLEPTRO</u>						
N022411 002	8133893	Mar 13, 2029	DS DP			
<u>TRIAMCINOLONE ACETONIDE - TRIESENCE</u>						
N022048 001	8128960	Dec 17, 2029	DP			
<u>VEMURAFENIB - ZELBORAF</u>						
N202429 001	8143271	Jun 21, 2026	DS DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N022567 001	>A> 8193195	Jun 05, 2022	U-839			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N022567 002	>A> 8193195	Jun 05, 2022	U-839			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N022567 003	>A> 8193195	Jun 05, 2022	U-839			
<u>VISMODEGIB - ERIVEDGE</u>						
N203388 001					NCE	Jan 30, 2017
<u>VORINOSTAT - ZOLINZA</u>						
N021991 001	8093295	May 16, 2026	DP			
	8101663	Mar 04, 2023	U-892			
<u>ZIPRASIDONE HYDROCHLORIDE - ZIPRASIDONE HYDROCHLORIDE</u>						
A077560 001					PC	Aug 29, 2012
<u>ZIPRASIDONE HYDROCHLORIDE - ZIPRASIDONE HYDROCHLORIDE</u>						
A077560 002					PC	Aug 29, 2012
<u>ZIPRASIDONE HYDROCHLORIDE - ZIPRASIDONE HYDROCHLORIDE</u>						
A077560 003					PC	Aug 29, 2012
<u>ZIPRASIDONE HYDROCHLORIDE - ZIPRASIDONE HYDROCHLORIDE</u>						
A077560 004					PC	Aug 29, 2012

Footnote:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 31st Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm>

The current complete list of patent terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm>